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Transmembrane proteins of the C-type lectin family are major carbohydrate-binding 
components of the immune system that are present in abundance on the surfaces of 
cells, such as macrophages and dendritic cells, and function as receptors. Previous 
screening data using human placental extracts suggested that the glycoprotein 
pregnancy-associated plasma protein-A1 (PAPP-A1) may be a natural ligand for the 
C-type lectin DC-SIGN. Interaction data using state of the art dip-and-read real-time 
biosensor technology show that PAPP-A1 interacts with DC-SIGN and DC-SIGNR 
with dissociation constants consistent with the physiologically relevant, low 
nanomolar range. PAPP-A1 is a large glycoprotein complex and a metalloproteinase 
that influences insulin-like growth factor (IGF) bioavailability by cleaving IGF-
binding proteins (IGFBP) 4 and 5. PAPP-A1 is found in abundance in plasma during 
pregnancy in complex with its natural inhibitor, eosinophil major basic protein 
(proMBP). Moreover, studies have shown that in males and non-pregnant females, 
PAPP-A1 circulates at much lower levels and is positively associated with acute 
coronary syndromes. Notably, PAPP-A1 possesses a high density of glycosylation 
sites and subsequent glycoproteomic analysis of native PAPP-A1/proMBP, and also 
recombinant PAPP-A1 and proMBP, was carried out via nano-liquid 
chromatography mass spectrometry. This glycoproteomic study successfully 
characterised the N-linked oligosaccharide profile of these molecules, including N-
glycan site assignment. Additional interaction analysis also showed that cutting-edge 
star-shaped glycopolymers bind to DC-SIGN with picomolar affinity. Overall, the 
work illustrates the importance of glycoproteins and glycopolymers as potential 
modifiers of the immune system and also as factors associated with understanding 
the mechanisms of vascular diseases such as pre-eclampsia and acute coronary 
syndromes. There is also emphasis on the power of new, combined biophysical 
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CaCl2  Calcium chloride 
CD   Cluster of differentiation 
CRD   Carbohydrate recognition domain 
CLR  C-type lectin receptor (transmembrane protein of the C-type lectin 
family that functions as a receptor) 
CTL  C-type lectin 
CTLD   C-type lectin-like domain 
DC   Dendritic cell 
DC-SIGN  Dendritic cell-specific intracellular adhesion molecule [ICAM-3]-
grabbing non-integrin 1 
DC-SIGNR  Dendritic cell-specific intracellular adhesion molecule [ICAM-3]-
grabbing non-integrin 1-Related (protein) 
ddH2O  Double distilled water 
EDTA   (Ethylenediamine)tetraacetic acid 
Fuc  fucose 
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Hex  Hexose 
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IGF   Insulin-like growth factor 
IGFBP   Insulin-like growth factor-binding protein  
kon  Association rate 
koff   Dissociation rate 




nLC-MS  Nano-liquid chromatography mass spectrometry 
nLC-NSI-MS/MS Nano-liquid chromatography Nano-spray ionisation Tandem 
mass spectrometry 
Man9GlcNAc2  N-linked oligosaccharide of 9 mannose and 2 core GlcNAc 
residues 
MMR   Macrophage mannose receptor 
MS2 or MS2   spectrum obtained in a tandem mass spectrometry experiment 
MS/MS  Tandem mass spectrometry (experiment) 
MW    molecular weight 
NaCl   Sodium chloride 
NeuAc/ Neu5Ac N-acetylneuraminic acid 
NeuGc / Neu5Gc N-glycolylneuraminic acid 
N-glycan  N-linked glycan 
nM   nanomolar 
NSI   Nano-electrospray ionisation 
PAPP-A/PAPP-A1  Pappalysin-1; Pregnancy-associated plasma protein A1 
pM   picomolar 
proMBP   Proform of the eosinophil major basic protein 
PAGE    polyacrylamide gel electrophoresis 
rpm   revolutions per minute 
RU    response unit(s) 
SDS   Sodium dodecyl sulphate  
TRIS    2-Amino-2-(hydroxymethyl)-1,3-propanediol 























Thirty years ago, the term glycobiology was coined by biochemist Raymond Dwek 
with the intention to reconnect the findings in the field of carbohydrate chemistry 
with basic biology as well as biochemistry (Blow, 2009).  
Glycobiology aims to elucidate the structures and functional roles of covalent 
carbohydrate attachments to biomacromolecules within their biological context. The 
glycan modification of biomolecules such as proteins and lipids is referred to as 
glycosylation. The International Union of Pure and Applied Chemistry (IUPAC) 
defines glycans “as synonymous with polysaccharides” and, therefore, glycans are 
sequentially linked sugar moieties via glycosidic bonds (IUPAC). Glycans can be 
found unconjugated, but are usually enzymatically and site-specifically attached to a 
range of biomacromolecules, such as proteins, lipids and other organic molecules. 
Such molecules modified with glycoconjugates are then referred to as glycoproteins, 
proteoglycans or glycolipids. A very broad diversity of glycans exists, ranging from 
simple to complex structures, and they are present in all domains of life (Cummings 
and Pierce, 2014). Their polydisperse and microheterogenerous nature is intrinsic and 
derives from the lack of a single template mechanism, as it is established for protein 
and nucleic acid synthesis (Roseman, 2001).  
Protein modification by glycosylation can occur as a co- as well as a post-translational 
event, depending on the nature of the protein and the cellular localisation of the 
enzymes involved. Glycosylation of proteins is mainly classified by the type of 
linkage to the polypeptide backbone: The major classes are N-linked and O-linked 
glycosylation (Taylor and Drickamer, 2011). It is has been found that nine amino acids 
are possible donors for modification via glycosylation, i.e. arginine (Arg/R), 
asparagine (Asn/N), serine (Ser/S), threonine (Thr/T), tyrosine (Tyr/Y), tryptophan 
(Trp/W), cysteine (Cys/C), hydroxylysine (Hyl) and hydroxyproline (Hyp) (Spiro, 
2002, Stepper et al., 2011).  
Cummings defines the glycome “as the repertoire of glycans expressed in a cell or 
organism” (Cummings and Pierce, 2014). Focusing on the mammalian glycome, the 
fundamental building blocks are glucose (Glc), N-acetylglucosamine (GlcNAc), 
galactose (Gal), N-acetylgalactosamine (GalNAc), mannose (Man), fucose (Fuc) and 




and glucuronic acid can also be found in specific types of O-glycans and proteoglycan 
chains. The mammalian genome encodes for numerous enzymes, transporters and 
other accessory molecules that allow for the variety of glycan structures comprised 
within the glycome (Henrissat et al., 2015).  
The approach of studying the relationship between structure and function of glycans 
has been termed as glycomics and even more specifically as glycoproteomics regarding 
protein glycosylation patterns and glycan-protein interactions (Raman et al., 2006).  
Functional glycomics emphasises on the research of specificity and affinity between 
glycan binding proteins (GBP), such as lectins, and their glycan-conjugated ligands. 
It aims to achieve the characterisation of these interactions as well as illuminating 
their roles within the biological context, i.e. in cells and organisms, and targets the 
detailed function of each interaction partner, the GBP and the glycoconjugate 
respectively (Zaia, 2011).  
To date, several functional roles have been proposed for glycans: They form 
extracellular matrices to provide tissue architecture and platforms for the regulation 
of cell and tissue interactions, and they serve as a marker for cellular identification. 
Glycans are involved in cellular processes including - but not limited to - the immune 
response, intracellular targeting and trafficking, intercellular recognition, as well as 
protein folding and stability (Varki, 1993). Particularly in the human body, studies 
have shown that glycans serve for communication purposes of self-tolerance, 
inflammation, blood clotting, and recognition of pathogens. Furthermore, it has been 
shown that metastasising cancer cells use glycans to evade the immune response 
(Alper, 2001). In summary, the structure, function, biosynthesis, variation and 
transformation of glycosylated molecules, cell organelles or cells are studied within 
the vast field of glycobiology (Alper, 2001, Taylor and Drickamer, 2011, Cummings 
and Pierce, 2014).  
A comprehensive understanding of glycan structures is crucial for the insight into the 
functions that glycans serve. This will provide invaluable insight into the role of 
glycosylation in physiological and pathophysiological biologic events, since “one of 
the major goals of glycoscience is to develop therapeutics based on glycans” (Zaia, 
2011). 
This thesis emphasises the novel characterisation of human glycoprotein and new 




human and other mammalian systems, which will be introduced and discussed in 
greater detail than plant, fungal, and microbial systems. 
1.1.1 Glycosylation of proteins 
The glycosylation of proteins can be found ubiquitously, in prokaryotes as wells as 
eukaryotes, inside the cell but also on the cellular surface, extracellular matrices and 
secreted glycoproteins (Roseman, 2001). In 1999, Apweiler concluded “that more than 
half of all proteins in nature will eventually be found to be glycoproteins” by a 
computerised analysis of a renowned protein sequence data bank (Apweiler et al., 
1999). 
The glycosylation of a protein extends not only its structure but also function: Glycan 
structures provide additional information on top of the already complex information 
content of the proteome. The glycan structures are generated enzymatically via 
glycosyltransferases, which create and extend oligosaccharide and polysaccharide 
chains by the formation of specific glycosidic linkages, and glycosidases, which trim 
and shape structures through the hydrolysis of specific glycosidic linkages (Bourne 
and Henrissat, 2001, Lairson et al., 2008). 
Glycosylation can contribute to the protein folding itself and serves as a tool for 
surveillance of quality control in the rough endoplasmic reticulum. Moreover, the 
glycans stabilise polypeptides by maintaining the protein conformation and 
enhancing solubility of glycoproteins as well as marking them for transfer and 
selective targeting through the secretory pathway (Varki, 1993, Xu and Ng, 2015). 
From a more holistic point of view, the glycans of glycoproteins regulate cytosolic 
and nuclear functions, mediate and modulate immune responses including 
inflammatory reactions, autoimmunity and self-tolerance. Glycans mediate 
interactions with pathogens, including viruses, bacteria, fungi and helminths, and are 
involved in the development of cancer and tumour metastasis. Glycan structures are 
also involved in hormone action and homeostasis (Helenius and Aebi, 2004, 




1.1.1.1 N-linked glycosylation 
Asparagine-linked glycans, referred to as N-linked glycans based on the One Letter 
Code for amino acids, have been comprehensively studied regarding their structural 
and functional aspects (Cummings, 2014). The consensus sequence N-X-S/T that 
guides N-linked glycosylation at the asparagine (N) in the polypeptide backbone, 
whereby X must not be proline (Spiro, 1970, Marshall, 1972). However, it has also 
been described that the N-X-S/T sequon is not strictly occupied by glycans and thus 
many N-X-S/T motifs in the human proteome display the unmodified amide side 
chain of asparagine (Petrescu et al., 2004). 
The biosynthesis pathway for N-glycans is a co-translational as well as post-
translational process, which mainly takes place at the endoplasmic reticulum (ER) 
and in some cases has been shown to start as early as a dozen amino acids after the 
ribosome at the nascent polypeptide (Hubbard and Ivatt, 1981). The biosynthesis of 
N-linked glycans can be roughly divided into three stages: First, the synthesis of the 
precursor polysaccharide that is linked to a lipid, namely a Glc3Man9GlcNAc2 
structure linked to dolichol. Secondly, the precursor Glc3Man9GlcNAc2 is transferred 
from the lipid-linker to an asparagine in a sequon via the membrane-associated 
oligosaccharyl transferase (OST) protein complex in the ER lumen. Thirdly, the 
glycan is processed further, which can include trimming by glycosidases, extension 
through glycosyltransferases and potential modification by various enzymes. The 
processing of the glycan occurs from the ER throughout the Golgi complex (Helenius 
and Aebi, 2004, Weerapana and Imperiali, 2006, Taylor and Drickamer, 2011). 
Resultant to the common biosynthesis pathway of N-linked glycans, the protein-
glycan linkage is always initiated at the reducing end by N-acetylglucosamine 
(GlcNAc) and all N-glycans contain a (Man3)GlcNAc2 pentasaccharide core structure 
(Kornfeld and Kornfeld, 1985). 
Furthermore, the different stages of maturation of N-glycans serve specific purposes: 
The initial precursor Glc3Man9GlcNAc2 is partially trimmed down to 
Glc1Man9GlcNAc2, which interacts transiently and selectively with the calreticulin-
calnexin chaperone complex. The trimming and subsequent interaction serves as a 
surveillance tool for the folding status of the protein and indicates quality control. 




successful folding of the glycoprotein and initiates the transition into the Golgi 
complex for further processing of the N-linked glycans, which reflects the second 
stage of glycan maturation (Helenius and Aebi, 2004, Weerapana and Imperiali, 2006, 
Xu and Ng, 2015).  
After modification of the glycans in the Golgi complex and trans-Golgi network, the 
glycoprotein is trafficked to its target site, which can be located in the cell, on the cell 
surface or in the extracellular space. N-glycan structures are typically classified into 
high-mannose, hybrid or complex types. The glycans belonging to the high-mannose 
class undergo processing by mannosidase enzymes (or, rarely, none at all) and 
usually contain between five and nine mannose residues. Additional processing - 
including addition of an N-acetylglucosamine residue or extension with galactose, 
N-acetylgalactosamine, fucose and sialic acid on one of the antennae - leads to the 
formation of a glycan that is classified as hybrid glycan. If hybrid glycans are 
processed even further, they can form multi-antennary, complex glycans that are 
extended with N-acetylglucosamine, galactose and sialic acid units.  However, the 
classification of glycans is rather a guidance, due to the numerous possibilities of 
branching, extensions with various glycan moieties and anomeric linkages 
(Cummings, 2009, Taylor and Drickamer, 2011). 
The mature glycans on the glycoprotein serve their individual roles, such as cell-cell 
and receptor-ligand interactions, triggers for immune responses and apoptosis, and 
underlying cause of the pathogenesis of various diseases (Helenius and Aebi, 2004, 
Moremen et al., 2012). 
1.1.1.2 O-linked glycosylation 
All types of O-linked glycosylation share the characteristic of being attached to a bio-
macromolecule by an O-glycosidic linkage between the glycan and the conjugate. In 
the case of glycoproteins, this is often realised through formation of a covalent bond 
with the hydroxyl group present on serine (Ser), threonine (Thr), hydroxylysine (Hyl) 
or tyrosine (Tyr) (Moremen et al., 2012).  
Apart from that, O-linked glycans are not attached to a specific consensus sequence 
at the polypeptide backbone, which makes the prediction of O-glycosylated sites 




made that include more complex algorithms than solely the amino acid sequence of 
a given glycoprotein (Julenius et al., 2005, Steentoft et al., 2013).  
O-glycosylation mainly takes place as a fully post-translational modification in the 
Golgi complex. O-linked glycans are extended stepwise and modifications are driven 
by specific enzymes. Several core structures have been elucidated so far: α-linked 
O-fucose, β-linked O-xylose, α-linked O-mannose, β-linked N-acetylglucosamine, 
α-linked N-acetylgalactosamine, α- or β-linked O-galactose, and α- or β-linked 
O-glucose glycans. However, the predominant type of O-linked glycans found in 
mammalian glycoproteins belongs to the mucin type, which is defined as an α-linked 
N-acetylgalactosamine (GalNAc) residue linked to the protein backbone (Van den 
Steen et al., 1998). The name originates from the high level of α-linked O-GalNAc 
glycosylation on mucins, which can be found on epithelial surfaces where they 
mainly bind water to provide a gel-like matrix (Julenius et al., 2005, Taylor and 
Drickamer, 2011). 
Another major class of O-glycosylated proteins are proteoglycans. Proteoglycans 
serve mainly structural roles through their attached glycosaminoglycans (GAGs). 
The GAG core structure consists of an O-linked tetrasaccharide and is extended by a 
repetitive sequence of alternating linear disaccharide units. Further modification via 
sulfation and epimerisation leads to an extensive variety of possible GAG structures. 
GAG glycosylations can also be implemented in the transmembrane with or without 
a glycosylphosphatidiylinositol (GPI)-anchored lipid. Well-known proteoglycans are 
Heparin, Heparan sulfate, Chondroitin sulfate and Dermatan sulfate. However, 
GAGs can also be found as free complex polysaccharides, e.g. hyaluronic acid (Taylor 
and Drickamer, 2011, Moremen et al., 2012). 
O-linked glycans are very heterogeneous and attachments of one single mono-
saccharide up to high-mass polysaccharides of several kilodaltons, e.g. in mucous 
secretions, have been identified on glycoproteins (Rose, 1992).  
Hart et al. discovered in the 1980s that β-linked O-GlcNAc can be attached on 
cytosolic and nuclear proteins and regulate cellular functions, including gene 
expression, as well as compete with the phosphorylation of selected Ser/Thr 
residues. The β-linked O-GlcNAc moieties are not extended but remain as a 




crosstalk between GlcNAc-glycosylation and phosphorylation exists, as both 
compete for the sites of modification (Butkinaree et al., 2010). This phenomenon has 
been described by some as the hexosamine signalling pathway. 
The functional roles of O-linked glycans are just as diverse as their structures. Besides 
the aforementioned functions, O-glycans are involved in the formation of 
extracellular matrices and connective tissues in organs, in cell adhesion and 
trafficking, in immunological processes by recognition through cell-surface lectins, in 
apoptosis, antibody function, and antigen receptor activation  (Carraway and Hull, 
1991, Underhill, 1992, McEver and Cummings, 1997, Zachara et al., 2015). 
Furthermore, studies have shown that O-GalNAc glycans could be potential markers 
for cancer and chronic inflammation (Hollingsworth and Swanson, 2004, Dube and 
Bertozzi, 2005).  
1.1.1.3 C-linked glycosylation 
In the 1990s, another type of glycosylation was found to exist in polypeptide 
backbones through a C-glycosidic linkage between the C2 atom of the indole moiety 
of a tryptophan residue and a mannose moiety. For C-linked mannosylation, the 
consensus sequence Trp-X-X-Trp (W-X-X-W) has been identified and usually the first 
tryptophan (Trp/W) residue of the sequon is mannosylated (Hofsteenge et al., 1994, 
Loffler et al., 1996, Dutta et al., 2017). 
Within the last decades, it became clear that C-mannosylation is a common post-
translational modification in mammalian proteins and driven by an enzymatic 
C-mannosyltransferase complex in the ER lumen (Doucey et al., 1998, Maeda and 
Kinoshita, 2008). 
The C-mannosylation has been observed in a variety proteins, which includes - but is 
not limited to - interleukin-12, human RNase 2, mucins, thrombospondins as well as 
on the complement proteins properdin, C6, C7, C8 and C9 (Hofsteenge et al., 1994, 
Doucey et al., 1999, Hofsteenge et al., 1999, Hartmann and Hofsteenge, 2000, 
Hofsteenge et al., 2001, Perez-Vilar et al., 2004). 
Interestingly, it has been shown that C-mannosylation is not recognised by 
conventional mannose-binding lectins, such as the plant lectin concanavalin A or 




2004). Considering the biological context of the C-mannosylated glycoproteins, 
involvement in regulation of enzyme activity and immune responses, roles in 
molecular recognition and signalling, and even functions related to protein folding 
have been hypothesised for α-linked C-mannosylation. However, the function(s) 
have not been successfully elucidated so far (Furmanek and Hofsteenge, 2000, Ihara 
et al., 2011). 
  Lectins 
Lectins are one of two subcategories of non-immune glycan-binding proteins (GBP), 
which generally exclude glycan-binding antibodies. The second subcategory of GBP 
is named glycosaminoglycan-binding proteins (Taylor et al., 2015).  
The term lectin, originating from the Latin legere ‘to choose, to select’, was coined by 
William C. Boyd in 1954 (Boyd, 1954). At the time, the term mainly referred to 
plant-derived proteins that cause agglutination and precipitation with specific blood 
group antigens that are based on carbohydrate moieties. Within the following 
decades, the definition of a lectin was refined to “a sugar-binding protein or 
glycoprotein of non-immune origin which agglutinates cells and/or precipitates 
glycoconjugates” (Boyd and Shapleigh, 1954, Goldstein et al., 1980). It became clear 
that lectins are common and important in all domains of life and beyond, including 
viruses, bacteria, fungi, plants, insects and animals (Ofek et al., 1977, Sharon and Lis, 
1989, Lis and Sharon, 1991, Gabius, 1997, Singh et al., 2011, Van Damme, 2014, Xia et 
al., 2018). 
On molecular and cellular levels, lectins recognise carbohydrate moieties non-
covalently via specific carbohydrate recognition domains (CRDs). The structural 
characteristics of a CRD classifies the lectin proteins and can provide insight into their 
typical glycan-binding properties. However, the classification is very complex due to 
an overlapping nature, i.e. lectin proteins can carry multiple CRDs that belong to 
different classes. Therefore, a final and definite assignment is not feasible for all GBPs 
but can rather be examined within the particular biological context. At present, 
numerous different lectin families are established, which includes - but is not limited 
to - the Calnexin type, Chitinase-like lectins, C-type lectins, F-box lectins, Ficolins, F-




M-type lectins, P-type lectins, and R-type lectins (Taylor and Drickamer, 2011, 
Drickamer, 2014c, Drickamer, 2014b, Taylor et al., 2015). The terminology is even 
more complex since additional names exist for some classes, e.g. intelectins are also 
known as eglectins or X-lectins. 
Briefly mentioned, other systems of classification can be used, such as an intracellular 
or extracellular localisation of the CRD. Intracellular lectins are found in luminal 
compartments, e.g. the proteins calnexin and calreticulin that bind via their CRD to 
the remaining glucose residues of a maturing N-linked glycan in the ER lumen. 
Extracellular lectins can be found as transmembrane proteins with the CRD or CRDs 
reaching into the extracellular space, or as secreted lectins (Drickamer, 2014c, Xu and 
Ng, 2015).  
This thesis focuses on mammalian lectins which are integrated into the plasma 
membrane via a transmembrane region and possess one or more extracellular CRD. 
These lectins recognise glycan structures outside the cell and mediate various 
functions, such as cell adhesion and cell signalling, as well as the trafficking, targeting 
and clearance of glycoproteins. Furthermore, the involvement in immune 
homeostasis and responses are a major functional role of lectins (Drickamer, 2014c).  
The main classes of mammalian lectins with extracellular CRDs are summarised 
below: 
Lectin proteins are ubiquitously expressed in leguminous plants, which coined the 
term ‘L-type’ lectin. They were the first class of lectins to be discovered in the late 19th 
century (Van Damme, 2014). This class was established on the basis of the common 
tertiary structure of their CRDs and they have been found present in plant, fungal 
and animal lectins. Many L-type CRDs preferably interact with high-mannose-type 
oligosaccharides in a calcium-dependent manner, a good example being 
concanavalin A (Kamiya et al., 2008, Van Damme et al., 2008).  
 
The ‘immunoglobulin-type’ (I-type) lectins bind carbohydrate ligands via 
immunoglobulin superfamily domains. The best characterised I-type lectin subgroup 
are the Siglecs (sialic-acid-binding immunoglobulin-like lectins), which are type 1 
membrane proteins and bind to sialic acid moieties. Siglecs, as well as other members 




homologous to the variable region of immunoglobin G (IgG) antibodies (Powell and 
Varki, 1995, Crocker et al., 2007, Varki et al., 2015). 
 
Members of the P-type lectin family have the ability to recognise phosphorylated 
mannose residues, which is a crucial function in the context of lysosomal trafficking 
within the cells of higher eukaryotes. After arrival at the luminal side of the lysosome, 
the acidic pH triggers the dissociation of receptor and cargo and the receptors are 
trafficked back to the Golgi apparatus of the cell (Dahms and Hancock, 2002, Ghosh 
et al., 2003). 
 
The R-type carbohydrate-recognition domain, named after the CRD present in the 
castor bean protein ricin, can be found in many glycosyltransferases, bacterial and 
fungal hydrolases and other animal, plant, and bacterial lectins. Remarkably, the 
R-type CRD is well conserved throughout the domains of life and can be 
accompanied by an additional subunit that acts a potent toxin (Rutenber et al., 1987, 
Cummings and Schnaar, 2015).  
 
The main focus of this thesis lies on C-type lectin receptors and, therefore, they will 
be discussed comprehensively in the following section. 
C-type lectins contain a carbohydrate recognition domain that binds glycan 
structures and most members recognise the glycans in a calcium-dependent manner. 
C-type lectins serve a wide range of functions in mammalians (Zelensky and Gready, 
2005). 
1.2.1 C-type lectins 
The C-type lectins (CTL) bind glycans via their carbohydrate-recognition domain in 
a calcium-dependent manner, which coined the term “C-type”. The C-type CRDs 
share a homologous primary structure of 110-130 amino acids with two highly 
conserved disulfide bridges, and specific hydrophobic as well as polar residues. 
These interaction partners form a secondary structure of a double-loop, which is 
flexible and the key arrangement for the calcium-dependent interactions with the 
ligand, which forms the ternary complex between the protein, calcium ion and 




the coordination of calcium-ions. The coordinated Ca2+ ions enable themselves the 
coordination bonds to hydroxyl groups of the glycan or other ligands. Furthermore, 
hydrophobic interactions can stabilise the binding between the glycosylated 
interaction partner and the C-type lectin, referred to as secondary interactions 
(Zelensky and Gready, 2005, Drickamer, 2014a, Cummings and McEver, 2015).  
However, due to the structural and evolutionary flexibility of this particular domain 
fold, not all members of this protein superfamily require calcium for the interaction 
between the CRD and the ligand. Therefore, the distinction between the sugar-
binding C-type CRDs and the broad family of C-type lectin-like domains (CTLDs) 
has been introduced to refer to the homologous domains. Some CTLDs that carry a 
C-type-like CRD bind neither glycan structure nor behave in a calcium-dependent 
manner. Therefore, the C-type lectin (like) domain superfamily has been created, 
which also encloses the traditional C-type lectins (Weis et al., 1998).  
The superfamily of CTLDs has been categorised into 16 groups (see figure 1.1.). The 
categorisation is based on characteristics and the sequence alignment of the domain. 
The groups cover soluble C-type lectins, such as the mannose-binding lectin (MBL) 
or the lung surfactant proteins A (SP-A) and D (SP-D) which are both collectins 
(Figdor et al., 2002, Jakel et al., 2013). Other groups include membrane-integrated 
proteins with C-type lectin (like) domains. To date, about 100 proteins carrying one 
or more CTLDs have been identified in the human genome (Drickamer, 2014d, 





Figure 1.1: Different groups of C-type lectins (CTLs) and their domain structures.  
(A) Sixteen groups are shown, defined by their phylogenetic relationships and domain 
structures. Some of the groups are soluble proteins and others are transmembrane proteins.  
(B) The group 3 collectins form oligomeric structures, shown as cruciform and bouquet 
structures in the box. Each of the domains is named as indicated in the key. For abbreviations 
see the text.   
(Figure and caption have been adapted from (Cummings and McEver, 2015) with kind 
permission from [Essentials of Glycobiology (Third Edition), Chapter 34, Figure 3, Cold 





The focus of this thesis lies on animal lectins. Particularly, lectins expressed on human 
immune cells that bind to sugar moieties in a calcium-dependent manner. They are 
referred to as C-type lectin receptors (CLRs) and are assigned into the CTL group 2 
for the Dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin 
(DC-SIGN; CD209) and Dendritic cell-specific intercellular adhesion molecule-
grabbing non-integrin-related protein (DC-SIGNR; CD299, L-SIGN), and the CTL 
group 6 for the Macrophage Mannose Receptor 1 (MMR; CD206), respectively. 
Membrane-integrated C-type lectins are single-pass transmembrane proteins with 
the majority being type II transmembrane proteins, except for the Macrophage 
Mannose Receptor (MMR), Endo-180 and DEC-205, which are type I transmembrane 
receptors (Figdor et al., 2002). Type I proteins have their N-terminus on the ER 
luminal or extracellular side of the membrane. However, type II transmembrane 
proteins span the membrane with their N-terminus on the cytoplasmic side of the 
membrane (Curtis et al., 1992). 
Typically, carbohydrate-protein interactions are selective but weak; for example, 
CRD-monosaccharide interactions of the C-type lectins DC-SIGN, DC-SIGNR, and 
MBL with mannose show dissociation constants (KD) about one millimolar, 
respectively. This weak affinity is counterbalanced by nature through a multivalent 
presentation of CRDs. For example, DC-SIGN as well as DC-SIGNR form tetramers 
via parallel alpha-helical coiled-coil domains, which results in a supercluster effect 
and high-avidity binding platforms for multivalent ligands (Lee et al., 1992, Lee and 
Lee, 2000, Mitchell et al., 2001, Cummings and McEver, 2015). However, the single-
polypeptide chain and non-oligomerising membrane protein MMR overcomes the 
weak affinity of a single CRD by the presentation of eight consecutive, tandem C-
type CRDs that are intrinsic in the primary structure (Taylor et al., 1990). Both styles 
of arrangement ensure recognition of biologically relevant targets by the requirement 
of matching target density as well as configuration. 
As mentioned, C-type lectins recognise glycans selectively and many can be broadly 
classified into either the mannose-binding subtype, e.g. DC-SIGN, DC-SIGNR, and 
MMR, or the galactose binding subtypes, e.g. the Asialoglycoprotein receptor 
(ASGPR) and the Macrophage Galactose-type Lectin (MGL; CD301) (Zelensky and 
Gready, 2005). The specificity for mannose-type sugars of some CLRs derives from 




the primary structure of the calcium-binding site in the loop region of the CRD. The 
resulting secondary structure causes less steric hindrance for adjacent equatorial 3-
hydroxyl and 4-hydroxyl groups, which can be found in D-mannose, N-acetyl-D-
glucosamine, D-glucose, or L-fucose. On the other hand, the galactose binding CTL 
subtypes carry a Gln-Pro-Asp sequon (QPD motif) within their calcium-dependent 
CRD, which favours the axial 4-hydroxyl group sterically and involves ligands such 
as galactose and N-acetylgalactosamine residues (Drickamer, 1992, Sharon and Lis, 
2007). 
 
However, C-type lectins can bind ligands in several modes as it has been elucidated 
for DC-SIGN, DC-SINGR and MGL (Probert et al., 2013, Marcelo et al., 2014, Pederson 
et al., 2014). The putative diversity in binding modes of the ligand to the CRD as well 
as the importance of secondary interactions sites to certain CRDs broadens the 
specificity for some CTLs (Sharon and Lis, 2007, Drickamer and Taylor, 2015). 
 
The recognition of ligands by animal lectins can initialise and concert various 
processes, which include but are not limited to adhesion events, intracellular 
signalling, involvement in homeostasis and inflammation, recognition of (damaged) 
self, and regulation of embryonic development (Gabius, 1997, Brown et al., 2018). 
The functions of lectins can also to a large extent be assigned according to the lectin 
family. For example, members of the Calnexin family are involved in protein sorting 
in the endoplasmic reticulum, while members of the M-type lectins are involved in 
the ER-associated degradation of glycoproteins. L-type lectins have been found to be 
mainly involved in protein sorting in the endoplasmic reticulum and P-type lectins 
take part in protein sorting and trafficking, as well as ER-associated degradation of 
glycoproteins, and enzyme targeting. The extracellular lectin family of Galectins 
provides the crosslinking of glycans in the extracellular matrix. The I-type lectins, 
including their well characterised subfamily of Siglecs, has been found to contribute 
to cell adhesion. R-type lectins have been found in processes of enzyme targeting and 
glycoprotein hormone turnover. The members of the lectin family of F-box lectins is 
involved in the degradation of misfolded glycoproteins. Members of Ficolins, F-type 
lectins and Intelectins are associated with various processes in innate immunity such 




events, endocytosis and clearance of glycoproteins, recognition of pathogens and 
regulation of the innate immunity (Drickamer, 2014c). Since specific CLRs are 
expressed on the cell surface of various but distinct types of immune cells, the CLRs 
can serve as markers for specific cell types or even their cellular states (Brown et al., 
2018). However, the intracellular signalling pathways of CLRs subsequent to ligand 
binding events is still “the least well understood function of these receptors” 






1.2.1.1  Dendritic cell-specific intercellular adhesion 
molecule 3-grabbing non-integrin 1 (DC-SIGN) 
The Dendritic cell-specific intercellular adhesion molecule [ICAM-3]-grabbing non-
integrin (DC-SIGN) is a member of the group 2 of the superfamily of CTLDs. It is also 
referred to as the surface marker CD209 or the C-type lectin domain family 4 
member L (CLEC4L). It was first discovered in the early 1990s as an entry site for the 
human immunodeficiency virus via interaction with its glycosylated envelope 
protein gp120, and simply described as a gp120-binding C-type lectin (Curtis et al., 
1992, Geijtenbeek et al., 2000b). It later became clear that the physiological 
relationship with the immune system is even more prominent: the actual 
nomenclature derives from DC-SIGN’s characteristic to bind to the intercellular 
adhesion molecule 3 (ICAM-3), mainly expressed on lymphocytes. This interaction 
mediates an adhesion between Dendritic cells (DCs) and resting T cells, which 
express ICAM-3 on their cell surface. The interaction is an essential trigger for T cell 
proliferation (Geijtenbeek et al., 2000c). DC-SIGN 
itself is abundantly expressed on the surface of 
immature dendritic cells, and also on mature 
dendritic cells of dermal, lymphoid, and mucosal 
DCs, as well as on a subset of blood DCs. 
Furthermore DC-SIGN has been found to be 
expressed by hepatic sinusoidal endothelial cells, 
subpopulations of B cells, and on subsets of 
platelets. Moreover, DC-SIGN has been found on 
M2-type macrophages, such as interstitial and 
alveolar macrophages, as well as on maternal 
decidual macrophages and foetal-derived 
macrophages (Hofbauer cells) in the placenta 
(Geijtenbeek et al., 2000c, Engering et al., 2002c, 
Soilleux et al., 2002, Kammerer et al., 2003, Puig-
Kroger et al., 2004, Chaipan et al., 2006, Lai et al., 
2006). 
The location of the gene that encodes for DC-SIGN 
has been identified on human chromosome 19p13 
Figure 1.2: Crystal structure of the 
CRD from DC-SIGN (shown in 
blue) bound to a pentasaccharide 
(presented in ball-and-stick model in 
yellow; G for GlcNAc; M for 
mannose). Two of the three calcium 
binding sites (cyan, Ca1/3) are 
crucial for structural integrity of the 
CRD and one (Ca2) is important for 
coordination of the carbohydrate 
ligand via hydrogen bonds. Figure 
and caption have been adapted and 
altered with kind permission from 




(Soilleux et al., 2000). The encoded information includes an extracellular, a trans-
membrane and a cytosolic domain within a total of 404 amino acids. DC-SIGN 
belongs to the majority of CLRs which are type II transmembrane proteins 
(Geijtenbeek et al., 2000c). The C-terminal, extracellular domain (depicted in figure 
1.2) carries one calcium-dependent CRD with an EPN motif for recognition of 
carbohydrates, and shows a typical long-form C-type lectin fold. The CRD contains 
three calcium binding sites, whereby one site is important for coordination of the 
carbohydrate ligand via hydrogen bonds formed with its hydroxyl groups. The other 
calcium binding sites mainly ensure structural integrity of the C-type lectin fold 
(Feinberg et al., 2001, Feinberg et al., 2007).  
The CRD region is preceded by a hydrophobic stretch of 15 amino acids within the 
extracellular domain. The following tandem-repeating neck region consists of 7.5 
α-helical repeats, whereby each repeat is formed by 23 highly conserved amino acids. 
Figure 1.3: Schematic overview of the DC-SIGN structure. The carbohydrate recognition 
domain (CRD) of DC-SIGN is separated from the transmembrane (TM) region by a neck 
domain that consists of seven complete and one incomplete tandem repeat and facilitates 
oligomerisation. The cytoplasmic tail includes internalisation motifs, such as the di-leucine 
(LL) motif and the tri-acidic (EEE) clusters, and an incomplete immunoreceptor tyrosine-based 
activation motif (ITAM). Figure and caption have been adapted and altered with kind 




The repeats serve as an oligomerisation motif and form alpha-helical stalks that non-
covalently homo-tetramerise. The tetramerisation provides a high-avidity binding 
platform resulting in a supercluster effect, which not only increases affinity via 
avidity but also specificity (Mitchell et al., 2001). The increase in specificity is realised 
by the defined spacing of the CRDs through tetramerisation. Moreover, the 
arrangement ensures that the CRDs are projected away from the cell surface for 
improved recognition of extracellular ligands (Svajger et al., 2010).  
A hydrophobic transmembrane region with predicted alpha-helical character 
connects the extracellular domains of the CLR with the cytoplasmic tail (Geijtenbeek 
et al., 2000c). The N-terminal, cytoplasmic domain of DC-SIGN carries a di-leucine 
motif (LL), a tri-glutamate acidic cluster (EEE), as well as a tyrosine motif (YKSL) 
(The UniProt Consortium, 2004). These have been linked to intracellular signalling 
pathways as well as triggering antigen/pathogen internalisation for processing and 
subsequent presentation at the surface of the antigen presenting cell (APC) (Mellman, 
1996, Engering et al., 2002a, Yon et al., 2009). In 2007, Hodges et al showed in a study 
using mutated DC-SIGN constructs that “[l]oss of signalling occur[ed] exclusively for 
the double mutant (with both the dileucine motif and the relevant tyrosine replaced 
by alanine), which suggested a critical function for the tyrosine residue in the DC-
SIGN cytoplasmic tail in the transmission of intracellular signals.” (Hodges et al., 
2007).  
It has become clear over the past decade that DC-SIGN modulates signalling 
pathways which are initiated by toll-like receptors (TLR), also referred to as crosstalk 
with other pattern recognition receptors (PRR). DC-SIGN has been shown to rely on 
the prior activation of the nuclear factor‑κB (NF-κB) signalling pathway by other 
PRRs. NF‑κB is a nuclear transcription factor and plays a prominent role in inducing 
gene expression within immunological responses. Prior to activation, DC-SIGN is 
bound by the adaptor protein Lymphocyte-specific protein 1 (LSP1). Furthermore, 
the proteins Kinase Suppressor of Ras 1 (KSR1), Connector Enhancer of KSR (CNK), 
and the kinase RAF1 form a KSR1-CNK-RAF1 triad which serves as a signalling 
complex (signalosome). The KSR1-CNK-RAF1 signalosome forms a complex with 
LSP1. Upon ligand binding at the CRD of DC-SIGN, the signalosome is activated and 







Findings from the Gringhuis and Geijtenbeek groups showed that the modulation of 
the signalosome is dependent on the nature of the carbohydrate ligand that binds to 
the CRD of DC-SIGN. Recognition of mannose-containing glycan structures leads to 
activation of the RAF1 signalosome and results in a production of pro-inflammatory 
cytokines as shown in figure 1.4. Briefly, the serine/threonine-protein kinase RAF1 
signalosome serves as a docking site for signalling proteins Transforming protein 
RhoA (RhoA) and the Leukaemia-associated Rho guanine nucleotide exchange factor 
12 (LARG). Subsequently, the activation of the RAF1 signalosome results in 
phosphorylation and deacetylation of the p65 subunit of NF-κB (Gringhuis et al., 
2007, Geijtenbeek and Gringhuis, 2009, Geijtenbeek and Gringhuis, 2016, Brown et 
Figure 1.4: DC‑SIGN signalling pathway triggered by mannose-containing ligands.(shown 
in the coloured section). DC-SIGN associates with the adaptor lymphocyte-specific protein 1 
(LSP1) and can recruit the serine/threonine-protein kinase RAF1 signalosome, upon binding 
a mannose-containing ligand as well as parallel activation of other PRRs. DC-SIGN then 
requires the recruitment of Transforming protein RhoA (RhoA) and the Leukaemia-
associated Rho guanine nucleotide exchange factor 12 (LARG) for activation of the RAF1 
signalosome. The activation of the RAF1 signalosome results in phosphorylation and 
deacetylation of the p65 subunit of NF-κB in the nucleus. This leads to an increase in pro-
inflammatory immune responses via cytokines IL-12, IL-23 and IL-6. Figure and caption 





al., 2018). On the other hand, recognition of fucose-containing structures by DC-SIGN 
have not only been found to be independent of RAF1 activation but the KSR1-CNK-
RAF1 signalosome is detached from DC-SIGN whilst LSP1 remains attached. The 
proteins Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) and the 
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD) attach to LSP1. This complex 
has been termed the ‘fucose signalosome’ in the literature. After activation of CYLD 
and IKKε, an atypical member of the NF-κB protein family gets transported into the 
nucleus. The accumulating B-cell lymphoma 3 protein (Bcl3) forms complexes with 
other transcription factors that lead to upregulation of the expression of anti-
inflammatory cytokine interleukin 10 (IL-10) as well as the suppression of pro-
inflammatory cytokines IL-12, IL-23 and IL-6 (Gringhuis et al., 2009, Gringhuis et al., 
2014, Geijtenbeek and Gringhuis, 2016). This shows that modulation of intracellular 
signalling by DC-SIGN is even more complex and suggests a high degree of plasticity 
in DC-SIGN signalling. The overall resultant production of cytokines by the cell 
reflects a tailored immune response to specific antigens or pathogens (Geijtenbeek 
and Gringhuis, 2009, Gringhuis et al., 2009).  
DC-SIGN was identified through the investigation of the mechanisms that underpin 
the contact between dendritic cells (DCs) and resting T cells, leading to T cell 
activation. Studies highlighted DC-SIGN on DCs as the mediator for adhesion via its 
characteristic to bind to the Intercellular adhesion molecule 3 (ICAM-3) that is 
abundantly expressed on T cells. Initially, the β2 integrin receptors leukocyte 
adhesion protein 1 (LFA-1 or integrin α-L/β-2) and the integrin α-D/β-2 were 
thought to mediate the DC-T cell interaction. Since “DC interact with ICAM-3 
through an integrin-independent mechanism that requires Ca2+, [Geijtenbeek] 
designated this receptor DC-specific ICAM-3 grabbing nonintegrin 
(DC-SIGN)”(Geijtenbeek et al., 2000c). It was shown that DC-SIGN also binds to 
ICAM-2 but with a higher binding affinity than ICAM-3, and contributes to the 
tethering and rolling of DCs on surfaces such as vascular endothelium that express 
ICAM-2 (Geijtenbeek et al., 2000a). DC-SIGN interacts with N-linked high-mannose 
oligosaccharide structures with submillimolar affinity (Mitchell et al., 2001), 
preferentially with structures from Man5GlcNAc2 to Man9GlcNAc2. These glycans 
have been identified on ICAM-2, ICAM-3 and HIV gp120. The EPN motif in the CRD 




adjacent equatorial 3-hydroxyl and 4-hydroxyl groups, e.g. mannose, 
N-acetylglucosamine, glucose, and L-fucose (Drickamer and Taylor, 2015). Through 
the use of glycan arrays, further endogenous ligands for DC-SIGN have been 
identified, and these are fucose-containing Lewis blood-group antigens such as 
LewisX, LewisY, Lewisa, and Lewisb carbohydrate epitopes, in addition to fucose-
containing ABH Blood Group oligosaccharides, i.e. Blood Groups A and B (Guo et 
al., 2004). 
The CRD of DC-SIGN binds the trisaccharide structure Manα1-3[Manα1– 6]Man four 
times better than the monosaccharide mannose. A key characteristic for the 
recognition is the α-linkage of the core mannose, which is only found in high 
mannose oligosaccharides. This finding was elucidated by Feinberg et al. via X-ray 
crystal structure analysis of a pentasaccharide bound to the CRD of DC-SIGN and 
subsequent molecular modelling. A representation of the arrangement is shown in 
figure 1.2., where the annotation M2 marks the core mannose residue that interacts 
with the ligand-coordinating calcium ion. Furthermore, Feinberg et al. determined 
the precise interaction sites on the polypeptide chain and demonstrated that 
DC-SIGN interacts with distal components of the pentasaccharide  structures also via 




Similar carbohydrate structures have been found on the surfaces of various 
microorganisms, which are exogenous ligands for DC-SIGN. This includes bacteria, 
fungi, and viruses, e.g. mycobacterium tuberculosis, mycobacterium leprae, 
lactobacilli spp., helicobacter pylori, candida albicans, HIV‑1, measles virus, dengue 
virus, SARS coronavirus, and filoviruses. All of them have been found to exploit the 
modulating immune function of activated DC-SIGN to escape the immune 
surveillance of the host and mitigate neutralisation by the immune system (van 
Kooyk and Geijtenbeek, 2003, Guo et al., 2004, Geijtenbeek and Gringhuis, 2009).  
Curtis et al. showed in 1992 that a hitherto undefined C-type lectin binds strongly to 
the HIV glycoprotein 120 (gp120), which is an envelope protein of the virus (Curtis 




DC-SIGN and it was suggested that it might enhance the viral infection of T cells in 
trans via the exploitive nature of HIV (Geijtenbeek et al., 2000b). The high affinity 
interaction is facilitated between the CRD of DC-SIGN and the densely clustered high 
mannose glycan structures present on gp120 (Mizuochi et al., 1990, Feinberg et al., 
2007). DC-SIGN has been a prominent target for HIV prophylaxis or therapeutic 
intervention since 2000, although unfortunately, this has not resulted in a 
commercially viable HIV treatment or prophylaxis option so far. However, the 
development of anti-viral agents with a higher affinity than HIV gp120 for the CRD 
of DC-SIGN have recently made significant progress with the synthesis and 
characterisation of mannose-containing glycopolymers (Becer et al., 2010). 
Human milk glycans (HMGs), also referred to as human milk oligosaccharides 
(HMOs), have been defined as pathogen receptor decoys, modulators of neonatal 
immunity in the infant gut, regulators of host physiology, and act as prebiotics for 
the infant’s gut microbiome (Bode, 2012). Noll et al. showed recently that DC-SIGN 
binds to human milk glycans – primarily to those which contain an α-linked fucose 
moiety, with an affinity that matches the physiological HMG concentrations. They 
suggested “that DC-SIGN may serve as an HMG receptor, which may have 
implications in infant immunity, physiology and development“ via regulating gene 
expression and subsequent immune responses in the developing gut (Noll et al., 
2016). 
Moreover, it is still not fully understood why DC-SIGN-expressing cells are very 
prominent on both sides of the foetal-maternal interface during human pregnancy. 
Pregnancy can be interpreted as a highly immunologically privileged state in which 
the maternal immune system accepts the allogeneic embryo and subsequently the 
developing foetus without fully suppressing the maternal immune system. There is 
growing evidence that DC-SIGN plays an important role for the immune responses 
in human pregnancy, although the mechanisms underpinning this are not fully 
understood (Kammerer et al., 2003).  
 
As a result of the structural and binding characteristics, human DC-SIGN acts as an 
adhesion molecule for the endogenous, N-glycosylated ICAM-2 and ICAM-3: 
DC-SIGN facilitates the tethering and rolling of DCs on surfaces that express ICAM-2, 




through interactions with ICAM-3. This process helps to bridge the innate and 
adaptive immune responses and is crucial for the activation of T cells (Geijtenbeek et 
al., 2000c, Geijtenbeek et al., 2000a).  
DC-SIGN also recognises carbohydrate structures on self-antigens as well as on 
foreign antigens, which is important for maintaining immune homeostasis 
(Geijtenbeek et al., 2004). When DC-SIGN binds foreign ligands, internalisation can 
be induced by activation of the di-leucine motif as well as the tri-glutamate acidic 
cluster in the cytoplasmic domain. The internalised ligand is transferred to 
proteolytic compartments and either degraded or processed for downstream antigen 
presentation via major histocompatibility complex (MHC) class II molecules on the 
surface of Dendritic cells (Engering et al., 2002b). Therefore, DC-SIGN also functions 
as an endocytic antigen receptor (Geijtenbeek et al., 2004).  
It has been shown that the release of the ligand from the CRD is pH sensitive. Ligands 
bind to DC-SIGN at a physiological pH 7.4 and the CRD releases the cargo under 
more acidic conditions (pH 5.5) in lysosomal compartments, which was shown by 
Guo et al (2004). It also has been speculated that DC-SIGN might serve as a clearance 
receptor of glycoproteins in the human body, which are simply degraded in 
lysosomal compartments after uptake and internalisation (Guo et al., 2004). Initially, 
DC-SIGN was considered to be a scavenger receptor only. However, the knowledge 
that DC-SIGN can modulate immune responses after binding to glycan ligands via 
influencing cytokine production suggests that it is more sophisticated than a simple 
scavenger. As discussed above, mannose-containing ligands can promote expression 
of a mixture of pro-inflammatory cytokines, notably IL-6, and fucose-containing 
ligands suppress pro-inflammatory responses as well as driving anti-inflammatory 
cytokine production (Gringhuis et al., 2009). DC-SIGN can also passively modulate 
immune responses by antigen presentation on DCs, which will trigger downstream 
adaptive immune responses via T and B cells (Engering et al., 2002b).  
In summary, DC-SIGN functions as a signalling, adhesion as well as antigen-uptake 
molecule (Svajger et al., 2010). Given the extent of the known functions, it is very 
likely that DC-SIGN binds more, yet unknown endogenous glycan ligands and 




1.2.1.2 Dendritic cell-specific intercellular adhesion 
molecule 3-grabbing non-integrin 1-related protein 
(DC-SIGNR) 
Encoded adjacent to the DC-SIGN gene on the human chromosome 19p13, a very 
similar CLR receptor was identified and named Dendritic cell-specific intercellular 
adhesion molecule 3 [ICAM-3]-grabbing non-integrin 1-related protein (DC-SIGNR) 
(Soilleux et al., 2000). Since the DC-SIGNR receptor is mainly expressed on 
endothelial cells in the liver sinusoid, lymph nodes sinuses, and in capillary 
endothelial cells in term placenta, it is also referred to as L-SIGN (Liver/Lymph node-
specific ICAM-3 grabbing non-integrin) (Bashirova et al., 2001, Pohlmann et al., 2001). 
However, DC-SIGNR has not been found on dendritic cells or macrophages (Figdor 
et al., 2002). Furthermore, it has been assigned the cluster of differentiation name of 
CD299 and the CTLD family member name CLEC4M. 
DC-SIGN and DC-SIGNR share 73% identity within their nucleic acid sequence and 
even 77% identity of the primary protein structure. This results in a high level of 
homology in secondary and tertiary structure, i.e. both CLRs are type II 
transmembrane proteins with similar domains  (Soilleux et al., 2000). However, 
DC-SIGNR’s cytoplasmic domain only possesses a di-leucine motif and no strategic 
tyrosine motif. The transmembrane domain is followed by an extended neck domain 
that also facilitates tetramerisation via interactions of hydrophobic amino acid 
residues (Drickamer and Taylor, 2015). The research group around Kurt Drickamer 
showed that DC-SIGN and DC-SIGNR neck regions as well as CRDs differ 
considerably: DC-SIGNR presents a higher degree of neck length polymorphism, 
with potential for up to nine tandem repeats. The C-terminal CRD of DC-SIGNR also 
shows calcium-dependent mannose-binding specificity (Soilleux et al., 2000), but 
binds with comparatively very weak affinity to fucosylated glycan structures, such 
as Lewis antigens, compared with DC-SIGN (Mitchell et al., 2001, Guo et al., 2004, 
Feinberg et al., 2009).  
Past studies by Guo et al. showed that the CRD of DC-SIGN can release ligands in a 
pH sensitive manner (Guo et al., 2004). However, DC-SIGNR remained to be 
investigated in full for the ability to facilitate endocytic functions. In 2013, it was 




von Willebrand factor and influences its in vivo blood plasma levels. This suggest a 
potential role in von Willebrand factor bioavailability and clearance (Rydz et al., 
2013). Furthermore, recent studies using heteronuclear NMR spectroscopy showed 
that DC-SIGNR does indeed release glycan ligands at a pH of 4.2, which indicates a 
potential role as an endocytic receptor for the clearance of senescent glycoproteins 
(Probert et al., 2014).  
 
DC-SIGNR binds to endogenous ICAM-3, which suggested roles in cell adhesion and 
in immune responses and trafficking by interacting with resting T cells (Bashirova et 
al., 2001, Yabe et al., 2010). A study illuminating the interaction between DC-SIGNR 
and the respiratory syncytial virus (RSV) also revealed that DC-SIGNR is involved in 
cell signalling via phosphorylation of kinases within signalling cascades for 
activation of immune responses (Johnson et al., 2012). 
Furthermore, DC-SIGNR has been found to bind to mannose-containing ligands on 
pathogens including HIV, the severe acute respiratory syndrome coronavirus 
(SARS), the influenza virus, as well as the dengue virus (Chan et al., 2006, Boily-
Larouche et al., 2009, Dejnirattisai et al., 2011, Londrigan et al., 2011, Johnson et al., 
2012).  
DC-SIGNR also recognises glycan structures which are associated with cellular 
damage or cell death. These indicator molecules are referred to as damage-associated 
molecular patterns (DAMPs) (Neumann et al., 2014). 
Given the substantial number of mannose-rich biomolecules, neither the range nor 
extent of exogenous and endogenous ligands for DC-SIGNR is likely to have been 
fully described to date. The identification and characterisation of further ligands 
could therefore provide more insight into the mechanism of binding as well as the 






1.2.1.3 Macrophage Mannose Receptor (MMR) 
The macrophage mannose receptor (MMR), or macrophage C-type lectin (MCL), is 
another member of the C-type lectin superfamily and belongs to the CTL group VI, 
which are multi-CTLD endocytic receptors (see figure 1.1. on page 43). It has been 
assigned the cluster of differentiation number CD206 and the C-type lectin domain 
family 13 member D (CLEC13D). 
The MMR is a type I transmembrane CLR with multiple tandem extracellular 
domains (Martinez-Pomares, 2012). The N-terminal domain is a cysteine-rich (CR) 
domain that mainly recognises carbohydrates with terminal sulfated glycans, such as 
SO4-(3)-galactose or SO4-(3/4)-N-acetylgalactosamine (Fiete et al., 1998, Leteux et al., 
2000). Interestingly, this domain is an R-type CRD (Napper et al., 2006). The CR 
domain is followed by a domain “which resembles the type II repeats of fibronectin” 
(FNII) (Taylor et al., 1992). The FNII domain is involved in cellular interactions as 
well as recognition and internalisation of antigens such as collagen (Martinez-
Pomares et al., 2006, Napper et al., 2006). Following these domains, and less 
commonly amongst the CLRs, the MMR contains a series of eight C-type CRDs in 
tandem within a single polypeptide that has been shown to increase avidity to 
overcome the weak affinity of single CRDs (Taylor et al., 1990, Taylor and Drickamer, 
1993). CRDs 1-3 contribute only weakly to carbohydrate binding, CRD 4-5 together 
have a high affinity in the low nanomolar range for binding mannose/ 
fucose/GlcNAc-containing glycans, and CRDs 6-8 contribute to ligand-binding 
(Taylor et al., 1992, Taylor and Drickamer, 1993). The CRDs recognise mainly high 
mannose oligosaccharides, but recognition of antigens with single mannose moieties 
is evident as well, in addition to glycans with terminal fucose and N-acetyl-
glucosamine residues (Taylor et al., 2015). The MMR is anchored via a 
transmembrane domain. Interestingly, the MMR can also undergo proteolytic 
cleavage from its transmembrane region, which results in the release of a soluble form 
(Jordens et al., 1999). 
Figure 1.5 depicts the variety of exogenous ligands, such as viruses, fungi and 





MMR has been extensively studied in immature monocyte-derived DCs and 
macrophages, where it is abundantly expressed (Sallusto et al., 1995). Furthermore, it 
can be found on nonvascular endothelium, e.g. liver sinusoidal endothelial cells 
(LSECs) (Malovic et al., 2007). 
The MMR is a multifunctional receptor: It mediates the “clearance of many 
potentially antigenic proteins from the circulation” (Figdor et al., 2002); it is a defence 
mechanism against microorganisms and capable of driving their endocytosis directly 
(Lee and Lee, 2000). The receptor is involved in antigen uptake and processing within 
adaptive immune responses (Sallusto et al., 1995, Weis et al., 1998). Collagen is 
released on sites of inflammation and since MMR’s characteristic is to adhere to 
collagen, a role in augmenting immune responses has been proposed (Napper et al., 
2006). Overall, the macrophage mannose receptor has been considered to provide a 































Figure 1.5:  Structural properties of MMR. MMR is a type I membrane molecule with three 
types of extracellular domains. Through the CR domain, MR binds sulfated glycans that can 
be found in lymphoid tissues and kidney, as well as the major cat allergen Fel d 1 and lutropin. 
The FNII domain binds collagens, and the CTLDs bind endogenous and exogenous molecules, 
including allergens and microbial products.  
Abbreviations: MΦ - macrophage; HBV - hepatitis B virus; CPS - capsular polysaccharide; 
SEA - secreted egg antigen; Adam-13 - a disintegrin and metalloprotease 13  





 Thesis Aims 
Affinity chromatography using DC-SIGN immobilised on Sepharose resin, was used 
to screen for potential ligands from a solubilised placental extract in a prior research 
project (Ilyas, 2010).  
Preliminary analysis of material selectively eluted from DC-SIGN-Sepharose 
(referenced against non-specific column binding on non-immune IgG-Sepharose) 
suggested PAPP-A1 (pregnancy-associated plasma protein A1) as a potential 
DC-SIGN ligand (figure 1.6). The identity of PAPP-A1 was determined via peptide 
mass spectrometry of bands excised from the SDS-PAGE gel and also validated via 
Western blotting.  
Bioinformatic analysis revealed that the PAPP-A1 polypeptide chain possesses 14 
potential N-glycosylation sites and is likely to be secreted. In its native form, 
PAPP-A1 is found most commonly in the plasma of pregnant women as a secreted 
2:2 heterotetrameric complex with the proform of eosinophil major basic protein (pro-
MBP). The level of potential N-glycosylation in this complex makes the PAPP-
A1/pro-MBP complex an attractive candidate as a soluble, natural ligand for 
DC-SIGN. 
 
When this discovery was made in 2010, techniques were not available to measure 
reliably the interaction kinetics with native glycoproteins that are only available as 
purified reagents in low amounts (typically microgram quantities). The same was the 
case for comprehensive glycan analysis of scarce, native human glycoproteins. 
 However, with the development of highly sensitive and sample-efficient analytical 












Figure 1.6: Placental ligands eluted from DC-SIGN-Sepharose. IgG-Sepharose was used as 
negative control. DC-SIGN-exclusive bands are visible in the late elution fractions (arrows) 
and represent good candidate ligands. Figure and caption have been adapted and altered with 



























  Materials for interaction studies 
2.1.1 Chemical reagents 




2-Mercaptoethanol 161-0710 Bio-Rad Laboratories Ltd., 
UK 
Ampicillin sodium salt A9518 Sigma-Aldrich Company 
Ltd., UK 
Bovine serum albumin A2153 Sigma-Aldrich Company 
Ltd., UK 
Calcium chloride dihydrate 31307 Sigma-Aldrich Company 
Ltd., UK 
D-(-)-Fructose F0127 Sigma-Aldrich Company 
Ltd., UK 
D-(+)-Galactose G0625 Sigma-Aldrich Company 
Ltd., UK 
D(+)-Glucose Anhydrous G/0500/53 Fisher Scientific, Thermo 
Fisher Scientific, UK 
D-(+)-Mannose M2069 Sigma-Aldrich Company 
Ltd., UK 
DL-Dithiothreiol (DTT) D0632 Sigma-Aldrich Company 
Ltd., UK 













21335 Thermo Scientific, Thermo 
Fisher Scientific, UK 
Glycerol 99 % 158920010 Acros Organics, Thermo 
Fisher Scientific, UK 
Glycine G/0800/60 Fluka Honeywell, 
Honeywell Specialty 
Chemicals Seelze GmbH, 
Germany 
Glycogen from bovine liver, Type IX G0885 Sigma-Aldrich Company 
Ltd., UK 
Guanidine-HCl G3272 Sigma-Aldrich Company 
Ltd., UK 
HEPES sodium 215001000 Acros Organics, Thermo 









HEPES H4034 Sigma-Aldrich 
Company Ltd., UK 
Isopropyl β-D-thiogalactoside (IPTG) I6758 Sigma-Aldrich 
Company Ltd., UK 
Lysogeny broth (LB) L3022 Sigma-Aldrich 
Company Ltd., UK 
Lysozyme 62971 Sigma-Aldrich 
Company Ltd., UK 
Magnesium chloride M/0600/53 Fisher Scientific, Thermo 





Company Ltd., UK 
N-Hydroxysuccinimide (NHS) 130672 Sigma-Aldrich 
Company Ltd., UK 
Sodium Chloride S5886 Sigma-Aldrich 
Company Ltd., UK 
Sodium deoxycholate D6750 Sigma-Aldrich 
Company Ltd., UK 
Sodium hydroxide S8045 Sigma-Aldrich 
Company Ltd., UK 
TEMED T-9281 Sigma-Aldrich 
Company Ltd., UK 
Tris(hydroxymethyl)aminomethane 
(TRIS) 
BP152-1 Fisher Scientific, Thermo 
Fisher Scientific, UK 
Triton X-100 X100 Sigma-Aldrich 
Company Ltd., UK 
Tween-20 P1379 Sigma-Aldrich 
Company Ltd., UK 
Urea ZU10001 Invitrogen, Thermo 
Fisher Scientific, UK 
2.1.2 Materials and reagents 
Table 2: Materials, consumables and other reagents  
Reagent/Material/Consumable Product Code/ size Manufacturer 
1-Step Ultra TMB-Blotting Solution 37574 Thermo Scientific, 
Thermo Fisher 
Scientific, UK 
Biosensor, Amine Reactive Second 
Generation (AR2G) 
18-5092 Pall ForteBio 
Europe, UK 
Biosensor, Streptavidin (SA) 18-5019 Pall ForteBio 
Europe, UK 






Table 2: Materials, consumables and other reagents (continued) 
Reagent/Material/Consumable Product Code/ size Manufacturer 
Dialysis Device, Slide-A-Lyzer 
MINI, 10K MWCO, 0.1 mL 
69570 Thermo Scientific, 
Thermo Fisher 
Scientific, UK 
Dialysis Device, Slide-A-Lyzer 
MINI, 3.5K MWCO, 0.5 mL 
88400 Thermo Scientific, 
Thermo Fisher 
Scientific, UK 










Eppendorf reaction tubes 0.5/1.5 mL various 
Halt Protease and Phosphatase 
Inhibitor Cocktail (100X) 
78440 Thermo Scientific, 
Thermo Fisher 
Scientific, UK 
InstantBlue Protein Stain ISB1L Expedeon Ltd., UK 
Membrane filter Durapore, pore 
size 0.45 µm 
HVLP04700 Millipore (U.K.) 
Ltd., UK 
NuPAGE Novex 10% Bis-Tris Midi 
Protein Gels, 26 well 
WG1203BOX Invitrogen, Thermo 
Fisher Scientific, 
UK 
Needles, single use 
 
orange 25G ×  5⁄8″ 
(0.5 × 16 
mm)  
Becton, Dickinson 
U.K. Limited, UK 
blue 23G ×  1″  
(0.6 × 25 
mm) 
Becton, Dickinson 
U.K. Limited, UK 
green 21G ×  1 1⁄2″  
(0.8 × 40 
mm) 
Becton, Dickinson 
U.K. Limited, UK 






Precast Gels, SDS 12 Well 10x10, 
SDS-PAGE 
NXG41212K Expedeon Ltd., UK 
Proteoloc Protease Inhibitor 
Cocktail 
44202 Expedeon Ltd., UK 
ProteOn 1 M Ethanolamine HCl  1762450 Bio-Rad 
Laboratories Ltd., 
UK 
ProteOn EDAC 10004488 Bio-Rad 
Laboratories Ltd., 
UK 






Table 2: Materials, consumables and other reagents (continued) 
Reagent/Material/Consumable Product Code/ size Manufacturer 
RunBlue LDS Sample Buffer 4X  NXB31010 Expedeon Ltd., UK 
RunBlue Tris Glycine SDS Run 
Buffer 
NXB82500 Expedeon Ltd., UK 
Sepharose 6B, bead-formed 
agarose-based gel filtration matrix 
17011001 GE Life Sciences, 
GE Medical 
Systems Ltd, UK 
Serological pipettes  5/10/25 mL Greiner Bio-One 
Ltd., UK 
Syringe 1/2/10/50 mL Becton, Dickinson 
U.K. Limited, UK 
Syringe filter Minisart, pore size 0.2 
μm 
16534 Sartorius UK Ltd., 
UK 
2.1.3 Buffers and solutions 
All buffers and solutions are prepared in double distilled, filtered water (ddH2O). 
 
Column Washing Buffer  pH 7.4 
10 mM HEPES, 150 mM NaCl, 5 mM CaCl2 
 
Column Eluting Buffer pH 7.4 
10 mM HEPES, 150 mM NaCl, 5 mM EDTA 
 
Dialysis Buffer 
25 mM TRIS, 1.25 M NaCl 
 
EDTA stock solution pH 8.0 
0.5 M EDTA 
 
EGTA stock solution pH 8.0 





Loading Buffer pH 8.0 
25 mM TRIS, 1.25 M NaCl, 25 mM CaCl2 
 
Lysis Buffer pH 8.0 
25 mM TRIS, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 0.5 mg/mL lysozyme 
 
Lysogeny broth medium 
20 g Lysogeny broth medium (Sigma-Aldrich) in 1 L double distilled water, 
autoclaved 
 
Magnesium chloride stock solution 
1 M MgCl2 
 
Resolubilisation/Guanidine Denaturing Buffer  pH 7.8 
6 M Guanidine-HCl, 100 mM TRIS, 0.01% 2-Mercaptoethanol (freshly added) 
 
Resuspension Buffer 1  pH 8.0 
25 mM TRIS, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 
 
Resuspension Buffer 2 pH 8.0 
25 mM TRIS, 500 mM NaCl, 1 M Urea, 1 g/L Sodium Deoxycholate 
 
Sample Buffer, reducing 





Sodium chloride stock solution 
1 M NaCl 
 
Sodium hydroxide solution 
1M NaOH 
 
TRIS buffer pH 8.0 
50 mM TRIS 
 
TRIS stock solutions 
1 M TRIS pH 8.0 
50 mM TRIS pH 8.0 
 
TRIS buffered saline (TBS) pH 8.0 
10 mM TRIS, 150 mM NaCl 
 
TRIS buffered saline with Tween-20 (TBST) 





2.1.4 Commercial proteins and glycoproteins 
for interaction studies 
The (glyco)proteins of interest were purchased from commercial sources as stated 
below. 
Table 3: Commercial proteins and glycoproteins used in interaction studies 









• Alternative names: 
Bone Marrow 
Proteoglycan, (BMPG), 
Proteoglycan 2 (PRG2), 
Eosinophil Granule 
Major Basic Protein 
(MBP or EMBP), 
Pregnancy-Associated 
Major Basic Protein 
• Species: human 


























• Species: human 
• Sequence: aa 82-1214 
• Source species: Mouse 
myeloma cell line, 
NS0-derived 
• Carrier-free 













Table 3: Commercial proteins and glycoproteins used in interaction studies (continued) 








form (htPAPP-A),  
native,  
human 
• consisting of PAPP-A1 
and pro-MBP subunits 
(2:2 PAPP-A1/proMBP 
complex) 
• Sequence: human, 
• Source species: human 
• purified from pooled 
human retro-placental 
blood  
• material was tested 
and found negative for 
HBsAg, HCV, HIV-1 











• Alternative names: 
Macrophage Mannose 




Receptor C type 1 
(MRC1),  CLEC13D 
(C-type lectin domain 
family 13, member D 
• Species: human 
• Source species: Mouse 




















2.1.5 Plasmids for recombinant protein 
expression 
The generation of soluble, recombinant 
lectin proteins (see Table 4) was carried 
out in the Escherichia coli strain BL21 
DE3, which expresses the T7 RNA 
polymerase. 
The plasmids used for transformation 
of the bacteria were either the 
established pT5T vectors from the 
Mitchell lab (Eisenberg et al., 1990, 
Mitchell et al., 2001) (see Figure 2.1), or 
novel plasmids produced by the 
Protein Expression Laboratory 
(PROTEX) at the University of 
Leicester. 
 
For generation of the novel bacterial 
expression vectors, the construct 
pLEICS-05 (see figure 2.2) was used, 
which is a member of the in-house 
vector family B and carries a resistance 
cassette for ampicillin as the antibiotic 
selection marker. Furthermore, the 
vector includes the Lac I operon which 
is required for an IPTG-induced 
expression of the protein of interest.  
The affinity chromatography, described in section 2.3.3.1, served as purification step 
as well as functionality test for the expressed lectin proteins. 
Table 4: Recombinant lectin proteins expressed in transformed E. coli via the pLEICS-05 
vector construct 
Plasmid Recombinant lectin Encoded structures Antibiotic resistance 
DC020 DC-SIGN Extracellular domain Ampicillin 
DSR034 DC-SIGNR Extracellular domain Ampicillin 
Figure 2.2: pLEICS-05 vector, family B (N-terminal 
genetic sequence AGGAGATATACATATG...;  
C-terminal genetic sequence GAAGTACAGG-
TTCTCTCA...), provided by Protein Expression 
Laboratory (PROTEX), University of Leicester 
Figure 2.1: vector pT5T (adapted and altered 




  Instruments and software for interaction 
studies 
2.2.1 Instruments  
Table 5: Laboratory apparatus and instruments 
Instrument Manufacturer 
Balance CS200 OHAUS Europe GmbH, Switzerland 
Balance PF-6001 Fisherbrand, Fisher Scientific, Thermo 
Fisher Scientific, UK 
Balance PS-100 Fisherbrand, Fisher Scientific, Thermo 
Fisher Scientific, UK 
BioLogic DuoFlow chromatography 
system, Fast protein liquid 
chromatography (FPLC) including 
BioLogic Maximizer, BioLogic 
QuadTec UV-Vis Detector, BioLogic 
BioFrac Fraction Collector 
Bio-Rad Laboratories Ltd., UK 
Bio-Silect SEC 250-5 Column Bio-Rad Laboratories Ltd., UK 
Block Heater, QBT4, Digital Grant Instruments, UK 
Centrifuge Micro Centaur MSE (UK) Ltd, UK 
Centrifuge Sorvall Evolution RC Thermo Scientific, Thermo Fisher 
Scientific, UK 
Centrifuge Sorvall Legend RT Thermo Scientific, Thermo Fisher 
Scientific, UK 
ChemiGenius2 Bio Imaging System Syngene, Synoptics Ltd, UK 
Incubator-shaker CERTOMAT BS-1  Sartorius Stedim UK Ltd., UK 
NanoDrop ND-1000 UV-Vis Spectro-
photometer 
NanoDrop, Thermo Fisher Scientific, 
UK 
pH meter electrode, Orion ROSS Ultra 
pH/ATC Triode 
Thermo Scientific, Thermo Fisher 
Scientific, UK 
pH meter, ORION STAR A211 Thermo Scientific, Thermo Fisher 
Scientific, UK 
Pipet aid, PIPETBOY acu INTEGRA Biosciences Ltd, UK 
Pipettes, FINNPIPETTE 1-10/10-100/ 
30-300/100-1000 μL 
Thermo Scientific, Thermo Fisher 
Scientific, UK 
Power supply, PowerEase 500 Invitrogen, Thermo Fisher Scientific, 
UK 
Quartz cuvettes, Spectrosil Precision 
Cells (FAR UV Spectral Range) 
Thermal Syndicate Ltd., UK 
Roll mixer, Spiramix 5, MPR-455-020F/ 
DS507V  
Thermo Scientific/Denley, Thermo 
Fisher Scientific, UK 
Rotor for Sorvall Evolution RC, 
Aluminium Fixed Angle, SS-34  
Thermo Scientific, Thermo Fisher 
Scientific, UK 
Shake mixer, orbital shaker SSL1 Stuart, Cole-Parmer, UK 




Table 5: Laboratory apparatus and instruments (continued) 
Instrument Manufacturer 
Spectrophotometer 6505 UV/Vis  Jenway, Cole-Parmer, UK 
Stirrer CB161 Stuart, Cole-Parmer, UK 
Superose 12 FPLC, 17-5173-01  GE Life Sciences, GE Medical Systems 
Ltd, UK 
Superose 6 FPLC, 17-5172-01  GE Life Sciences, GE Medical Systems 
Ltd, UK 
Super-Q Plus water purification 
system with carbon filter, ion 
exchange and pore size filter 
Durapore 0.2 μm 
Millipore (U.K.) Ltd., UK 
UNO Q1 Column, #720-0001 Bio-Rad Laboratories Ltd., UK 
Vortex mixer, VX100 Labnet MO BIO Laboratories, Inc 
Vortex-Genie 2 Scientific Industries, Inc., USA 
XCell SureLock Mini-Cell Invitrogen, Thermo Fisher Scientific, 
UK 
XCell4 SureLock Midi-Cell Invitrogen, Thermo Fisher Scientific, 
UK 
 
Surface plasmon resonance (SPR) technique was performed with the ProteOn XPR36 
Protein Interaction Array System (Bio-Rad Laboratories Ltd, UK). The instrument 
provides real-time label-free analysis of the specificity, affinity and kinetics of 
biomolecular interactions. The sensor chips provide six channels for ligand binding 
as well as perpendicular analyte flow-through that enables a simultaneous analysis 
of up to 36 interactions. 
Bio-layer interferometry (BLI) was performed using the Octet RED96 instrument (Pall 
ForteBio Europe, UK), which provided the opportunity to run experiments with up 
to eight sensors simultaneously, via state-of-the-art dip-and-read protocol. Kinetic 
parameters and affinity analysis can be measured through a sequence of 
time-resolved analyte contact and subsequent wash steps. 
2.2.2 Software 
The ProteOn XPR36 System used the ProteOn Manager Software (Bio-Rad 





The Octet RED 96 instrument obtained data with the Data Acquisition Software 
(version 9.0.0.49) and data analysis was performed using the Data Analysis Software 
(version 9.0.0.14), from Pall ForteBio Europe, respectively. 
The ChemiGenius2 Bio Imaging System (Syngene, Synoptics Ltd, UK) used the 
GeneSnap 6.08.04 Software as well as GeneTools 4.00.00 Software for acquisition of 
gel pictures and analysis of data. 
The BioLogic DuoFlow chromatography System (Bio-Rad Laboratories Ltd., UK) was 
controlled with the BioLogic DuoFlow Version 5.10 Build 2 software. 
Software used for further data analysis and interpretation were OriginPro 2018b 
(OriginLab Corporation) as well as the Office 365 programmes (Microsoft). 
Furthermore, EndNote X9 (Clarivate Analytics) was used for management of 
literature references. 
  Methods for interaction studies 
2.3.1 Generation of transfected E. coli 
cultures 
The generation of novel transformed E. coli was carried out in the laboratories of the 
collaborating research group of Prof Russell Wallis (University of Leicester, United 
Kingdom) following the procedure described by Furze (2013): 
Prior to the transformation, cells of the E. coli strain BL21 DE3 were treated with 
calcium chloride to induce competence. The cells were grown in Lysogeny Broth (LB) 
medium to an OD590 between 0.6-0.8, decanted, and subsequently cooled on ice for 
10 min, followed by centrifugation at 3500 rpm, 4°C for 10 minutes. The supernatant 
was discarded, and the pellet resuspended in 2.5 ml of ice cold 0.1 M CaCl2 solution. 
The cells were incubated for 20 minutes (on ice) and centrifuged at 3500 rpm, 4°C for 
10 minutes. The pellet was resuspended in 5 ml of ice cold 0.1 M CaCl2 with 15% 
glycerol (v/v) and 100 μL aliquots prepared. The aliquots were frozen on dry-ice and 




The frozen cell aliquots were thawed on ice, and transformed with the plasmid of 
interest (see section 2.1.5) by adding 2 µL of ligation reaction to each tube. A heat-
shock at 42ºC was applied for 60-90 s and the tubes incubated on ice for 15 min. To 
each tube, 300 µL of LB medium was added and the cultures incubated for 60-90 min 
at 37 ºC whilst shaking until the culture reached an OD590=0.6. 150 µL of the cell 
suspension was plated onto ampicillin agar plates via the streak plate method. The 
plates were incubated at 37 ºC overnight and stored at 4 ºC afterwards. 
2.3.2 Generation and extraction of soluble 
lectins in the bacterial expression system 
E. coli 
2.3.2.1 Generation of pre-cultures 
The pre-cultures were set up by picking a single colony from the agar plate that 
contained ampicillin as selection factor. The colony was diluted in approximately 
5 mL LB medium (containing 50 µg/mL ampicillin) in a 15 mL falcon tube and was 
incubated in the shaking incubator (150 rpm) for 3-4 hours at 37 °C. When the pre-
culture reached an OD590=0.8, glycerol was added to a final concentration of 15% 
(v/v) and the suspension was mixed thoroughly. The pre-cultures were frozen and 
stored at -80 ºC. 
2.3.2.2 Lysogeny Broth (LB) medium expression  
Starter cultures were set up from the pre-culture by inoculating 200 mL LB medium 
(containing 50 µg/mL ampicillin as final concentration) with a small piece of the 
frozen pre-culture. The starter cultures were grown over night (approximately 15 h) 
in the incubator-shaker at 200 rpm and 37 °C. 
The main cultures were set up by inoculating two 2 L Erlenmeyer baffle flasks with 
50 mL starter culture each. Both Erlenmeyer flasks contained 1 L LB medium and 
50 µg/mL freshly added antibiotic. The main cultures of the transfected E. coli were 
grown at 37 °C in the shaking incubator (200 rpm) until they reached an absorbance 




β-D-1-thiogalacto-pyranoside (IPTG, final concentration 100 µg/L) and the main 
cultures were incubated for another 150 min at 37 °C with shaking. 
The bacteria were harvested by centrifugation at 3,440 x g for 30 min at 4 °C. The cells 
were washed in 40 mL Washing Buffer pH 8.0 and centrifuged again. The pellet was 
either processed immediately or frozen at -20 ºC. 
2.3.2.3 Extraction and purification of recombinant 
proteins 
Either the fresh or thawed pellet was resuspended in approximately 25 mL Lysis 
buffer pH 8.0. After 20 min of incubation at room temperature, 5 mM MgCl2 and 
4 µL of DNAse I (277.3 U/µL) were added to the lysing cell suspension and incubated 
for 15 min at room temperature during shaking. Finally, the cells were completely 
lysed by sonication (10 bursts of 30 s duration each, approximately 70 W) with breaks 
for chilling. The suspension was treated with protease inhibitors and centrifuged at 
20,000 x g for 20 min at 4 ºC (applicable to all following centrifugation steps if not 
stated otherwise). The pellet containing the inclusion bodies was purified by 
resuspension with 40 mL Resuspension Buffer 1 pH 8.0, followed by a centrifugation 
step. For further refinement, the pellet was resuspended in 40 mL Resuspension 
Buffer 2 pH 8.0 and the suspension was centrifuged. The last purification step of the 
pellet containing the inclusion bodies was carried out by a wash with 50 mM TRIS 
buffer pH 8.0. The suspension was centrifuged to obtain a smooth, consistent pellet 
with inclusion bodies containing the protein of interest.  
After discarding the supernatant, the inclusion bodies were solubilised in 15 mL 
6 M Guanidine Denaturing Buffer pH 7.8 per litre of harvested medium at the 
beginning of the extraction. The mixture was gently rotated for 60 min at 4 °C, 
sonicated on ice for 30 sec, and 0.01% 2-mercaptoethanol added. The mixture was 
incubated at 4 °C on the roller shaker. After 30 min, the suspension was centrifuged 
at 50,000 x g for 40 min at 4 °C.  
The supernatant was added drop-wise at 4 °C, through a 23-gauge needle into 
Loading Buffer to treble the volume whilst stirring. The diluted protein mixture was 
dialysed (11-14 kDa MW cut-off) against 10 volumes of Dialysis Buffer with a 




removed by centrifugation at 50,000 x g for 30 min at 4 °C. Protease inhibitor cocktail 
was added to the supernatant, which contained the refolded protein of interest, and 
was carefully transferred into a new vial. 
2.3.3 Purification of lectins by chromato-
graphy 
2.3.3.1 Affinity chromatography 
Purification of the soluble recombinant C-type lectin receptors DC-SIGN and 
DC-SIGNR was performed by affinity chromatography (Axen et al., 1967). Given the 
affinity for carbohydrates of the carbohydrate recognition domain of the receptors, 
the purification was carried out using sugar-derivatised resins, specifically mannose-
derivatised Sepharose 6B matrix. The mannose-Sepharose matrix was kindly 
provided by Prof Russell Wallis, University of Leicester. 
Prior to further purification steps, CaCl2 was added up to a final concentration of 
25 mM to the protein solution, since the proteins of interest were C-type lectins (see 
Figure 2.3: Representative SDS-PAGE gel after DC-SIGN purification via mannose-
Sepharose affinity chromatography. The arrow shows the molecular weight that is expected 

























































































section ‘2.3.2.3 Extraction and purification of recombinant proteins’). Eight millilitres 
of mannose-Sepharose matrix were equilibrated with Column Washing Buffer, 
added to the protein solution (approximately 180 mL; derived from 2 L culture 
medium) and gently stirred at 4 °C overnight. The mannose-Sepharose matrix was 
loaded onto a disposable gravity column, washed initially with 10 mL Column 
Washing Buffer, followed by 5 fractions of 1 mL Column Washing Buffer, and eluted 
with Column Eluting Buffer (containing EDTA) in 0.5-1 mL fractions. The absorbance 
of the fractions at 280 nm was detected via spectrophotometry using either a quartz 
cuvette or the NanoDrop method. 
The fractions were further analysed by SDS polyacrylamide gel electrophoresis (SDS 
PAGE) under denaturing and reducing conditions. A representative gel of the 
fractions is shown in figure 2.3. 
2.3.3.2 Ion exchange chromatography and size exclusion 
Chromatography 
Soluble recombinant lectins were purified via fast protein liquid chromatography 
(FPLC). 
Size exclusion chromatography (SEC) was performed using either a GE Healthcare 
Superose 12 FPLC column or a Bio-Rad Bio-Silect SEC 250-5 column (flow rate 
0.5 mL/min, fraction size 1 mL, buffer 10 mM TRIS 5 mM EDTA pH 7.8); where a 
0.5 mL protein sample was applied to the column in isocratic flow mode within the 
BioLogic DuoFlow chromatography system.  
After analysis of the obtained fractions via SDS PAGE gel, the pooled protein solution 
was loaded onto a Bio-Rad UNO Q anion-exchange column and run at a flow rate of 
1 mL/min (fraction size 1 mL). The column was eluted using a 0 mM-500 mM NaCl 
gradient (buffer A 10 mM TRIS pH 7.8; buffer B 10 mM TRIS 1 M NaCl pH 7.8) over 
20 column volumes.  
2.3.4 Biotinylation of proteins 
Sulfo-N-hydroxysuccinimide (sNHS) biotin solution was prepared as a 10 mM 




The 10 mM biotin solution was added in a 5:1 molar ratio of biotin:protein to the 
protein solution (concentration range 0.3-3 mg/mL; buffer 10 mM HEPES, 150 mM 
NaCl) to start the biotinylation reaction. 
The mixture was incubated on ice for 2 hrs and the reaction was stopped by adding 
1 M ethanolamine pH 8.0 up to a final concentration of 100 mM. The biotinylated 
protein was subsequently desalted via overnight dialysis.  
The recovered samples were stored at 4 ºC and used for SPR experiments with NLC 
sensor chips (Neutravidin chips) or BLI experiments with SA (streptavidin) 
biosensors. 
2.3.5 Surface Plasmon Resonance (SPR)  
The technique of Surface Plasmon Resonance (SPR) is an optical method to detect 
changes of the refractive index of incident light on the surface of a sensor in relation 
to changes in mass in real time. In particular, the ligand is immobilized on the surface 
of the sensor and the analyte flows through the cell over the ligand. In the event of 
an interaction between the ligand and the analyte, a change of the mass on the surface 
occurs which shifts the refractive index. The difference between the sensorgrams of 
the refractive index over time is measured as response units (RU) (Lottspeich, 2006). 
The SPR technique provides real-time, partially label-free analysis of the specificity, 
affinity and kinetics of biomolecular interactions. The sensor chips have 6 channels 
for ligand binding as well as perpendicular analyte flow-through that enables a 
simultaneous analysis of up to 36 interactions. 
Recombinant soluble lectins were immobilised as ligands on sensor chips and 
purified native human glycoproteins, synthetic glycopolymers or other potential 
interaction partners served as analytes in the solution phase. Depending on the set-up 
of the experiment, a blank channel for monitoring of system drifts as well as a channel 
with a negative control for non-specific binding were included. The polymers were 




2.3.5.1 GLM chip 
The GLM sensor chip is an amine-coupling based chip which can be activated by 
reagents such as EDAC and sulfo-NHS to react specifically with free surface amines 
of proteins. The deactivation step is achieved using 1 M ethanolamine pH 8.0. After 
the activation of the surface, the amount of the injected ligand controls the density of 
ligand on the surface. The GLM chip has thickened surface layer of coupling matrix 
with a medium capacity (~12 kRU) and is ideal for probing both, protein-protein as 
well as protein-small molecule interactions. 
2.3.5.2 NLC chip 
The NLC sensor chip is designed for site-specific capturing of biotinylated targets via 
NeutrAvidin molecules which is a low nonspecific-binding streptavidin derivative. 
The chip is used for capturing biotinylated proteins or peptides and has the capacity 
to capture ~2 kRU of ligand. The NLC sensor chip is ideal for immobilizing ligands 
without amine-coupling but requires a modification of the ligand with biotin prior to 
immobilisation (see section 2.3.6). 
2.3.6 Biolayer-Interferometry (BLI)  
Bio-Layer Interferometry (BLI) is an optical analytical method, which is closely 
related to the SPR technique (see section ‘2.3.5 Surface Plasmon Resonance (SPR)’). It 
provides complementary data to the SPR approach since it is used to perform real-
time interaction studies with a high sensitivity for biomolecular interactions. 
The underlying physical phenomenon is the interference pattern of white light 
caused by reflection from a biosensor-internal surface (λ1) and the tip of the biosensor 
with the immobilised macromolecule of interest (λ2). The interaction between the 
immobilised ligand and the analyte during association results in a shift of the 
wavelength λ2. The resulting change in the interference pattern Δλ reveals 
information about the putative interaction between ligand and analyte (see figure 2.4 
adapted from ForteBio Molecular Devices (2019a)). Furthermore, kinetic screenings 
via different concentrations of the analyte of interest can be performed and the 






The instrument used for the BLI experiments was the Octet RED96 system (Pall 
ForteBio Europe, UK), which allows for real-time analysis of the specificity, affinity 
and kinetics of biomolecular interactions. Access to the instrument was kindly 
provided by Prof Matthew Gibson, Department of Chemistry, University of 
Warwick. 
Either the soluble lectins or the glycoproteins of interest were immobilised on 
biosensor probes from Pall ForteBio Europe. Two types of “Dip and Read” biosensors 
were used for the experiments: Streptavidin biosensors or amine-coupling 
biosensors.  
 
Biosensors were hydrated in assay buffer (10 mM HEPES pH 7.4, 150 mM NaCl) for 
10 minutes prior to the experiment, which included loading of the ligand of interest, 
setting the baseline, as well as association phase and dissociation phase of the analyte 
of interest, respectively.   
Depending on the set-up of the experiment, a sensor with immobilised ligand but 
without analyte in the association phase (reference well) for monitoring of a system 
drift as well as a sensor with a negative control for non-specific binding were 
Figure 2.4: Scheme of the BLI technology, which measures a change of the reflected light’s 





included. All glycoproteins were categorised as ‘heterogeneous analyte’ for the 
kinetic fitting model.  
2.3.6.1  Streptavidin (SA) sensors 
The streptavidin (SA) biosensors (Pall ForteBio, UK) make use of the high affinity 
interaction between streptavidin and biotin for immobilisation of the 
biomacromolecule of interest on the tip of the biosensor. The sensor tip comes pre-
coated with streptavidin and the biomacromolecule of interest is modified with an 
attachment of biotin units, referred to as biotinylation (see section ‘2.3.4. Biotinylation 
of Proteins’).  
After pre-hydration of the sensors in assay buffer for 10 minutes, the biosensor was 
dipped into the solution containing the biotinylated ligand for 120 s. The interaction 
between biotin and streptavidin is considered one of the strongest non-covalent 
interactions with a dissociation constant KD between 10−16 and 10-14 M (Laitinen et al., 
2006). However, any non-specifically bound molecule was removed through a 
washing step of 60 s. 
The high affinity interaction between biotin and streptavidin, which immobilises the 
ligand on the tip of the biosensor, provides a stable baseline for interaction 
experiments including kinetic analyses with the analytes of interest.  
2.3.6.2 Amine-coupling (AR2G) sensors 
The Amine Reactive 2nd Generation (AR2G) biosensor type (Pall ForteBio Europe, 
UK) is an amine-coupling sensor, which requires activation of the surface via reagents 
such as EDC and sulfo-NHS to react specifically with free surface amines of 
biomacromolecules, especially proteins.  
After pre-hydration of the sensors in assay buffer for at least 10 minutes and 
activation of the biosensor surface, the tip was dipped into the solution containing 
the ligand of interest for 120 s. The pH of the buffer used during immobilisation 
significantly influences the amount of protein binding to the biosensor surface. 
Therefore, a pH range was tested prior to the experiment. The pH can also affect the 




was chosen that facilitated a good binding response but did not influence the 
functionality of the immobilised ligand. 
 The deactivation of the surface was achieved by using 0.1 M ethanolamine at pH 8.0, 
also referred to as quenching.  
The covalent binding between the biosensor tip and amines present in the protein of 
interest provides a stable baseline for interaction experiments and allows for kinetic 
analyses of the analytes of interest.  
Figure 2.5: Schematic overview of the process for covalent immobilisation of the ligand of 
interest on AR2G biosensors as well as representation of the association and dissociation phase 





  Materials for mass spectrometry 
2.4.1 Chemical reagents 




2,5-Dihydroxybenzoic acid 149357 Sigma-Aldrich Corp., 
USA 
Acetic acid 338826 Sigma-Aldrich Corp., 
USA 
Acetone 650501-M Sigma-Aldrich Corp., 
USA 
Acetonitrile 34998-M Sigma-Aldrich Corp., 
USA 
Ammonium bicarbonate 40867 Honeywell Fluka, 
Honeywell International, 
Inc., USA 
Chymotrypsin, Sequencing Grade V1061 Promega Corp., USA 
Dichloromethane 650463 Sigma-Aldrich Corp., 
USA 
Dimethyl sulfoxide (DMSO) 34869 Sigma-Aldrich Corp., 
USA 
DL-Dithiothreitol 43815 Sigma-Aldrich Corp., 
USA 
Formic acid 56302 Honeywell Fluka, 
Honeywell International, 
Inc., USA 
Iodoacetamide I1149 Sigma-Aldrich Corp., 
USA 
Iodomethane I8507 Sigma-Aldrich Corp., 
USA 
Isopropanol, 2-Propanol 650447 Sigma-Aldrich Corp., 
USA 
Methanol 900688 Sigma-Aldrich Corp., 
USA 
Nitrogen, Ultra High Purity 5.0 Grade NI 
UHP300 
- 
PNGase F, glycerol-free, 500,000 
units/ml, 
size 75,000 units 
P0705L New England Biolabs, 
Inc., USA 
Sodium borohydride 213462 Sigma-Aldrich Corp., 
USA 
Sodium Hydroxide, 50%(w/w) solution 3727-01 J.T.Baker, Avantor, Inc., 
USA 




2.4.2 Material and reagents 
Table 7: Material, consumables and other reagents  
Reagent/Material/Consumable Product Code Manufacturer 
AG 50W-X8 Cation Exchange Resin 
(DOWEX), analytical grade, 100–








C18 SPE Cartridges, 1 mL, 100 mg 26030 Restek 
Corporation, 
USA 
Calibrated Micropipettes, 1-5 μL 2-000-001 Drummond 
Scientific 
Delicate Task Wipers, Premium 1 
ply small 
07-301- 005 Fisherbrand, 
Fisher Scientific 
Co. L.L.C., USA 
Disposable Borosilicate Glass 





Co. L.L.C., USA 
Freeze dry glassware, Complete 
Fast-Freeze Flask  
Various sizes Labconco 
Corporation, 
USA 
Hamilton GASTIGHT 1700 series 
syringe, volume 25 μL/500 μL 
Model 1702N /1750N Hamilton 
Company, USA 
LTQ Velos ESI Positive Ion 
Calibration Solution 
88323 Pierce, Thermo 
Fisher Scientific 
Inc., USA 
National 9mm Screw Thread Cap, 






National Target DP Vials, 9mm, 












Opti-TOF plate, 384 well, 123 x 81 
mm, 1 insert 
P/N 1016491 Applied 
Biosystems Inc. 
USA/  




Table 7: Material, consumables and other reagents (continued) 
Reagent/Material/Consumable Product Code Manufacturer 






PYREX 10 mL Sterile Glass 
Serological Pipets, plugged, 
sterile, disposable 
7077-10N Corning Inc., 
USA 
Screwcap Glass Culture Tubes, 
Pyrex, 13 x 100mm Round Bottom  
99449-13 Corning Inc., 
USA 
Screwcaps with White Rubber 
Liner, Disposable Phenolic, 13-415 
GPI Thread Finish 
99999-13 Corning Inc., 
USA 




Spatula, Disposable  smartSpatula 
macro/micro 
LevGo, Inc., USA 





Universal Indicator paper pH 1-11 37035 Sigma-Aldrich 
Corp., USA 
2.4.3 Buffers and solutions 
All buffers and solutions are prepared in double distilled water (ddH2O) if not stated 
otherwise. 
 
50 mM Ammonium bicarbonate pH 8.0-8.5 
0.1 % Formic acid (v/v) 
5 % Acetic acid (v/v) 
10 % Acetic acid (v/v) 
20 % Isopropanol in 5 % Acetic acid (v/v) 
40 % Isopropanol in 5 % Acetic acid (v/v) 
100 % Isopropanol (v/v) 




2.4.4 Glycoproteins used for mass 
spectrometry 
The glycoproteins of interest were purchased from commercial sources as stated 
below. 
Table 8: Commercially available glycoproteins for analysis with mass spectrometry technique 









• Alternative names: Bone 
Marrow Proteoglycan, 
(BMPG), Proteoglycan 2 
(PRG2), Eosinophil 
Granule Major Basic 
Protein (MBP or EMBP), 
Pregnancy-Associated 
Major Basic Protein 
• Species: human 
• Source species: Human 
Cells 

















• Alternative names: 
Pregnancy-associated 
plasma protein-A1 
/Pappalysin-1 (PAPP-A1)  
• Species: human 
• Sequence: aa 82-1214 
• Source species: Mouse 














form (htPAPP-A),  
native, human 
• consisting of PAPP-A1 
and pro-MBP subunits 
(PAPP-A1/proMBP 
complex) 
• Sequence: human, 
• Source species: human 
• purified from pooled 
human retro-placental 
blood  
• material was tested and 
found negative for 
HBsAg, HCV, HIV-1 and 
2 antibodies, HCV 
antibodies, and syphilis 






  Instruments and software for mass 
spectrometry 
2.5.1 General instruments  
Table 9: Laboratory apparatus and instruments 
Instrument Company 
Blocks Heaters, various  VWR Scientific, VWR International LLC , 
USA 
Freeze Dryer BenchTop, K Series  VirTis, SP Scientific, SP Industries, Inc., 
USA 
LSE Mini Microcentrifuge 6765 Corning, Sigma-Aldrich Corp., USA 
Nanopure Diamond water purifier 
with Hollow Fiber 0.2µm Final 
Filter 
Barnstead Water Purification Systems 
Thermo Scientific, Thermo Fisher Scientific 
Inc., USA 
Nitrogen evaporator system Not applicable/ custom-made 
Savant USV400 Universal SpeedVac 
Vacuum System with Savant 
SPD131DDA SpeedVac 
Concentrator 
Thermo Scientific, Thermo Fisher Scientific 
Inc., USA 
Vortex-Genie 2 Scientific Industries Inc., USA 
2.5.2  Mass spectrometers and software for 
mass spectrometry 
Two techniques of mass spectrometry were used within the scope of the structural 
analysis of the glycoproteins of interest. 
Matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry 
(MALDI-TOF MS) was performed on an AB SCIEX MALDI TOF/TOF 5800 (Applied 
Biosystems Inc., USA) mass spectrometer. All data was acquired in positive ion mode 
and the samples measured on an Opti-TOF sample plate. Data analysis was 
performed using AB SCIEX Analyst Software and Data Explorer. 
Electrospray ionisation (ESI) mass spectrometry (MS) and tandem mass spectrometry 
was performed with a nano-electrospray ion (NSI) source at an Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific Inc., USA) on-line to a prior 
nano-flow liquid chromatography (nanoLC) system, namely the UltiMate 3000 




nanoLC system used a pre-packed Acclim PepMap RSLC C18 column 
(75 μm x 15 cm, 3 μm particle size, Thermo Scientific, Thermo Fisher Scientific Inc., 
USA). The nanoLC and the MS systems were integrated via the Chromeleon 
Chromatography Data System (CDS) software from Thermo Scientific, Thermo 
Fisher Scientific Inc., USA. 
Software used for further data analysis and interpretation were Xcalibur 3.0 (Thermo 
Scientific, Thermo Fisher Scientific Inc., USA), GlycoWorkbench 1.1 (Imperial College 
London, United Kingdom and University of Giessen, Germany), Byonic v2.3.5 
(Protein Metrics Inc., USA). Furthermore, PeptideCutter (SIB Swiss Institute of 
Bioinformatics, Switzerland), ProteinProspector v5.22.1 (UCSF Mass Spectrometry 
Facility, University of California, San Francisco, USA), GlycoMod (SIB Swiss Institute 
of Bioinformatics, Switzerland) and NetNGlyc 1.0 (DTU Bioinformatics, Center for 
Biological Sequence Analysis, Technical University of Denmark, Denmark), which 
were available via the ExPASy tools page (http://www.expasy.org/tools). 
  Methods for mass spectrometry 
Sample preparation, data acquisition, data analysis, as well as data interpretation 
were carried out according to the state-of-the-art procedures in the Analytical Service 
and Training Laboratory, Complex Carbohydrate Research Center at the University 
of Georgia, United States of America (Shajahan et al., 2017a, Shajahan et al., 2017b).  
The commercially available glycoproteins had sufficient purity; certified through the 
data sheets that were provided by the manufacturers, and confirmed in-house by 
SDS-PAGE. Therefore, direct processing of the samples without additional 
purification steps was conducted. 
2.6.1 Digestion of the glycoproteins 
The analysis of the glycoproteins followed a bottom-up approach, i.e. the enzymatic 
digestion of the full-length glycoprotein into smaller glycopeptide units (Chait, 2006).  
The glycoproteins of interest are known to form intra- and intermolecular disulfide 
bonds. Explicitly, PAPP-A1 homodimerises via one inter-chain disulfide bond and 




2:2 PAPP-A1/proMBP-complex, one PAPP-A1 unit links to another pro-MBP unit 
via two disulfide bonds. Therefore, the 2:2 PAPP-A1/proMBP-complex has been 
shown to contain a total of seven inter-polypeptide disulfide bonds (Overgaard et al., 
2003). 
a) In-solution digestion 
For further analysis via Glycomics and Glycoproteomics, the glycoproteins required 
reduction of the disulfide bonds: Approximately 150 μg of the protein of interest was 
dissolved in 25 μL of 50 mM ammonium bicarbonate pH 7.5 and 25 μL of 
25 mM dithiothreitol (DTT) added for reduction. The mixture was incubated at 45 ˚C 
for 45 min. This reaction was followed by a carbamidomethylation of the thiol groups 
with 25 μL of 90 mM iodoacetamide at room temperature for 45 min in the dark. If 
not broken apart via chemical reactions, intra- and intermolecular disulfide bonds 
limit the efficacy of the enzymatic digest of the glycoprotein into glycopeptides. 
Subsequently, the samples were dialysed in a 4 kDa cut-off dialyser tube against 
nanopure water at 4 ˚C overnight. After lyophilisation, the sample was redissolved 
in 50 mM ammonium bicarbonate buffer pH 7.5 and digested with at least one 
suitable protease that produces target peptides of ideal length, polarity and charge 
state for detection via mass spectrometry (Chen et al., 2009, Froehlich et al., 2013). 
Through analysis with the software tool PeptideCutter, trypsin was chosen as the 
protease for digestion of the recombinant proMBP. A sequential digest with the 
proteases trypsin and chymotrypsin was selected for the recombinant PAPP-A1. The 
tryptic digest was performed for 12-16 hours at 37 ˚C, whereas the proteolytic digest 
with chymotrypsin was incubated for 12-16 hours at room temperature. Each 
protease was used in a protease to glycoprotein molar ratio of 1:20. The proteolytic 
digestions were stopped by heat inactivation at 100 ˚C for 5 min and lyophilised 
afterwards. The prepared samples were used for glycan identification by Glycomics 
and Glycoproteomics. 
b) In-gel digestion 
This particular part of the research project was performed in the Analytical Service 
and Training Laboratory at the Complex Carbohydrate Research Center (University 




carried out with assistance from the CCRC analysts Dr Ganapati Bhat and Dr Nitin 
Supekar. 
The lyophilised sample was redissolved in 50 mM ammonium bicarbonate buffer pH 
7.5 and loaded onto a 4-15% polyacrylamide gel electrophoresis (PAGE) gel under 
denaturing conditions. The gel was Coomassie-stained and the bands at 200 kDa as 
well as 75 kDa were isolated and processed separately. The gel bands were cut into 
pieces of approximately 1 mm3, and de-stained by repeated washing with a buffer 
containing ammonium bicarbonate and aceto-nitrile. Reduction via DTT and 
alkylation by iodoacetamide of the thiol groups was performed in-gel. After removal 
of the denaturing chemicals through washes with ammonium bi-carbonate buffer, 
the 200 kDa and 75 kDa bands of the native 2:2 PAPP-A/proMBP-complex were 
digested with trypsin and chymotrypsin. The resulting peptides and glycopeptides 
were extracted with increasing proportions of acetonitrile acidified with formic acid. 
The proteases were heat inactivated at 100 ˚C for 5 min and subsequently lyophilised. 
The prepared samples were used for glycomic and glycoproteomic analysis. 
2.6.2 Glycoproteomics 
After the proteolytic digest, the lyophilised glycopeptides were redissolved in 
nanopure water containing 0.1% formic acid and either directly analysed via 
nanoLC-MS/MS or stored at -30˚C until further analysis. 
a) Recombinant proMBP/Recombinant PAPP-A1 
For analysis, the sample was injected at 4 ˚C via the autosampler of the UltiMate 3000 
RSLCnano System into a pre-loading C18 column that led the sample into the 
analytical nano-flow Acclim PepMap RSLC C18 column. The system was 
equilibrated in solvent A (100% water, 0.1% formic acid). The separation was realised 
by a 61 min long, linear elution gradient (table 10, figure 2.6) generated with an 
increase of 1-99% of solvent B (100% Acetonitrile, 0.08% formic acid) over a total of 
72 min. The nano-flow liquid chromatography ensured the best separation of 
peptides and glycopeptides, including possible glycoforms, for on-line mass 













Figure 2.6: Elution gradient used for separation of the glycopeptides derived from recombinant 
proMBP and recombinant PAPP-A1, respectively. The final spike in solvent B ensures the 






Table 10: Elution gradient programme used on the Acclaim PepMap 100 C18 LC column for 





Percentage of solvent 
A (100% water, 
0.08% formic acid) 
[%] 
Percentage of solvent 
B (100% Acetonitrile, 
0.08% formic acid) 
[%] 
0 300 99 1 
0 300 99 1 
60 300 50 50 
61 300 1 99 
65 300 1 99 
65.5 300 37.5 62.5 
66 300 99 1 








The data acquisition of the glycopeptides was carried out on the Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific Inc., USA) with an Orbitrap as 
well as an Iontrap detector type available. The samples were sprayed in positive ion 
mode via a metal emitter tip using the method of nano-electrospray ionisation (NSI). 
NSI provides better sensitivity, lower sample consumption, as well as a higher 
compatibility with the method of nano-LC than conventional electrospray ionisation 
(ESI), due to a lower flow rate in comparison to ESI (Burlingame, 1996).  
Full MS scans were acquired from m/z 200-2000 at a resolution of 120,000 of the 
Orbitrap analyser. The downstream method selected precursor ions at a time frame 
of 3 s for fragmentation using the criteria of monoisotopic precursor selection, charge 
states (included states 1-8, as well as undetermined), dynamic exclusion (exclusion 
duration of 60 s) and an intensity threshold of 50,000 A.U. The following decision tree 
of the method programme included, first, the highest charge state and, second, the 
most intense ion precursors for MS/MS analysis. 
MS/MS scans were performed via fragmentation with the methods of collision-
induced dissociation (CID) and higher-energy collisional dissociation (HCD). 
Fragment ions of HCD and CID were detected in the Orbitrap at 30,000 resolution. 
A subsequent fragmentation was carried out using a HCD-product-triggered 
electron-transfer-dissociation (ETD) programme. The ETD method detected 
fragment ions via the Iontrap after detection of listed diagnostic ions, i.e. oxonium 
ions derived from glycan structures, produced via HCD MS/MS. 
The complete workflow is depicted in figure 2.7.  
The acquired raw spectra were searched against FASTA sequences of the 
glycoproteins using the software Byonic with the mass tolerance set as 10 ppm for 
both, full MS and MS/MS scans. For N-and O-glycopeptide analysis, carbamido-
methylation as variable modification and oxidation of methionine as variable 
modification were used as search parameters. The assigned glycopeptides were 
initially filtered based on probability and further validated manually by evaluating 













Figure 2.7: Schematic overview of the MS method used for on-line nano-LC-MS/MS analysis 
of the glycomic and glycoproteomic characteristics of the glycopeptides derived from 




b) Native PAPP-A1/proMBP-complex 
The glycopeptide mix, derived from the native PAPP-A1/proMBP-complex, was 
analysed by the CCRC analysts Dr Ganapati Bhat and Dr Nitin Supekar in the 
Analytical Service and Training Laboratory at the Complex Carbohydrate Research 
Center (University of Georgia, USA).  
The sample was injected via the autosampler of the UltiMate 3000 RSLCnano System 
at 4 ˚C. The pre-loading C18 column adjusted the sample size and loading speed to 
the on-line analytical nano-flow Acclim PepMap RSLC C18 column. The system was 
equilibrated in solvent A (100% water, 0.1% formic acid) and the separation of the 
sample was realised over a 55.5 min long elution gradient (table 11, Figure 2.8) 
generated through an increase by 1-99% of solvent B (100% Acetonitrile, 
0.08% formic acid) over a total programme time of 72 min. The nano-LC method 
separated peptides and glycopeptides, including possible glycoforms, for on-line 






Figure 2.8: Elution gradient used for separation of the glycopeptides derived from the native 





Table 11: Elution gradient programme used on the Acclaim PepMap 100 C18 LC column for 





Percentage of solvent 
A (100% water, 
0.08% formic acid ) 
[%] 
Percentage of solvent 
B (100% Acetonitrile, 
0.08% formic acid ) 
[%] 
0 300 98 2 
0 300 98 2 
5 300 98 2 
10 300 96 4 
20 300 92 8 
35 300 75 25 
45 300 62.5 37.5 
48 300 50 50 
55 300 25 75 
55.5 300 1 99 
57 300 1 99 
57.2 300 37.5 62.5 
60 300 98 2 
72 300 98 2 
 
The data acquisition of the glycopeptides was carried out on the Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific Inc., USA) with an Orbitrap as 
well as an Iontrap analyser available. The samples were sprayed in positive ion mode 
via a metal emitter tip using the NSI method. 
Full MS scans were acquired from m/z 200-1600 at 120,000 resolution via the Orbitrap 
analyser. Within a cycle time of 3 s, precursor ions were selected for fragmentation 
using the criteria of monoisotopic precursor selection, charge states (included states 
2-8), dynamic exclusion (exclusion duration of 5 s) and an intensity threshold of 
50,000 A.U. The following decision tree of the method programme included, first, the 
highest charge state and, second, the most intense precursor ions for MS/MS 
analysis. 
MS/MS scans were performed via fragmentation of the precursor ions via the 
method of higher-energy collisional dissociation (HCD) as well as subsequent 
fragmentation using a HCD-triggered collision-induced dissociation (CID) 
programme. Both methods detected fragment ions via the Orbitrap analyser at a 
resolution of 15,000 after detection of listed diagnostic ions, i.e. oxonium ions derived 
from glycan structures, produced via HCD MS/MS. 




The acquired raw spectra were searched against FASTA sequences of the 
glycoproteins via Byonic with the mass tolerance set as 10 ppm for both, full MS and 
MS/MS scans. For N-and O-glycopeptide analysis, carbamidomethylation of 
cysteine as well as and oxidation of methionine were used as search parameters (as 
variable modification). Assigned glycopeptides were, first, software-filtered based on 
probability and, second, validated manually by evaluating glycan neutral loss 





















Figure 2.9: Schematic overview of the MS method used for on-line nano-LC-MS/MS analysis 






a) N-linked Glycans 
N-linked glycans can be released enzymatically from glycoproteins, but more 
efficiently from glycopeptides considering the lower level of steric hindrance. The 
commercially available enzyme PNGase F, purified from Flavobacterium 
meningosepticum, is able to cleave the glycosidic bond that connects the asparagine to 
the first, core GlcNAc residue of the glycan. Hence, PNGase F is the enzyme of choice 
for mammalian-derived glycoproteins/peptides. However, PNGase F is not able to 
efficiently release N-glycans that contain fucose linked α-1→3 as well as for many N-
linked oligosaccharides from plants, insects and microbes (Tretter et al., 1991). Given 
that the recombinant glycoproteins of interest were expressed in mammalian 
expression systems and the native PAPP-A1/proMBP-complex derived from human 
blood, PNGase F was the first choice.  
The lyophilised fraction of the reduced and alkylated glycopeptides was re-dissolved 
in 48 µL GlycoBuffer 2 (50 mM Sodium Phosphate buffer pH 7.5) provided for the 
PNGase F reaction (from New England Biolabs). For release of N-glycans, 2 μL 
PNGase F (equals 1000 units) were added and incubated at 37˚C for 16-18 hrs. 
Afterwards, the mixture was cooled to room temperature and loaded onto pre-
equilibrated C18 SPE cartridges. The cartridges were washed three times with 
1 mL 5% acetic acid and the flow-through collected, which contained the hydrophilic, 
released N-glycans. The more hydrophobic de-glycosylated peptides as well as 
O-linked glycopeptides were eluted in fractions from the C18 SPE cartridges with 
1 mL of 20%, 40%, 100% isopropanol in 5% acetic acid, respectively. The solvent was 
removed via evaporation by Nitrogen gas. The wash fraction containing the N-
glycans and the elution fraction containing peptides and O-glycopeptides were 
lyophilised.  
In the following step, the released N-glycans were permethylated, which replaces the 
hydrogen atoms of the hydroxyl groups with methyl groups. This derivatisation 
offers several advantages, such as reduced hydrophilicity that results in a more 
sensitive MS analysis, replacing negative charges that enable MS conducted 
completely in positive ionisation mode, enhancing cross-ring fragmentation for 




sequence of the glycans since linkages do not become permethylated (Harvey, 2011, 
Alley et al., 2013). 
The lyophilised N-glycans were dissolved in 200 μL anhydrous dimethyl sulfoxide 
(DMSO) and 300 μL of anhydrous sodium hydroxide in DMSO were added. After 
adding 150 μL iodomethane, the mixture was vortexed thoroughly for 10 min. The 
permethylation reaction was stopped by adding 2 mL nanopure water, which turns 
the sample opaque and indicates a successful permethylation. Excess iodomethane 
was volatilised by directing a stream of nitrogen gas through the sample that turned 
the sample transparent again. To extract the permethylated N-glycans, 2 mL 
dichloromethane were added. The mixture was vortexed vigorously and centrifuged 
briefly for separation of the layers. The aqueous layer was removed, and the 
dichloromethane layer washed again with 2 mL nanopure water. The procedure was 
repeated five times. Finally, the dichloromethane layer was removed carefully, 
transferred into a new vial and dried by a stream of nitrogen gas. 
The permethylated N-glycans were re-dissolved in 20 μL methanol using a gastight 
Hamilton syringe and 2 μL of the sample were mixed with 2 μL of 
2,5-dihydroxybenzoic acid matrix (10 mg/mL in 1:1 methanol/nanopure water). The 
mixture was incubated until solvents volatilised down to approximately 1 μL. With 
a micropipette, 0.5 μL of the mixture were placed on an Opti-TOF sample plate and 
air-dried. The spotted samples were analysed with an AB SCIEX MALDI TOF/TOF 
5800 mass spectrometer (Applied Biosystems Inc., USA) with the laser intensity set 
to 60% around 4,000 A.U. The data was acquired in positive ion mode and data 
analysis performed using AB SCIEX Analyst Software and Data Explorer. Data was 
interpreted and assigned with the GlycoWorkbench 1.1 software. 
b) O-linked Glycans 
The O-linked glycopeptides as well as unglycosylated peptides were separated from 
the released N-glycans during the C18 solid-phase extraction. The O-linked 
glycopeptides were found in the elution fraction due to a higher hydrophobicity. To 
date, no de-glycosylation enzymes with a wide specificity for O-glycans are available 
and, therefore, chemical reactions (i.e. reductive β-elimination, ammonia-based 
nonreductive β-elimination and hydrazinolysis) are typically used for a 




The alkaline-based β-elimination was the chemical method of choice for O-linked 
glycan release. The lyophilised O-glycopeptide fraction was re-dissolved in 250 μL of 
50 mM sodium hydroxide and the pH checked for a basic pH via indicator paper. 
Sodium borohydride was prepared at 76 mg/mL in 50 mM sodium hydroxide and 
250 μL of the solution added to the 250 μL of dissolved O-glycopeptides. The mixture 
was vortexed, incubated at 45 ˚C for 16-18 hrs and cooled down to room temperature 
afterwards. Carefully, 10% acetic acid solution was added dropwise to the sample for 
neutralisation of the pH, which stopped the alkaline-based β-elimination reaction, 
until no further formation of hydrogen gas was observable. 
For improvement of the MS analysis of the sample, the removal of salts was required. 
This step was realised with ion-exchange chromatography using the AG 50W-X8 
cation exchange resin (approximately 2 mL bed size volume) packed into a gravity 
column (10 mL reservoir volume). After equilibration of the resin with approximately 
5 mL 5% acetic acid, the 500 μL sample was loaded onto the column and washed with 
3 mL 5% acetic acid to elute the released O-glycans. The sample was lyophilised and 
re-dissolved in 500 μL of methanol:acetic acid (9:1) solution for removal of the 
remaining borates. The sample was dried under a stream of nitrogen gas to volatise 
the borates and the procedure repeated five times. 
 
The following step was the permethylation of the released O-glycans, which follows 
the same protocol as permethylation of N-glycans (see section ‘2.6.3. a) N-linked 
Glycans’). In summary, the glycans were dissolved in 200 μL anhydrous DMSO and 
300 μL of anhydrous sodium hydroxide in DMSO, followed by addition of 50 μL 
iodomethane. After vortexing for 10 min, the reaction was stopped by adding 2 mL 
nanopure water and excess iodomethane was volatilised with nitrogen gas. For 
extraction of the O-glycans, 2 mL dichloromethane were added and the mixture 
vortexed. The aqueous layer was removed, and the dichloromethane layer washed 
five more times with 2 mL nanopure water. Eventually, the dichloromethane layer 
was transferred into a new vial and dried by a stream of nitrogen gas. 
The lyophilised, released O-glycans were dissolved in 20 μL methanol. Before 
spotting on a MS sample plate, 2 μL of the sample were mixed with 2 μL 




mixture was incubated until solvents volatilised down to approximately 1 μL. With 
a micropipette, 0.5 μL of the mixture were spotted on an Opti-TOF sample plate and 
air-dried. Analysis of the spotted samples was performed with an AB SCIEX MALDI 
TOF/TOF 5800 mass spectrometer (Applied Biosystems Inc., USA) with the laser 
intensity set to 60% around 4,000 A.U. The data was acquired in positive ion mode. 
The analysis of the data was realised by use of AB SCIEX Analyst Software and Data 
















3 RESULTS AND DISCUSSION (I)     
BIOPHYSICAL INTERACTION STUDIES 









Preliminary findings (Ilyas, 2010) raised the possibility that there could be a 
significant interaction between the human glycoprotein PAPP-A1 (a metzincin 
protease) and human C-type lectins. Establishing the kinetic characterisation of these 
interactions is an area of great interest, since quantitative data can indicate whether 
the interactions lie within the physiologically relevant concentration ranges.  
Healthy, non-pregnant humans (male and female) typically have a blood plasma 
level of PAPP-A1 between 0 nM and at most 0.8 nM. However, in pregnant women 
PAPP-A1 plasma levels become detectable early in pregnancy and steadily rise 
during all three trimesters - with levels up to 85 nM at term (Gall and Halbert, 1972, 
Lin et al., 1974). The PAPP-A1 polypeptide circulates in plasma of pregnant women 
as a 2:2-complex with the propeptide of eosinophil major basic protein (proMBP), 
which appears to act as an inhibitor to the protease function of PAPP-A1. 
Interestingly, PAPP-A1 has been found - without the inhibition of its enzymatic 
nature via proMBP - in patients suffering from acute coronary syndromes (Bayes-
Genis et al., 2001). PAPP-A1 levels were determined to rise up to 3 nM in patients 
with a STEMI (ST-segment elevation myocardial infarction) heart attack.  
 
A set of soluble, recombinant C-type lectin receptors with a similar binding specificity 
to that of DC-SIGN were included in the biophysical interaction study, such as 
DC-SIGNR and MMR. All have a preference for binding to mannose-type 
oligosaccharides but differ in the patterns of recognition and the structural 
organisation of CRDs. 
Even though the mechanisms and principles of binding between C-type lectins and 
ligands have been widely investigated, much is still not known about the range of 
endogenous ligands for these immune-related receptors.  
 
The biophysical technique used for real-time interaction analysis was the state-of-the-




The native human PAPP-A1/proMBP-complex (purified from retroplacental blood) 
as well as the recombinant PAPP-A1 homodimer (human gene product derived from 
mouse myeloma cells) were only available in small amounts within the microgram 
range. This scarcity extended to the availability of commercial stocks; the advantages 
of the BLI platform are its high sensitivity and modest requirement of sample 
volumes. Therefore, it was possible to investigate and quantify protein-protein 
interactions that were previously too challenging to resolve via more popular 
techniques such as surface plasmon resonance (SPR). 
The experiments were set up and designed in keeping with the manufacturers’ 
technical notes - available through the official website www.fortebio.com.  
The flow rate for all steps within the experiments presented in this chapter was set to 
1000 rpm. Controls were included, such as blanks with assay buffer (10 mM HEPES 
pH 7.4, 150 mM NaCl, 5 mM CaCl2) to check for a system drift during the experiment, 
and a negative control, i.e. a channel with the highest analyte concentration within 
experiment but 5 mM ETDA instead of 5 mM CaCl2, since the analysed C-type lectins 
are calcium-dependent for carbohydrate binding.  
The control values were subtracted from the raw data prior to kinetic analysis. The 





 Functionality tests for BLI studies  
Biolayer interferometry is a recent technology with relatively little exposure to the 
field of glycobiology, therefore, functionality tests with an abundant ligand that is 
known to yield a clear interaction response with C-type lectins were conducted to 
validate the integrity of the method.  
The functionality of the C-type lectins was confirmed during the purification of the 
lectins by chromatography as described in section ‘2.3.3.1 Affinity chromatography’. 
3.2.1 Functionality of recombinant DC-SIGN 
Biotinylated, recombinant extracellular domain of DC-SIGN was immobilised on SA 
(streptavidin) biosensors and glycogen - an abundant, soluble and robust ligand 
(Geurtsen et al., 2009) - was used as the analyte at a concentration of 0.01 mg/mL in 
assay buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2). The protocol for the 
functionality test involved a baseline step for 60 s in assay buffer, a contact time for 
association between ligand and analyte for 350 s, and a dissociation period of 450 s in 
assay buffer. A clearly positive binding response with an interferometric deflection 









Figure 3.1: Representative sensorgram of immobilised DC-SIGN binding to glycogen at a 
concentration of 0.01 mg/mL. The shown binding event had a maximum binding response of 




3.2.2 Functionality of recombinant DC-SIGNR 
The recombinant extracellular domain of DC-SIGNR was biotinylated and tested for 
functionality, and comparability to obtained BLI data to SPR data.   
After immobilisation on SA (streptavidin) biosensors, the natural polymer glycogen 
was used as positive control at a concentration of 0.01 mg/mL in assay buffer (10 mM 
HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2).  
The protocol for testing the functionality of DC-SIGNR included a baseline step (60 s) 
in assay buffer, a contact time for association for 350 s, and a dissociation period of 
450 s in assay buffer. A clear binding response for glycogen to the extracellular 
domain of DC-SIGNR was observed, as shown in figure 3.2. This confirmed the 
integrity of the BLI detection and functionality of DC-SIGNR, although a 
comparatively lower overall interferometric response of 0.21 nm was observed. This 
is most likely due to gradually different preferences for spatial patterns of 






Figure 3.2: Representative sensorgram of immobilised DC-SIGNR binding to glycogen at a 
concentration of 0.01 mg/mL. The interaction reached a maximum binding response of 




 Biophysical interaction studies between 
glycoproteins and DC-SIGN 
3.3.1 Human native PAPP-A1/proMBP-
complex and DC-SIGN 
Two experimental protocols were tested, using streptavidin-binding as well as 
amine-coupling biosensors. 
For SA (streptavidin) biosensors, the biotinylated, recombinant DC-SIGN was 
immobilised at the probe as ligand, and the human native PAPP-A1/proMBP-
complex (MW=500 kDa) was tested as analyte in a range of serial dilutions 
(100 nM-1 nM). The protocol of the assay included a baseline step for 60 s in assay 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2), a contact time for 
association between ligand and analyte for 600 s, and a dissociation period of 600 s in 
assay buffer. Binding was observed in a concentration-dependent manner, as 












Figure 3.3: Representative sensorgram of the interaction between biotinylated DC-SIGN and 
the human native PAPP-A1/proMBP-complex via SA (streptavidin) biosensors. The 
sensorgram shows the shift in the wavelength of the reflected light, interpreted as binding 
response, over time during the association and dissociation phase, 600 s respectively. 
The interaction with the human native PAPP-A1/proMBP-complex (hnPAPP-A1) is 
significant and clearly concentration-dependent. Annotations:   
*1 75 nM hnPAPP-A1,     *2 50 nM hnPAPP-A1,     *3 25 nM hnPAPP-A1,     










Table 12 summarises the calculated kinetic parameters, whereby each 
run/experiment is based on n≥3. 
The average dissociation constant was calculated as KD=0.61 nM (6.14E-10 M) for the 
SA biosensors with immobilisation of the extracellular domain of DC-SIGN. One 
strinking detail of the interaction is the very slow off-rate (koff), indicating that once 
formed complexes between DC-SIGN and PAPP-A1/proMBP are very stable in the 
presence of calcium. 
 
Table 12: Overview of the kinetic parameters obtained from the binding studies between the 
immobilised extracellular domain of DC-SIGN and the human native PAPP-A1/proMBP-
complex (hnPAPP-A1). 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
Run 1 soluble hnPAPP-A1 8.79E+05 6.76E-04 7.69E-10 
Run 2 soluble hnPAPP-A1 8.77E+05 4.06E-04 4.62E-10 
Run 3 soluble hnPAPP-A1 8.72E+05 5.32E-04 6.10E-10 
 
 
For AR2G (amine-coupling) biosensors, the human native PAPP-A1/proMBP-
complex was immobilised (0.02 mg/mL; loading buffer 10 mM HEPES pH 5.5, 
150 mM NaCl) at the probe as ligand via amine-coupling (scarcity of 
PAPP-A1/proMBP material prohibited the biotinylation of this protein for use with 
SA probes). The soluble recombinant DC-SIGN extracellular domain (MWTETRAMER= 
150 kDa) was tested as analyte in a serial dilution (100 nM-50 nM). Negative controls 
included a buffer blank as well as 100 nM analyte in EDTA-containing buffer. The 
protocol for the assay included a baseline step (60 s) in assay buffer (10 mM HEPES 
pH 7.4, 150 mM NaCl, 5 mM CaCl2), a contact time for association between ligand 
and analyte for 1200 s, and a dissociation period of 1200 s in assay buffer. Binding 
was observed in a concentration-dependent manner, which is shown in figure 3.4. 
The kinetic parameters derived from experiments (n≥3 per single-experiment KD) are 
shown in table 13. The average dissociation constant was calculated as KD=0.44 nM 






Table 13: Overview of the kinetic parameters obtained from the binding studies between the 
immobilised human native PAPP-A1/proMBP-complex and the soluble extracellular domain 
of DC-SIGN. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
Run 1 soluble DC-SIGN 3.90E+05 1.45E-04 3.72E-10 
Run 2 soluble DC-SIGN 3.96E+05 2.29E-04 5.79E-10 





Figure 3.4: Representative sensorgram of soluble DC-SIGN binding to immobilised 
hnPAPP-A1. The graphs show a significant and concentration-dependent binding (dilution 
series from 100 nM to 50 nM of the soluble, extracellular domain of DC-SIGN). The EDTA 
reference was subtracted for analysis of kinetic parameters but is shown as a visual reference. 
Annotations: 
*1 100 nM DC-SIGN,     *2 75 nM DC-SIGN,     *3 50 nM DC-SIGN     









3.3.2 Human recombinant PAPP-A1 and 
DC-SIGN 
Homodimers of human recombinant PAPP-A1 (MW=400 kDa) were tested for 
binding to the extracellular domain of DC-SIGN. Biotinylated DC-SIGN was 
immobilised on the tip of SA (streptavidin) biosensors.  
The recombinant PAPP-A1 was prepared as solution-phase analyte in serial dilution 
(100 nM-1 nM). The protocol for the assay included a baseline step for 60 s in assay 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2), a contact time for 
association between ligand and analyte for 600 s, and a dissociation period of 840 s in 
assay buffer. As shown in figure 3.5, binding was observed in a concentration-
dependent manner using a dilution series from 100 nM to 1 nM. Evaluation of n=6 
experiments is presented in table 14. The analysis of the association and dissociation 
phase revealed an average dissociation constant KD= 1.3 nM (1.307E-09 M).  
Given that the recombinant PAPP-A1 was produced in murine NS0 myeloma cells, 
the N-glycosylation pattern was hypothesised to differ to the native PAPP-A1 form 
(human origin). The structural aspects of N-glycosylation were investigated in 
section ‘4.4 Recombinant human PAPP-A’. 
 
Table 14: Overview of the kinetic parameters obtained from the binding studies between the 
recombinant PAPP-A1 (homodimer) and the extracellular domain of DC-SIGN. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
Run 1 soluble recPAPP-A1 7.88E+05 5.31E-04 6.74E-10 









Figure 3.5: Representative sensorgram of human recombinant PAPP-A1 binding to the 
immobilised extracellular domain of DC-SIGN. The experiments revealed a significant and 
concentration-dependent binding (dilution series ranging from 100 nM to 1 nM) of 
recombinant PAPP-A1 (recPAPP-A1) to DC-SIGN. The EDTA reference was subtracted 
for analysis of kinetic parameters but is depicted for visual reference.  
Annotations: 
*1 80 nM recPAPP-A1,      *2 50 nM recPAPP-A1,     *3 30 nM recPAPP-A-1, 
 *4 10 nM recPAPP-A1,     *5 3 nM recPAPP-A1,       *6  1 nM recPAPP-A-1, 











 Biophysical interaction studies between 
glycoproteins and DC-SIGNR 
DC-SIGNR is closely related to DC-SIGN but with a more restricted binding 
specificity that does not favour fucosylated ligands. Furthermore, the disposition of 
the CRDs relative to the neck domain is different in DC-SIGNR compared to 
DC-SIGN (Feinberg et al., 2005, Feinberg et al., 2009).  
For more than decade, DC-SIGNR has been considered for potential involvement in 
the clearance of endogenous glycoproteins (Soilleux et al., 2000, Figdor et al., 2002). 
Rydz et al. (2013) showed the ability of DC-SIGNR to internalise the human plasma 
glycoprotein von Willebrand Factor (vWF) after binding. Since DC-SIGNR has a 
putative role in clearance and bioavailability of vWF, the blood serum levels of other 
human glycoproteins could be influenced by DC-SIGNR in vivo. 
 
Therefore, it was of interest to elucidate the binding affinity of the human native 
PAPP-1/proMBP-complex as well as the human recombinant PAPP-A1 homodimer, 





3.4.1 Human Native PAPP-A1/proMBP-
complex and DC-SIGNR 
For the characterisation of the binding between human native PAPP-1/proMBP-
complex and the extracellular domain of DC-SIGNR, two experimental protocols 
were tested, i.e. streptavidin-binding (SA) and amine-coupling (AR2G) biosensors. 
Biotinylated, recombinant DC-SIGNR was immobilised at the probe of SA sensors as 
ligand. The human native PAPP-A1/proMBP-complex (MW=500 kDa) was run in 
serial dilution (100 nM-1 nM) as analyte. The experiments were designed with a 
baseline step for 60 s in assay buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM 
CaCl2), a contact time for association between ligand and analyte for 600 s, and a 
dissociation period of 600 s in assay buffer. The concentration-dependent binding, as 
shown in figure 3.6, was analysed. A significant binding response was obtained for 
concentrations higher than 10 nM. Table 15 shows the obtained kinetic parameters 
(n≥3 for each experiment). The average dissociation constant was calculated as KD= 
17.5 nM (1.751E-08 M) for the SA biosensors with immobilisation of the extracellular 
domain of DC-SIGNR. 
 
 
Table 15: Overview of the kinetic parameters obtained from the binding studies between the 
human native PAPP-A1/proMBP-complex and the extracellular domain of DC-SIGNR. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
Run 1 soluble hnPAPP-A1 4.52E+04 1.05E-04 2.33E-09 
Run 2 soluble hnPAPP-A1 1.53E+05 7.33E-03 4.79E-08 













Interestingly, for the protocol using AR2G (amine-coupling) biosensors, it was not 
possible to detect significant binding nor obtain consistent kinetic parameters of the 
putative interaction between the immobilised human native PAPP-A1/proMBP-
complex (0.02 mg/mL; loading buffer 10 mM HEPES pH 5.5, 150 mM NaCl) and the 
soluble recombinant DC-SIGNR extracellular domain. Most of the experiments 
indicated no consistent binding of soluble DC-SIGNR to the immobilised human 
native PAPP-A1/proMBP-complex, as shown in figure 3.7.  
Figure 3.6: Representative sensorgram of the interaction between biotinylated DC-SIGNR and 
the human native PAPP-A1/proMBP-complex via SA (streptavidin) biosensors. The 
sensorgram shows the shift in the interference pattern of the reflected light, interpreted as 
binding response in nm, over time during the association phase (600 s) and dissociation phase 
(840 s). The interaction with the human native PAPP-A1/proMBP-complex (hnPAPP-A1) is 
significant and clearly concentration-dependent.  
Annotations: 
*1 80 nM hnPAPP-A1,     *2 50 nM hnPAPP-A1,     *3 30 nM hnPAPP-A1,     









Only during one experiment, evidence of a single binding event was observed: The 
kinetic parameters of this single experiments are shown in table 16 with an apparent 
dissociation constant of KD=2.3 nM (2.30E-09 M). However, the coarseness of the 




Table 16: Overview of the kinetic parameters obtained from the binding studies between the 
immobilised human native PAPP-A1/proMBP-complex and the extracellular domain of 
DC-SIGNR. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
Run 1 soluble DC-SIGNR 1.83E+04 4.20E-05 2.30E-09 
Other runs No binding 
Figure 3.7: Representative sensorgram of soluble DC-SIGNR binding to immobilised human 
native PAPP-A1/proMBP-complex. Only very high concentrations, i.e. more than 50 nM, 
enabled DC-SIGNR to bind to immobilised human native PAPP-A1/proMBP-complex. 
Overall, the binding response was very low and not significant. The EDTA reference was 
subtracted for analysis of kinetic parameters but is shown for visual reference. Annotations:    
*1 100 nM DC-SIGNR,     *2 50 nM DC-SIGNR,     








3.4.2 Human recombinant PAPP-A1 and 
DC-SIGNR 
The recombinant DC-SIGNR was investigated for potentially binding the human 
recombinant PAPP-A1 homodimer (MW=400 kDa).  
The biotinylated DC-SIGNR extracellular domain was immobilised on a streptavidin 
(SA) biosensor. The recombinant PAPP-A1 was set as soluble analyte in a serial 
dilution (80 nM-1 nM). The set-up of the assay included a baseline step for 60 s in 
assay buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2), a contact time for 
association between ligand and analyte for 720 s, and a dissociation period of 840 s in 
assay buffer. None of the experiments showed a convincing, significant binding 
response between DC-SIGNR and the recombinant PAPP-A1. Figure 3.8 shows 
clearly how weak the overall binding response was – even at higher concentrations 
of the analyte. However, the forced fitting suggests that any apparent binding 
response is nonspecific.   
Figure 3.8: Representative sensorgram of the interaction between human recombinant 
PAPP-A1 and the immobilised extracellular domain of DC-SIGNR. The experiments 
(dilution serial from 80 nM to 1 nM) yielded a very low overall binding response, which 
was non-specific. The EDTA reference was subtracted for analysis of kinetic parameters but 
is depicted for visual reference. Annotations: 
*1 80 nM recPAPP-A1,      *2 50 nM recPAPP-A1,     *3 30 nM recPAPP-A-1, 
 *4 10 nM recPAPP-A1,     *5 3 nM recPAPP-A1,      *6 1 nM recPAPP-A-1, 












 Biophysical interaction studies between 
glycoproteins and MMR 
The commercially available macrophage mannose receptor (MMR) was tested for 
interaction with the native human PAPP-A1/proMBP-complex. The MMR was 
chosen since it contains multiple CRDs of several CTLD categories that preferentially 
bind to mannose-type sugars and terminal mannose, fucose and N-acetyl-
galactosamine residues. MMR is a major receptor on the surface of subpopulations of 
macrophages and dendritic cells. 
Its structural characteristics make the MMR a very interesting C-type lectin for 
comparative investigation with regards to DC-SIGN and DC-SIGNR. Interestingly, 
DC-SIGN and MMR are often co-expressed on macrophages, and all three C-type 
lectins are strongly associated with immune responses. However, the extent of ligand 
range and subtle differential binding preferences between these receptors still remain 
unclear. 
Availability of soluble recombinant full-length MMR protein was a challenge, 
although the BLI platform did allow for comparative molar amounts to be used in 






3.5.1 Human Native PAPP-A1/proMBP-
complex and MMR 
For the investigation of a putative interaction between the human native 
PAPP-1/proMBP-complex and the recombinant macrophage mannose receptor, the 
method of amine-coupling (AR2G) biosensors was chosen.  
The human native PAPP-1/proMBP-complex was immobilised (0.02 mg/mL; 
loading buffer 10 mM HEPES pH 5.5, 150 mM NaCl) at the probe of AR2G sensors as 
ligand. The recombinant MMR was run as analyte. The experiments were designed 
with a baseline step for 60 s, and association and a dissociation periods of 1200 s in 
assay buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2). 
No consistent and significant binding response was detectable. Most runs showed 
only a very low level of interaction (see figure 3.9). Forced fitting of the data 
suggested that any apparent binding response is nonspecific. 
 
  
Figure 3.9: Representative sensorgram of soluble macrophage mannose receptor interacting 
with immobilised human native PAPP-A1/proMBP-complex. Only high concentrations 
(over 50 nM analyte) enabled the detection of a marginal binding response. The EDTA 
reference is depicted for visual reference.  
Annotations: 
*1 100 nM MMR,      *2 50 nM MMR,     








 Conclusion of the interaction studies 
between C-type lectins and human glyco-
proteins 
The binding studies between human C-type lectins and glycoproteins, performed via 
cutting-edge biolayer interferometry, have opened up the feasibility of working with 
low abundance samples, which is especially important for scarce materials, such as 
purified mammalian glycoproteins. 
Overall, it enabled the specific measurement of interaction between complex 
carbohydrates and the selected C-type lectins, as significant binding only occurred in 
the presence of calcium and was prevented in the presence of EDTA. 
The known binding affinities for C-type lectins to endogenous or exogenous ligands 
lie within the millimolar to mid-micromolar range for the C-type lectins examined 
here: DC-SIGN, DC-SIGNR and MMR (Taylor et al., 1992, Mitchell et al., 2001). 
Furthermore, all three lectins are known to mediate cellular uptake of glycoproteins 
ligands (Taylor and Drickamer, 1993, Figdor et al., 2002, Rydz et al., 2013). 
 
Within this study, the speculation that DC-SIGN binds to the human native 
PAPP-A1/proMBP-complex (hnPAPP-A1; derived from human retroplacental 
blood) has been confirmed. This finding represents a novel endogenous ligand for 
DC-SIGN. It is also important to note that this is a native, endogenous and soluble 
ligand, as hitherto most reported glycoprotein ligands for DC-SIGN have been 
membrane-bound.   
DC-SIGN revealed a clearly positive binding response to hnPAPP-A1. DC-SIGN was 
found to bind within the low nanomolar range (KD=0.61 nM) to soluble-phase 
hnPAPP-A1 as well as immobilised hnPAPP-A1 (KD= 0.44 nM). The parity of the data 
for the reciprocal experiments is encouraging. 
DC-SIGNR showed a lower binding response to the human native 
PAPP-A1/proMBP-complex. The dissociation constant for the interaction between 
DC-SIGNR and soluble hnPAPP-A1 lies in the low to medium nanomolar range with 




hnPAPP-A1 and DC-SIGNR did not provide a clear result and the binding signal was 
of lower quality and consistency compared to similar experiments with DC-SIGN. 
This discrepancy could arise from the marked difference in CRD clustering and steric 
availability between immobilised and solution-phase DC-SIGNR. Relative to the neck 
proportions of the molecule, the CRDs of DC-SIGNR project in a perpendicular 
fashion (Feinberg et al., 2009). In DC-SIGN, the CRDs face directly upwards from the 
neck. Therefore - in solution phase - the DC-SIGNR binding surface for 
PAPP-A1/proMBP would be greatly reduced, consisting possibly of only a single 
available CRD domain.  
Similarly, the MMR was not found to yield a significant binding signal in the presence 
of hnPAPP-A1. It is likely that the tandem organisation of CRDs in MMR do not 
favour the glycan arrangements on the surface of the glycoprotein.  
Figure 3.10 summarises a comparative sensorgram of all three C-type lectins as 
analytes with the human native PAPP-A1/proMBP-complex as immobilised ligand. 
The data demonstrates binding between DC-SIGN and hnPAPP-A1 with affinity 
values that lie well within the physiological range for in vivo interaction, especially 
considering the fact that hnPAPP-A1 plasma levels of 85 nM are found in pregnancy 
at term (Smith et al., 1979).  
 
The positive interaction between DC-SIGN and recombinant PAPP-A1 yielded a 
dissociation constant KD=1.3 nM. Even though the KD still lies within the low 
nanomolar range, it is nearly 3-fold higher in comparison to the interaction with 
PAPP-A1/proMBP. DC-SIGNR did not show any binding to the recombinant sample 
of PAPP-A1. This suggests that the glycosylation pattern of recombinant PAPP-A1 is 
different to the native form, and that the presence of the proMBP polypeptide may 
enhance the interaction with DC-SIGN. 
 
Notably, the immobilisation of the hnPAPP-A1 on the BLI probes gave rise to some 
discrepancy, especially for DC-SIGNR, as noted above. The immobilisation of the 
C-type lectin receptors, to some extent, mimics the physiological situation of the cell 
better: The C-type lectins used here are naturally anchored receptors within the cell 




all degrees of freedom. The reciprocal set-up via amine-coupling restricts the freedom 
significantly and might be the cause for steric hindrance of binding epitopes. 
DC-SIGN did not show a reduced binding affinity for the amine-coupling set-up of 
the experiment, which is an encouraging validation of the interaction and may point 
to a simple stoichiometry with the PAPP-A1/proMBP-complex, although further 
biophysical investigation would be required to establish this hypothesis.  
 
 
The significant differences in binding responses for DC-SIGN compared with the 
other two C-type lectins raises the attractive hypothesis that PAPP-A1/proMBP is a 
specific ligand for DC-SIGN and that selectivity is achieved not through the intrinsic 
monosaccharide preference of the CRDs, but rather through the specific arrangement 
of the multiple CRDs within the fully-folded DC-SIGN molecule. Reciprocally, the 
glycosylation pattern of PAPP-A1/proMBP could provide the spatial display of 





















Figure 3.10: Comparative sensorgram of all three C-type lectins (DC-SIGN, DC-SIGNR, MMR) as analytes interacting with the human native 
PAPP- A1/proMBP-complex as immobilised ligand, respectively, at different concentrations (ranging from 100 nM to 50 nM). The negative control 
with EDTA confirms that the interaction is calcium specific. Annotations: 
*1 100 nM DC-SIGN,      *2 75 nM DC-SIGN,     *3 50 nM DC-SIGN,      *4 100 nM DC-SIGNR,     *5 100 nM MMR,       





















4 RESULTS AND DISCUSSION (II)      
STRUCTURAL ANALYSES OF COMPLEX CARBO-
HYDRATE STRUCTURES ON GLYCOPROTEINS 







  Background 
The biophysical interaction study discussed in section 3.3.1 established not only the 
novel interaction between DC-SIGN and the native human PAPP-A1/proMBP-
complex but also demonstrated the dissociation constant KD to be within the low 
nanomolar and, therefore, well within the physiological range of blood plasma levels 
of native human PAPP-A1/proMBP. Furthermore, the interactions are disrupted in 
the presence of EDTA, which chelates calcium ions. Therefore, the calcium-
dependent interaction of glycans, present on the PAPP-A1/proMBP-complex, and 
the CRD of DC-SIGN has been described. Since this CRD has a binding preference 
for N-glycans of the mannose type, the structural analysis of the complex 
carbohydrate structures involved in this interaction is of great interest.  
The native human PAPP-A1/proMBP-complex is abundant in the plasma of 
pregnant women, although the enzymatic domain of PAPP-A1 has been found to be 
physiologically inhibited by proMBP. Overgaard et al. have stated that the human 
PAPP-A1 carries glycan structures on 11 sites out of the 14 potential N-glycosylation 
sites, which follow the consensus sequence N–X–S/T (except P for X) (Overgaard et 
al., 2003).  
Within this doctoral project, comprehensive analyses of the glycomic and 
glycoproteomic characteristics of PAPP-A1 samples were performed at the Analytical 
Service and Training Laboratory (Complex Carbohydrate Research Center, 
University of Georgia, USA), in collaboration with Dr Parastoo Azadi. Within this 
chapter, the glycomic and glycoproteomic characteristics of human recombinant 
proMBP, human recombinant PAPP-A1, and the human native PAPP-A1 derived 
from the PAPP-A1/proMBP-complex are described and analysed. 
For schematic representation of glycoforms, annotations are simplified by using 
antennary structures with the symbol nomenclature established by the Consortium 





  Detailed example of glyco(proteo)mic 
MS data analysis and structural 
interpretation 
The complex process of mass spectrometric data analysis and interpretation of glycan 
structures will be examined on one example in detail. However, the subsequent 
sections will be limited to describing the determinations reached through the process 
demonstrated within this specific section. 
The MS data acquired were searched for modification by glycosylation via the 
software Byonic. The search for N-linked glycosylation is presented for proMBP 
(alternative name BMPG), which carries one sequon for N-glycosylation (figure 4.11. 
in section 4.3.1.1). The MS data set was searched against specific parameters, such as 
the coverage of peptides, the amino acids expected to be cut during selective 
proteolytic digest, the assumed number of missed enzymatic cleavages, the tolerance 
of mass error, the quality of single spectra, expected contaminants, expected 
modifications and maximal quantity, databases for reference, etc. Table 17 provides 
an overview of the selected parameters/rules used by Byonic and shows exemplary 
values. Figure 4.1 shows the visualised result found for an N-glycan search in 
proMBP MS data. 
 
Table 17: Overview of selected parameters (rules) to search for in mass spectrometric data. 
Rule Value 
Cleavage residues (amino acid one-letter-
code) 
RK 
Digest cutter C-terminal cutter 
Peptide termini Semi specific 
Maximum number of missed cleavages 4 
Precursor tolerance 10.0 ppm 
Fragment tolerance (HCD) 10.0 ppm 
Fragment tolerance (ETD) 10.0 ppm 
Charges applied to charge-unassigned 
spectra 
1,2,3,4 
Precursor mass max. 10000.0 
N-glycan search common 2 
Skip bad spectrum true 
Off by x isotopes -2, -1, 0, +1, +2 
Contaminants added false 








Common modifications max. 5 
Rare modifications max. 2 
Carbamidomethyl / +57.021464 @ C common 2 
Oxidation / +15.994915 @ M  common 2 
Glycan Databases N-glycan 309 mammalian no 









Figure 4.1: Visualised data of peptide coverage (81.1%) and N-glycan modifications retrieved from MS data analysis of proMBP (alternative name 
BMPG). The first line names the peptide sequence searched against (in FASTA format). The sequence of amino acids is numbered in blocks of ten. The 
amino acids/peptides depicted in black were not covered. The amino acids/peptides depicted in green were covered by the software search through MS 
data. The number of spectra/scans assigned is represented in green bars/rows below the sequence. The red highlights indicate a modification, e.g. 




The rows, depicted below the peptide sequence of proMBP/BMPG in figure 4.1., 
represent single spectra and were assigned by Byonic. The assignment of the 
programme is based on theoretical data that fragment ions of a given glycopeptide 
would present, i.e. diagnostic ions. If the data matches with the acquired data, the 
peaks are annotated by Byonic accordingly. A successfully annotated spectrum 
through Byonic’s algorithm is shown representatively in figure 4.2.  
  
The HCD fragmentation method causes low-energy bonds to cleave, such as in the 
backbone of peptide ions that yields b- and y-ions (Zubarev et al., 1998). Diagnostic 
ions can be derived from the peptide, e.g. the b- and y-ions of fragmented peptide 
species, or from the attached glycan, e.g. glycan oxonium ions. As a first step towards 
the verification of the diagnostic ions, the original HCD spectrum is investigated 
(shown in figure 4.3.). The pattern of the peaks is identical for both spectra (figure 4.2. 
and figure 4.3.). 
Figure 4.2: HCD MS2 spectrum of the glycopeptide DGAVESISVPDMVDKNLT-
CPEEEDTVK (aa 71-97) derived from proMBP as presented in the software Byonic. The 
spectrum shows scan number 4820, which derived from sample eluted at retention time 
point 39.4670 min from the nanoLC. The highlighted and annotated C within the peptide 
sequence shows that the cysteine is carbamdiomethylated, i.e. 57.021 Da heavier than an 
unmodified cysteine. The highlighted and annotated N represents a modification of the 
asparagine with a putative glycan structure of about 2352 Da. Numerically matched b- (in 
blue) and y-ions (in red) of the peptide are marked in the associated spectrum as well as 
peptide sequence. MS fragment ions matching typical diagnostic ions derived from glycan 
structures are highlighted and annotated in green within the spectrum. Abbreviations: b – 
b-ion, Fuc – fucose/pentose, Hex – hexose, HexNAc - N-acetylhexosamine, NeuAc – sialic 
























Figure 4.4: HCD MS2 spectrum (m/z range 120-370) of MS scan (number 4820) of the 
glycopeptide DGAVESISVPDMVDKNLTCPEEEDTVK from proMBP. Diagnostic ions 
derived from glycans, i.e. oxonium ions, are highlighted in red and annotated with their m/z 
as well as charge state (z). Abbreviations: Hex – hexose, HexNAc - N-acetylhexosamine, 
NeuAc – sialic acid or N -acetylneuraminic acid, H2O – water molecule 
Figure 4.3: Original HCD MS2 spectrum (m/z range 50-2000; tandem MS step of peak m/z 
1333.5553 from the full MS) of the glycopeptide DGAVESISVPDMVDKNLT-
CPEEEDTVK as presented in the software Xcalibur from ‘Thermo Scientific LC-MS 
systems’. The spectrum shows scan number 4820 that derived from sample eluted at 





Figure 4.4. shows a lower m/z range (m/z 120-370) of HCD spectrum number 4820 
(figure 4.3) enlarged. Diagnostic ions originating from glycan structures (i.e. oxonium 
ions from hexoses [Hex], sialic acid residues [NeuAc], and hexosamines [HexNAc]), 
are strong indicators that the MS spectrum includes information derived from a 
glycosylated peptide of the protein of interest. The original software labelling (top 
right corner of the spectrum in figure 4.3.) also reveals that the tandem MS scan was 




Biomacromolecules contain naturally occurring stable isotopes of elements, such as 
carbon and nitrogen. For example, the 13C isotope of carbon occurs with a natural 
abundance of about one percent. Small, human N-glycan structures contain more 
than 50 carbon atoms, and any 13C isotope present instead of a 12C isotope adds 1 Da 
in mass. Ion signal peaks for ions of various isotopic compositions are detectable; for 
example, the enlarged m/z scale in figure 4.4. enables the observation of three peaks 
for one sialic acid fragment ion (m/z 291.0954 – 294.0964) versus the labelled average 
mass peak of m/z 292.1019. However, no ion signal peak exists at the average mass. 
This is also the cause of the rule “Off by x isotopes” being applied to the search in 
mass spectrometric data (see table 17). The software programmes Byonic, as well as 
Xcalibur, annotate peaks numerically with the average mass that takes into account 
all isotopic peaks. The annotation of the average mass but not the monoisotopic mass 
peak is evident throughout the following sections and is the cause of the difference 
between the annotated numeric values of peaks by some daltons from the calculated 
masses. The calculations performed with software tools required mainly 
monoisotopic mass values.  
The larger the glycan structure and/or the glycopeptide, the more atoms can be 
naturally substituted with stable isotopes, and the more prevalent will be the numeric 






For further analysis, the full mass spectrum was taken into account. It provided 
insight into the charge states of the glycopeptides detected. Since the spectra are 
always presented as relative abundance in relation to mass over charge (m/z), the 
information is helpful for identification of the numeric range of detection. 
Furthermore, the molecular mass of the original molecule can be re-calculated from 
m/z and results in a mass of 5334.2188 Da for m/z 1333.5547 with z=4. The HCD 
spectrum (figure 4.3.) shows the tandem fragmentation of precursor ion m/z 




Figure 4.5: Full mass spectrum (m/z 200-2000, MS scan number 4815) of the full MS scan 
that derived from the eluted sample of (glyco)peptides of proMBP at retention time 39.43 min 
from the on-line nanoLC. The average mass peak at m/z 1333.5547 is clearly identifiable, has 
a charge state of z=4, and is surrounded by multiple other peaks that either derive from 
isotopic ions of the same molecule or fragment ions from other molecules. The determination 
of the molecular mass of the original molecule after charge deconvolution of peak m/z 





The electron-transfer dissociation (ETD) fragmentation method targets the 
fragmentation of peptide bonds with higher energy than the HCD and CID methods. 
This causes the stronger amide bonds to cleave and yields c-ions and z-ions of the 
peptide with minimal fragmentation of the glycosylation (Zubarev et al., 1998). 
Empirically, not all glycopeptides fragment with the ETD method in a way that 
contributes easy-to-access information, since the m/z values reflect peptide ions that, 
ideally, contain an unmodified but still unidentified glycoform with an unknown 
mass. None of the analyses within the following sections was based on an ETD 
spectrum for this project. The ETD spectrum of the tandem fragmentation of the 
precursor ion m/z 1333.5553 derived from the full mass fragmentation is depicted in 
figure 4.6. 
Figure 4.6: ETD MS2 spectrum (m/z 120-2000) of precursor ion m/z 1333.5553 (full MS 
scan) derived from the glycopeptide DGAVESISVPDMVDKNLTCPEEEDTVK from 
proMBP. The retrieved m/z values of a fragmented glycopeptide reflect peptide ions with 
glycan modification. Ideally, the glycan remained unmodified throughout the ETD 
fragmentation process. However, the information is complex, since the glycan mass itself is 





The method of CID fragmentation preferentially targets glycosidic bonds over 
peptide bonds in a precursor ion deriving from a glycopeptide and yields mainly 
glycan oxonium ions but also minimal b-ion and y-ion coverage. CID is a method 
using even lower energy than HCD fragmentation and realises stepwise loss of single 
carbohydrate residues that enables determination of glycoforms including their 
structural characterisation, but does not allow for linkage information (Mechref, 
2012).  
However, the pattern of the spectra in CID (figure 4.7.) and HCD (figure 4.3) are 
comparable.  
The detailed analysis of this CID spectrum, deriving from a tandem fragmentation of 
the precursor ion at m/z 1333.5553 in the full MS fragmentation, is presented in a 
deconvoluted spectrum in figure 4.9.   
Figure 4.7: CID MS2 spectrum (m/z 360-2000) of the precursor ion m/z 1333.5553 (full MS 
scan) derived from the glycopeptide DGAVESISVPDMVDKNLTCPEEEDTVK from 
proMBP. The ion peaks represent multiply charged ions as annotated accordingly. Figure 
4.8. shows the same CID scan but with charge deconvolution applied, which simplifies the 




Noteworthy, the term ‘deconvolution’ has several meanings within the field of mass 
spectrometry. Here, the practice of charge deconvolution is defined as follows: A 
mass spectrum containing ions with various charge states (z=1/2/3/4/etc.) is 
mathematically processed to retrieve only singly charged species (z=1). This does not 
only simplify the spectrum but also reveals the molecular mass (m) of the original 
molecule, when z=1 in m/z values (Mallet and Down, 2009).  
Figure 4.8. shows the deconvoluted full MS spectrum: The deconvolution 
significantly simplifies the spectrum, as depicted in figure 4.8, in direct comparison 
with the original full MS spectrum (figure 4.5.). The average mass peaks at 
m/z 5040.0911, m/z 5185.1614, m/z 5331.1908, and m/z 5459.2920 have been 
identified as glycopeptides with different glycoforms. All of these glycopeptides 
were eluted from the nanoLC at the same time, fragmented in the full MS scan, and 
contributed to diagnostic ions identified. As already calculated on page 130, one 
glycoform of the original molecule species correlates closely with the calculated mass 







Figure 4.8: Deconvoluted full MS spectrum (m/z 4550-5540) derived from the glycopeptide 
DGAVESISVPDMVDKNLT-CPEEEDTVK from proMBP. Four glycoforms have been 
identified at m/z 5040.0911, m/z 5185.1614, m/z 5331.1908, and m/z 5459.2920. The 
detailed process of structural assignment by CID fragmentation is shown exemplary for 





Figure 4.9. shows the exact process of matching the species at m/z 5040.0911 from the 
deconvoluted full MS spectrum in figure 4.8. with a specific glycoform. The CID 
spectra are ideal to show loss of neutral sugar moieties from the glycan. This process 
also enables the structural assignment of the bi-antennary glycoform that belongs to 
the complex type with core fucosylation and terminal sialyation. 
 
Demonstrated peptide sequences carrying putative N-glycans are referred to as 
‘(glyco)peptide’ within the following sections. The sequences are presented in FASTA 
peptide format, e.g. XXXNX (with X being any amino acid). The sequences are also 
presented as (X)XXXNX(X) with the highlighted amino acid (N) depicting the 
asparagine within the N-glycan sequon, which was found to be glycosylated via 
analysis of glycan site attachment. The amino acids in brackets represent the sites 



























Figure 4.9: Deconvoluted CID MS2 spectrum (m/z 3140-5080) of the precursor ion m/z 1333.5553. This spectrum illustrates the final steps for the 
structural assignment of one of the glycoforms attached to the asparagine (red) within the sequon in the peptide 
DGAVESISVPDMVDKNLTC(57.02146)PEEEDTVK of proMBP. The neutral loss of carbohydrate moieties is demonstrated. 







  Recombinant human proMBP 
The sample investigated within this section is a recombinant preparation of the 
mature Proform of Eosinophil Major Basic Protein (proMBP; alternative names Bone 
Marrow Proteoglycan [BMPG], Proteoglycan 2 [PRG2]) that consists of 206 amino 
acids, since the signal peptide (aa 1-16) has been cleaved off before secretion by the 
eukaryotic expression system (expressed in human cells by the manufacturer). 
Remarkably, the propeptide (aa 17-105) sequence has acidic properties (isoelectric 
point [pI] around 4.0), whereas the pI of the sequence of the mature MBP lies at 11.0. 
Given that proMBP contains the sequences of the propeptide as well as the main 
chain, the pI is predicted and observed to lie around 6.1 (Wasmoen et al., 1988). The 
significantly different chemical characteristics underpin the foundation for diverse 
functions of proMBP and MBP, respectively. ProMBP is known to be a physiological 
proteinase inhibitor of PAPP-A1 during pregnancy (Overgaard et al., 2000). The full 
protein sequence for proMBP (protein ID P13727, FASTA format) shown in figure 
4.10, was retrieved from the Uniprot database (The UniProt Consortium, 1990). 
Since the amount of sample (50 μg) was neither sufficient to cover glycomic analysis 
nor analysis of the glycosaminoglycan attached, only glycoproteomic analysis for N-
linked and O-linked glycans was carried out.  
The study was conducted at the Analytical Services and Training Laboratory at the 
Complex Carbohydrate Research Center.  
MKLPLLLALL FGAVSALHLR SETSTFETPL GAKTLPEDEE TPEQEMEETP 
CRELEEEEEW GSGSEDASKK DGAVESISVP DMVDKNLTCP EEEDTVKVVG 
IPGCQTCRYL LVRSLQTFSQ AWFTCRRCYR GNLVSIHNFN INYRIQCSVS 
ALNQGQVWIG GRITGSGRCR RFQWVDGSRW NFAYWAAHQP WSRGGHCVAL 
CTRGGHWRRA HCLRRLPFIC SY 
 
Figure 4.10: FASTA peptide sequence of human proMBP. The sequence includes the signal 
peptide sequence (aa 1-16; highlighted in dark grey) and the propeptide sequence (aa 17-105; 
highlighted in light grey). The mature proMBP consists of 206 amino acids with 1 potential 
N-glycosylation site (sequon N-X-S/T, X not P, highlighted in yellow). Amino acids (T23, 
S24, T25, T34) that have been found to be O-glycosylated in past studies are highlighted in 
green. Furthermore, serine 62 (highlighted in magenta) has been found to be modified by a 




4.3.1 Glycoproteomic analysis of N-linked 
glycans on human recombinant proMBP 
The proMBP investigated for its N-linked glycosylation modifications had been 
recombinantly expressed in human cells (HEK293).  
The proMBP sample was pure enough to be directly processed with trypsin for 
enzymatic digestion. The expected proteolytic cleavages were therefore amino acids 
with a positive charge, i.e. lysine (K) or arginine (R), from the C-terminal side, if not 
followed by a proline (Baird and Craik, 2013). An in silico digest with PeptideCutter 
predicted the best theoretical peptide coverage for mass spectrometry with trypsin. 
Peptides are required to have a length between 5-30 aa to lie within the detection 
limit. 
The subsequent acquisition of MS data for glycoproteomic analysis of the 
(glyco)peptides was carried out with the nanoLC-MS/MS method described in 
section ‘2.6 Methods for Mass Spectrometry’. For the data analysis, the software 
programmes Xcalibur and Byonic were used. Byonic quantified the peptide coverage 
with 81.1% confidence with respect for search parameters set for N-glycan 
modification, carbamidomethylation of cysteines and oxidation of methionines. Most 
importantly, the peptide carrying the sequon NTL was well within the detectable 
range with a theoretical glycopeptide length of 12 amino acids.  
Oxvig et al. (1994) showed in the past that an ”N-linked glycan is bound to Asn-86” 





4.3.1.1 nLC-NSI-MS/MS analysis of N-linked glycoforms 
on glycopeptides from human recombinant proMBP 
For analysis of N-glycosylation on peptides derived from the Proform of Eosinophil 
Major Basic Protein (proMBP), the method of nano-scale liquid chromatography 
(nanoLC) with on-line tandem mass spectrometry (MS/MS) was performed, as stated 
in section ‘2.6 Methods for Mass Spectrometry’. 
Briefly, the sample derived from a tryptic digest of proMBP and the resulting 
peptides as well as glycopeptides were separated via nanoLC for better resolution, 
i.e. a significantly reduced amount of co-elution and co-ionisation of different 
glycopeptides for mass spectrometry. After ionisation by NSI, full MS scans were 
acquired, and precursor ions selected via various criteria. The selected precursors 
were then processed by tandem MS for parallel CID and HCD fragmentation. 
Diagnostic ions derived from glycan structures triggered further analysis via a 
subsequent fragmentation method, namely ETD. The glycoproteomic approach 
aimed to illuminate site-specific information of glycosylation, such as the site of the 
glycan attachment and prevalent glycoforms. 
Since the proMBP was sourced from human cells, the protein was expected to be 
partially processed and the signal peptide not to be present. All forthcoming 
references to amino acids represent the mature FASTA peptide sequence of human 
proMBP without the signal peptide. The database Uniprot lists the FASTA peptide 
sequence of human proMBP with one N-glycosylation being present within the 206 





LHLRSETSTF ETPLGAKTLP EDEETPEQEM EETPCRELEE EEEWGSGSED 
ASKKDGAVES ISVPDMVDKN LTCPEEEDTV KVVGIPGCQT CRYLLVRSLQ 
TFSQAWFTCR RCYRGNLVSI HNFNINYRIQ CSVSALNQGQ VWIGGRITGS 
GRCRRFQWVD GSRWNFAYWA AHQPWSRGGH CVALCTRGGH WRRAHCLRRL 
PFICSY 
Figure 4.11: FASTA format of the peptide sequence of human proMBP without the signal 
peptide. The mature proMBP consists of 206 amino acids, which includes the propeptide (aa 
1-89, highlighted in grey). The propeptide carries one sequon (N-X-S/T, X not P, highlighted 




a) Amino acid asparagine-70 
The programme PeptideCutter was used to predict the potential cleavage sites 
around the sequon NLTC at asparagine 70 (N70) for mature human proMBP. This 
resulted in the (glyco)peptide (K)NLTCPEEEDTVK(V) for an in silico digestion with 
trypsin. However, two distinct glycopeptides, (K)DGAVESISVP-
DMVDKNLTCPEEEDTVK(V) as well as (K)KDGAVESISVP-
DMVDKNLTCPEEEDTVK(V) were identified that cover this putative N-glycan site. 
For both (glyco)peptides found, trypsin missed the cleavage at amino acid lysine 69 
(L69). For a glycosylated asparagine 70, the steric hindrance could be the reason for 
the missed cleavage site by trypsin. Interestingly, proMBP carries two serial lysine 
residues at amino acid 53 (L53) and 54 (L54), which results in the two (glyco)peptides 
mentioned above that only differ by one amino acid.  
The glycosylation site at asparagine 70 was found to be occupied with seven different 
glycoforms that are classified as either complex type with fucosylation and sialyation 
(figure 4.12), or bisected type with terminal sialic acid residues (figure 4.13 and figure 
4.14). Annotated structures are based on the molecular weight, MS data, the N-glycan 
biosynthesis pathway and prevalent glycoforms in humans. 












Figure 4.12: Deconvoluted and annotated full MS spectrum of glycopeptides 
(K)DGAVESISVPDMVDKNLTCPEEEDTVK(V) and (K)KDGAVESISVPDMVDKNLT-
CPEEEDTVK(V)  (m/z 4550-5550) derived from human recombinant proMBP. Bi-antennary 
glycans of the complex type with fucosylation and sialylation (m/z 5040.0911, m/z 5185.1614, 






























Figure 4.13: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(K)DGAVESISVPDMVDKNLTCPEEEDTVK(V) (m/z 4100-5380) derived from human 
recombinant proMBP. Bi-antennary N-glycans of the bisected, complex type with 
fucosylation and sialylation (m/z 5040.0911, m/z 5331.1908) were found to be present on 
asparagine 70 of a subset of glycopeptides from proMBP. 
Figure 4.14: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(K)DGAVESISVPDMVDKNLTCPEEEDTVK(V) (m/z 3575-6025) derived from human 
recombinant proMBP. A tri-antennary glycan of the bisected, complex type with terminal 





4.3.2 Glycoproteomic analysis of O-linked 
glycans on human recombinant proMBP 
O-linked glycans are known to be attached to peptides by amino acids with a 
hydroxyl group side chain, such as serine (S) or threonine (T) residues within the 
protein sequence. O-glycosylation does not occur on distinctive sequons as 
N-glycosylation does. However, domains rich in serines, threonines and prolines 
have been shown to be modified with O-linked glycans of the mucin-type. They tend 
to be shorter regarding the degree of glycan extension, as well as showing a lower 
degree of branching. Studies have shown that the majority of O-linked glycans in 
human blood plasma proteins are short mucin-type glycans classified as structural 
core 1 and core 2 (Hoffmann et al., 2016). Mucin-type glycans share a core N-
acetylgalactosamine (GalNAc) residue linked to the peptide backbone and can be 
composed of GalNAc, GlcNAc, galactose, fucose and sialyl residues but not mannose 
or glucose residues (Brockhausen and Stanley, 2015). 
All references to amino acids represent the mature FASTA peptide sequence of 
human proMBP without the signal peptide, since the proMBP was sourced from 
human cells. The database Uniprot lists the FASTA peptide sequence of human 
proMBP with four sites of known O-glycosylation, which are highlighted in figure 
4.15 (The UniProt Consortium, 1990). 
Oxvig et al. (1994) showed that proMBP contains O-linked glycans that have been 
localised to amino acid threonine 7 (partially substituted), serine 8 (fully substituted), 
threonine 9 (fully substituted), and threonine 18 (partially substituted). Furthermore, 
they identified an O-linked glycosaminoglycan that modifies serine 46. Their analysis 
revealed an enormous heterogeneity of the glycan profile present on proMBP.  
LHLRSETSTF ETPLGAKTLP EDEETPEQEM EETPCRELEE EEEWGSGSED 
ASKKDGAVES ISVPDMVDKN LTCPEEEDTV KVVGIPGCQT CRYLLVRSLQ 
TFSQAWFTCR RCYRGNLVSI HNFNINYRIQ CSVSALNQGQ VWIGGRITGS 
GRCRRFQWVD GSRWNFAYWA AHQPWSRGGH CVALCTRGGH WRRAHCLRRL 
PFICSY 
Figure 4.15: FASTA format of the peptide sequence of human proMBP without the signal 
peptide. The mature proMBP is known to be fully or partially glycosylated on threonine 7, 
serine 8, threonine 9 and threonine 18 (aa positions with signal peptide would be threonine 




4.3.2.1 nLC-NSI-MS/MS analysis of O-linked glycoforms 
on glycopeptides from human recombinant proMBP 
For analysis of O-linked glycans on peptides derived from the Proform of Eosinophil 
Major Basic Protein (proMBP), the same methods were used as for N-linked glycan 
analysis: After the tryptic digest of proMBP, the (glyco)peptides were separated via 
on-line nanoLC, ionised by NSI, a full MS acquired and then precursor ions processed 
through tandem MS for parallel CID and HCD fragmentation. Diagnostic 
HCD-derived ions from glycan structures triggered further analysis via a subsequent 
ETD fragmentation.  
a) Amino acids serine 5, threonine 7, serine 8, threonine 
9, threonine 12 
In the literature and databases, amino acids threonine-7, serine-8, threonine-9 (amino 
acid positions with signal peptide: threonine-23, serine-24, threonine-25) are known 
to be modified with O-glycans (The UniProt Consortium, 1990). The programme 
PeptideCutter predicted the glycopeptide (R)SETSTFETPLGAK(T) that contains 
theses amino acids in the sequence of the mature human proMBP. The glycopeptide 
was confirmed via b-ions and y-ions in tandem MS spectra. All serines and threonines 
within the sequence are highlighted, since the identified glycoforms could be located 
on any of these. A detailed evaluation of the exact site of glycosylation within a 
glycopeptide could be achieved via β-elimination by Michael addition with 
dithiothreitol (BEMAD), which releases O-glycans and simultaneously labels the site, 
i.e. serine or threonine residue (Shajahan et al., 2017a). However, this method was not 
performed within the scope of this study. 
The glycopeptide (R)SETSTFETPLGAK(T) was found to be occupied with six 
different glycoforms of O-glycans of the mucin-type. Figure 4.16 shows the identified 
Tn antigen, i.e. a single GalNAc residue, at m/z 1570.7465 to be present on a subset 
of glycopeptides. Since no linkage information was obtainable with the MS methods 
performed, the following typification into core classes are unconfirmed; however, the 
structural composition is based on acquired MS data. Figure 4.17 depicts glycan 
structures of sialylated core 1 O-glycans (m/z 2972.2196, m/z 2681.1232), which form 
the most common O-GalNAc core. Figure 4.18 shows a glycopeptide at 




glycan, as both share the same glycopeptide mass.  Figure 4.19 shows evidence of a 
glycopeptide with two concurrent O-glycosylations (m/z 3629.4503) of the types 











Figure 4.17: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)SETSTFETPLGAK(T) (m/z 2420-3500) derived from human recombinant proMBP. The 
O-linked glycans at m/z 2681.1232 and m/z 2972.2196, are typified as of sialylated core 1 
O-glycans. 
Figure 4.16: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)SETSTFETPLGAK(T) (m/z 1250-2100) derived from human recombinant proMBP. The 
O-linked glycan (m/z 1570.7465) identified on the glycopeptide resembles the Tn antigen. 
Precise assignment of the glycan site was not possible, since several serines and threonines 















Figure 4.19: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)SETSTFETPLGAK(T) (m/z 2020-3860) derived from human recombinant proMBP. The 
glycopeptide with two concurrent O-GalNAc glycoforms (m/z 3629.4503) carries possibly 
sialylated core 1, as well as sialylated and extended core 3 type glycans. 
Figure 4.18: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)SETSTFETPLGAK(T) (m/z 1800-3320) derived from human recombinant proMBP. The 
identified glycopeptide at m/z 2519.0715 matches with two putative, isobaric glycan 
structures of either a sialylated and extended core 1 type or a sialylated and extended core 3 




b) Amino acids threonine 18, threonine 25, threonine 33 
From previous studies, the amino acid threonine-18 (positions with signal peptide: 
threo-nine-34) is known to be occupied with O-GalNAc glycosylation 
(The UniProt Consortium, 1990). The glycopeptide 
(E)TLPEDEETPEQEMEETPCR(K), containing the site of interest, was predicted 
through the programme PeptideCutter for the mature human proMBP and 
confirmed via b-ions and y-ions in tandem MS spectra. All three threonine residues 
in the sequence are highlighted because the identified glycoform could be located on 
any. The BEMAD method could also be used in future studies for a precise site 
mapping of the glycan. However, since threonine-25 and threonine-33 are directly 
followed by a proline, they are less likely to be modified with glycosylation. 
The glycopeptide TLPEDEETPEQEMEETPCR showed one O-GalNAc glycoform at 
m/z 3634.4155 that is shown in figure 4.20. The glycoform was confirmed in several 
full MS as well as HCD tandem spectra (data not shown) within the MS data set and 
represents putatively an extended core 3 O-GalNAc with branching and sialyation. 
 
  
Figure 4.20: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(E)TLPEDEETPEQEMEETPCR(K) (m/z 2360-4300) derived from human recombinant 
proMBP. The peak at m/z 3634.4155 matches the glycopeptide modified with an extended 
core 3 O-GalNAc glycan with branching and sialyation. The glycoform was confirmed 




4.3.3 Glycoproteomic analysis of glycosamino-
glycan-site on human recombinant proMBP 
ProMBP, that is also referred to as Bone marrow proteoglycan (BMPG) or 
Proteoglycan 2 (PRG2), is itself a member of the CTL superfamily. Interestingly, it 
recognises glycans of the heparan sulfate glycosaminoglycan type as well as heparin, 
but not via its CTL ligand-binding domain (Swaminathan et al., 2005, Glerup et al., 
2006). Moreover proMBP carries within its own protein sequence of the main chain, 
i.e. mature proMBP, a glycosaminoglycan (GAG) on serine-46 (amino acid 62 with 
signal peptide) of the heparan sulfate type. Glerup et al. (2006) demonstrated that 
proMBP binds to glycosaminoglycan-lined cell surfaces and, furthermore, that this 
interaction is independent of the GAG structure of proMBP. 
Figure 4.21: HCD MS2 spectrum of the glycosaminoglycan detected on mature proMBP. 
HCD spectrum of the glycopeptide (R)ELEEEEEWGSGSEDASK(K) as presented in the 
software Byonic. The spectrum shows scan number 3751 that derived from sample eluted at 
retention time point 29.9289 min from the nanoLC. The highlighted and annotated S within 
the peptide sequence reflects a modification of the serine(s) with a putative glycan 
structure(s) of about 5133 Da (resulting from 1038Da and 673 Da, both z=3) in total. This 
aligns with the most prominent peak at m/z 1038, which was not annotated by Byonic. From 
past studies it is known that site S46 is occupied with a glycosaminoglycan of the heparan 
sulfate type (Glerup et al., 2006). Matched b- (in blue) and y-ions (in red) of the peptide as 
well as diagnostic ions derived from glycan structures (green) are labelled in the spectrum. 
Abbreviations: b – b-ion, Fuc – fucose/pentose, Hex – hexose, HexNAc - N-acetylhexosamine, 




The predicted peptide, which derived from a tryptic digest in silico with 
PeptideCutter, was (R)ELEEEEEWGSGSEDASK(K). The software Byonic did detect 
a modification within this peptide as shown in figure 4.21. 
A prominent peak at m/z 1038 with z=3 is dominating the HCD MS2 spectrum 
(depicted in figure 4.21.) However, the software Byonic is not designed for 
identification of GAG-sites. Instead, diagnostic oxonium ions of N-
acetylhexoseamine-hexose (HexNAcHex) residues were identified by the software 
and resulted in the prediction of glycosylation of the peptide. The peptide sequence 
itself was fully covered by b- and y-ions, which verified the presence of the peptide 
ELEEEEEWGSGSEDASK. 
The deconvoluted full MS spectrum of this scan (presented in Xcalibur software) is 
shown in figure 4.22. The prominent peak at m/z 4944.8696 was identified as the 
glycopeptide with GAG-modification. The peptide mass was calculated with 
1909.77 Da. This allows for a glycoform mass of approximately 3032 Da, considering 
monoisotopic mass differences. The glycan search of the monoisotopic mass of 
m/z 4942.87221 via the tool GlycoMod resulted in about 1400 possible glycan 
structures. 
The complete study of glycosaminoglycan structures is even more complex than 
standard O-glycan analysis and requires several milligrams of the glycan. Due to the 
scope of this study and the availability of only 50 μg of glycosylated protein in total, 
the structural analysis of the GAG attached to proMBP was not attempted. However, 
preliminary evaluation of its size has been obtained.  
Figure 4.22: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)ELEEEEEWGSGSEDASK(K) (m/z 3420-5260) derived from human recombinant 
proMBP. The peak at m/z 4944.8696 shows the glycopeptide modified with a 




4.3.4 Conclusions from the glycoproteomic 
analysis of the recombinant human proMBP 
As early as 1993, it became evident that proMBP is heavily glycosylated with complex 
carbohydrate structures of the O-linked glycan, N-linked glycan and a 
glycosaminoglycan (GAG) type (Shikata et al., 1993).  
Within this part of the study, the mass spectrometric data obtained from 
glycopeptides derived from recombinantly expressed human proMBP was analysed 
via glycoproteomics. The findings fully confirm the glycosylation of the propeptide 
with N-linked glycoforms on asparagine-70, and O-linked glycans on two 
glycopeptides that include serine-5, threonine-7, serine-8, threonine-12, threonine-18, 
threonine-25 and threonine-33 (all amino acid positions without signal peptide). 
However, the exact site analysis for O-glycans would require an in-depth technique, 
such as the β-elimination by Michael addition with dithiothreitol (BEMAD), which 
releases the O-glycans and simultaneously labels the site of attachment for 
subsequent analysis. Furthermore, a modification of serine 46 was found, which 
presented diagnostic MS ions of glycans when analysed. It is without much doubt 
that this data represents the glycosaminoglycan, which is known to modify the 
serine-46 in past studies. 
In summary, N-linked and O-linked glycans were detected and their structural 
characteristics analysed within this study, which is in keeping with earlier, 
preliminary information available in the database Uniprot as well as the study 
conducted by Oxvig et al. (1994). 
 
The novel insight gained via this study is the composition of the N-linked and 
O-linked glycans attached to proMBP. 
The sole N-glycan attachment site at asparagine 70 was found to be occupied with 
N-glycans of the complex type. The glycoforms were identified as bi- and tri-
antennary structures with some of them presenting fucosyl residues at the core as 
well as terminal ends. About half of the glycoforms elucidated belong to the bisected 
category of the complex glycan type that carries a core GlcNAc residue, which is not 




are known to be recognised by DC-SIGN, with a GalNAc residue. Most importantly, 
no high mannose glycoform has been detected. The lack of high mannose type 
glycans and the underrepresentation of core mannose structures in N-glycans of 
proMBP indicate that an interaction between the CRD of DC-SIGN and the 
glycosylations of proMBP cannot be excluded; however, the overall interaction 
would be anticipated to be of a nature of lower affinity, since the CRD of DC-SIGN 
favours mannose-type sugars. On the other hand, the fucosylation of some N-linked 
glycoforms could provide the basis of a weaker interaction between proMBP and 
DC-SIGN. 
In contrast, DC-SIGNR only recognises mannose residues. Therefore, no interaction 
between the CRD of DC-SIGNR and the N-linked glycans of proMBP would be 
expected. 
Furthermore, all of the identified N-linked glycoforms contained galactose residues 
that were predominantly capped by sialic acid residues.  
Excluding the GAG, the remaining O-glycans of proMBP belong to the mucin-type. 
They are found to be shorter regarding the degree of glycan extension and show a 
lower degree of branching than the identified N-glycans. This aligns with finding 
from studies about O-linked glycans in human blood plasma proteins. The Tn antigen 
and, partially extended and branched, core 1 and core 3 O-glycans were identified for 
O-linked glycans on proMBP. 
Since the O-glycan analysis in this study did not show any O-glycans with Lewis-
type glyco-epitopes present for recombinant proMBP, it seems unlikely that DC-Sign 
interacts with the O-glycans present on proMBP – presuming they are sterically 





  Recombinant human PAPP-A1 
The sample of recombinant human PAPP-A1 was expressed in mouse myeloma cells 
(derived from the NS0 cell line), as stated by the manufacturer. The expressed protein 
sequence does not cover the full sequence of native PAPP-A1 (signal peptide aa 1-22; 
propeptide aa 23-80; mature chain aa 81-1627), but the amino acids 82/84-1214. The 
recombinant protein sequence corresponds to approximately three quarters of the 
native, mature PAPP-A1 sequence, and was confirmed prior to the glycoproteomic 
analysis through MS-derived proteomic data. In the interest of clarity and better 
MRLWSWVLHL GLLSAALGCG LAERPRRARR DPRAGRPPRP AAGPATCATR 
AARGRRASPP PPPPPGGAWE AVRVPRRRQQ REARGATEEP SPPSRALYFS 
GRGEQLRLRA DLELPRDAFT LQVWLRAEGG QRSPAVITGL YDKCSYISRD 
RGWVVGIHTI SDQDNKDPRY FFSLKTDRAR QVTTINAHRS YLPGQWVYLA 
ATYDGQFMKL YVNGAQVATS GEQVGGIFSP LTQKCKVLML GGSALNHNYR 
GYIEHFSLWK VARTQREILS DMETHGAHTA LPQLLLQENW DNVKHAWSPM 
KDGSSPKVEF SNAHGFLLDT SLEPPLCGQT LCDNTEVIAS YNQLSSFRQP 
KVVRYRVVNL YEDDHKNPTV TREQVDFQHH QLAEAFKQYN ISWELDVLEV 
SNSSLRRRLI LANCDISKIG DENCDPECNH TLTGHDGGDC RHLRHPAFVK 
KQHNGVCDMD CNYERFNFDG GECCDPEITN VTQTCFDPDS PHRAYLDVNE 
LKNILKLDGS THLNIFFAKS SEEELAGVAT WPWDKEALMH LGGIVLNPSF 
YGMPGHTHTM IHEIGHSLGL YHVFRGISEI QSCSDPCMET EPSFETGDLC 
NDTNPAPKHK SCGDPGPGND TCGFHSFFNT PYNNFMSYAD DDCTDSFTPN 
QVARMHCYLD LVYQGWQPSR KPAPVALAPQ VLGHTTDSVT LEWFPPIDGH 
FFERELGSAC HLCLEGRILV QYASNASSPM PCSPSGHWSP REAEGHPDVE 
QPCKSSVRTW SPNSAVNPHT VPPACPEPQG CYLELEFLYP LVPESLTIWV 
TFVSTDWDSS GAVNDIKLLA VSGKNISLGP QNVFCDVPLT IRLWDVGEEV 
YGIQIYTLDE HLEIDAAMLT STADTPLCLQ CKPLKYKVVR DPPLQMDVAS 
ILHLNRKFVD MDLNLGSVYQ YWVITISGTE ESEPSPAVTY IHGSGYCGDG 
IIQKDQGEQC DDMNKINGDG CSLFCRQEVS FNCIDEPSRC YFHDGDGVCE  
EFEQKTSIKD CGVYTPQGFL DQWASNASVS HQDQQCPGWV IIGQPAASQV 
CRTKVIDLSE GISQHAWYPC TISYPYSQLA QTTFWLRAYF SQPMVAAAVI  
VHLVTDGTYY GDQKQETISV QLLDTKDQSH DLGLHVLSCR NNPLIIPVVH 
DLSQPFYHSQ AVRVSFSSPL VAISGVALRS FDNFDPVTLS SCQRGETYSP  
AEQSCVHFAC EKTD 
Figure 4.23: FASTA peptide sequence of human recombinant PAPP-A1. The full sequence 
would consist of the signal peptide sequence (aa 1-22; highlighted in light grey), the 
propeptide sequence (aa 23-80; highlighted in dark grey) and the mature chain (aa 82/84-
1214). Highlighted in magenta are aa82 and aa84. The expressed recombinant PAPP-A1 
does neither hold the signal peptide nor the propeptide sequence. As per the manufacturer, 
the protein consists of 1133/1131 aa with 9 potential N-glycosylation sites (sequon N-X-S/T, 





comparability between the data sets, the amino acids will be referred to within the 
numeric frame of the full mature chain, i.e. aa 81 set as the first amino acid of the 
protein sequence (aa 1). The database-retrieved and adapted sequence is shown in 
figure 4.23. (The UniProt Consortium, 2001), including highlighted sequences that 
represent the signal peptide (light grey), propeptide (dark grey), valid 
N-glycosylation sequons (N-X-S/T, X not P; yellow) and invalid sequons N-P-S/T 
(cyan).   
The available amount of recombinant PAPP-A1 was limited at 20 μg, which restricted 
the structural analysis of the glycan structures to a glycoproteomic approach only.  
This study was carried out at the Analytical Services and Training Laboratory at the 





4.4.1 Glycoproteomic analysis of N-linked 
glycans on human recombinant PAPP-A1 
The recombinant human PAPP-A1 was investigated for its N-linked glycan 
modifications. 
The PAPP-A1 sample had sufficient purity (>90% purity as certified) for a direct and 
consecutive enzymatic digest with trypsin and chymotrypsin. The same enzymes 
were also chosen for the enzymatic digest of the native human PAPP-A1 (see section 
‘4.5.2 Glycoproteomic analysis of N-linked glycans on human native PAPP-
A1/proMBP-complex’) to facilitate the mass spectrometric analysis. The proteolytic 
cleavages were expected according to the cleavage specificities of the enzymes: 
Lysine (K) and arginine (R) (from the C-terminal side, if not followed by a proline) 
for trypsin, and bulky hydrophobic amino acids (from C-terminus, if not followed by 
a proline), such as tyrosine, tryptophan, and phenylalanine, for chymotrypsin 
(Perona and Craik, 1995, Baird and Craik, 2013, Gráf et al., 2013). Per in silico digest, 
the proteases trypsin and chymotrypsin yielded the best theoretical peptide coverage 
for mass spectrometry with peptide lengths between 5-30 aa. Importantly, most 
peptides carrying a sequon were theoretically within this range, except for NISW (aa 
310-313). For convenience of identification, the sequons of N-glycosylation sites will 
be presented in a peptide sequence of four amino acids. 
In a study carried out in 2003, Overgaard et al. showed the occupation of 11 sequons 
out of 14 potential N-glycosylation sites for the human mature PAPP-A1, i.e. N322 
(NSSL), N349 (NHTL), N400 (NVTQ), N521 (NDTN), N539 (NDTC), N645 (NASS), 
N745 (NISL), N946 (NASV), N1146 (NCSS), N1243 (NNSL), and N1439 (NVTV). The 
asparagine residues N310 (NISW), N1142 (NASL), and N1405 (NGSF) were found 
without glycosylation within their study (Overgaard et al., 2003). All data was 
acquired on basis of liquid chromatography and N-terminal sequence analysis of 
(glyco)peptides, but no mass spectrometric method was applied. Furthermore, no 






4.4.1.1 nLC-NSI-MS/MS analysis of N-linked glycoforms 
on glycopeptides from human recombinant PAPP-A1  
For the glycoproteomic analysis of glycopeptides derived from recombinant 
PAPP-A1, the technique of nano-scale liquid chromatography with on-line tandem 
MS (nLC-MS/MS or nLC-MS2; see section ‘2.6 Methods for Mass Spectrometry’ for 
details) was the method of choice to determine site-specific information of 
glycosylation, such as the site of the glycan attachment and prevalent glycoforms. 
The nLC-MS/Ms is able to separate isobaric glycans, which have the same mass but 
different sugar compositions and/or conformations (Shajahan et al., 2017a). After 
ionisation via the NSI method, full MS scans were acquired, and precursor ions 
selected applying various criteria. The selected precursors were then processed by 
tandem MS for parallel CID and HCD fragmentation. Diagnostic ions derived from 
glycan structures triggered further analysis via a subsequent fragmentation method, 
namely ETD. For data analysis of MS data, the software programmes Xcalibur and 
Byonic were used. Byonic quantified the peptide coverage with 75.1% confidence for 
recombinant PAPP-A1, applying search parameters for N-glycan modification, 
carbamidomethylation of cysteines, and oxidation of methionines.  
Since the peptide sequence of the recombinant human PAPP-A1 covers about 1133 
amino acids (full sequence reference aa 82/84-1214), only N322 (NSSL), N349 
(NHTL), N400 (NVTQ), N521 (NDTN), N539 (NDTC), N645 (NASS), N745 (NISL), 
and N946 (NASV) are the putative sites present. Out of these, N310 (NISW) would 
not be expected to be modified via glycosylation, according to Overgaard et al. (2003). 
The two sequons with a proline (N-P-S/T) are not expected carry glycan structures, 
according to the existing criterion for N-linked glycosylation sequons. 
The following subchapters present the glycoforms identified on the confirmed 
glycosylation sites. The spectra do not contain information about linkages between 
the sugar moieties, since linkage information was not part of the analysis and requires 
additional methods. The annotations in the HCD tandem (MS2 or MS/MS) mass 
spectra illustrate the assigned glycan structure based on the mass, the pathway of 
synthesis of N- linked glycans, and the species-specific glycosylation pattern for 




a) Amino acid asparagine-349  
The peptide sequence around the sequon NHTL at asparagine 349 (N349) was 
predicted via PeptideCutter for the recombinant PAPP-A1, which resulted in the 
(glyco)peptide (K)IGDENCDPECNHTLTGHDGGDCR(H) for a combined in silico 
digest with trypsin and chymotrypsin. This glycopeptide was confirmed and showed 
seven different glycoforms that are presented in an overview in figure 4.26. The 
glycan structure depicted in figure 4.24. at m/z 3848.4396 was identified as high 
mannose type, whereas the bi-antennary glycoforms at m/z 4050.5135 and 
m/z 4212.5654 belong to the hybrid type - since they contain one antenna with 
unsubstituted terminal mannose residues as well as another antenna with GlcNAc-
substituted mannose residues. The annotated glycoforms at m/z 4577.6993, 
m/z 4942.8297, and m/z 5105.8859 represent bi-antennary complex glycans in figure 
4.25. The additional glycoform m/z 4561.6986 in figure 4.26. is classified as a complex 
N-linked glycan with core fucosylation.  
The data of the ion fragments was retrieved via on-line nano-LC-MS/MS. All figures 














Figure 4.24: Deconvoluted and annotated full MS spectrum of glycopeptide 
(K)IGDENCDPECNHTLTGHDGGDCR(H) (m/z 2980-4340) derived from human 
recombinant PAPP-A1 via nanoLC-NSI-MS/MS. Glycoforms identified in this spectrum 









Figure 4.25: Deconvoluted and annotated full MS spectrum of glycopeptide 
(K)IGDENCDPECNHTLTGHDGGDCR(H) (m/z 3400-5160) derived from 
recombinant PAPP-A1 via nanoLC-NSI-MS/MS. Glycoforms identified in this 









Figure 4.26: Deconvoluted and annotated full MS spectrum of the glycopeptide (K)IGDENCDPECNHTLTGHDGGDCR(H)  (m/z 3720-5160) 
that provides an overview of the glycoforms identified at N349 for the recombinant PAPP-A1. All classes of glycoforms have been found, i.e. high-
mannose type (m/z 3848.4396), hybrid type (m/z 4050.5135, m/z 4212.5654) or complex N-glycan type (m/z 4561.6986, m/z 4577.6993, 





b) Amino acid asparagine-400  
The predicted (glyco)peptide, around the sequon NVTQ at asparagine-400 for the 
recombinant human PAPP-A1, was (R)FNFDGGECCDPEIT-
NVTQTCFDPDSPHR(A) according to the in silico enzymatic digest with 
PeptideCutter. The identified sequence confirmed the prediction. The determined 
glycoform at asparagine-400 is shown in figure 4.27. at m/z 5938.2722. The glycan 
structure is classified as tri-antennary complex type with a core fucosylation. 




Figure 4.27: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)FNFDGGECCDPEITNVTQTCFDPDSPHR(A) (m/z 4880- 6000) derived from human 
recombinant PAPP-A1. The glycoform found to occupy asparagine-400 is a glycan structure 




c) Amino acid asparagine-521 
The (glyco)peptides carrying the sequon NDTN (asparagine-521) for the recombinant 
human PAPP-A1 were predicted as (R)GISEIQSCSDPCMETEPSF(E) and 
(F)ETGDLCNDTNPAPK(H) as per in silico digestion with both, trypsin and 
chymotrypsin. However, the glycopeptide identified was (R)GISEIQSCS-
DPCMETEPSFETGDLCNDTNPAPK(H). Very likely, the proximal proline caused a 
change in the secondary structure, that might have prevented chymotrypsin from 
cleavage before the amino acid phenylalanine-514 and caused the elongated peptide.  
The glycopeptide was found to carry a tri-antennary carbohydrate structure of the 
complex glycan type, which is presented in figure 4.28. at m/z 6001.3410.  
The data was retrieved via on-line nano-LC-MS/MS and shows a full MS spectrum. 
  
Figure 4.28: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)GISEIQSCSDPCMETEPSFETGDLCNDTNPAPK(H) (m/z 5000-6200) obtained 
from human recombinant PAPP-A1 via nanoLC-NSI-MS/MS. The glycoform identified 




d) Amino acid asparagine-539 
After an in silico digest with trypsin and chymotrypsin, the programme PeptideCutter 
predicted the (glyco)peptide (K)SCGDPGPGNDTCGF(H) around the sequon NDTC 
at asparagine-539 for the recombinant human PAPP-A1 protein sequence. The 
glycopeptide was confirmed and the glycosylation site at asparagine-539 found to be 
occupied with two different tri-antennary glycoforms that are both classified as 
complex type with core fucosylation (m/z 3900.3958, m/z 4062.4443), as annotated 
in figure 4.29. 






Figure 4.29: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(K)SCGDPGPGNDTCGF(H) (m/z 2980-4400) derived from human recombinant 
PAPP-A1. The identified glycoforms at m/z 3900.3958 and m/z 4062.4443 represent 




e) Amino acid asparagine-745 
The programme PeptideCutter was used to predict the potential cleavage sites 
around the sequon NISL at asparagine-745 (N745) for human recombinant PAPP-A1. 
For an in silico digest with trypsin and chymotrypsin, the resulting (glyco)peptide 
(K)NISLGPQNVF(C) was confirmed by MS data. 
The glycosylation site at N745 was found to be occupied with two different 
glycoforms that are classified as complex type with core fucosylation at 
m/z 3531.4396 (bi- or tri-antennary glycan structure shown in figure 4.30.), and 
m/z 3710.5058 (tri-antennary glycan structure depicted in figure 4.31.). Interestingly, 
the glycoform at m/z 3710.5058 in figure 4.30 is the only glycan structure with a N-
glycolylneuraminic acid (NeuGc) residue. NeuGc is an abundant glycan moiety in 
the murine glycosylation system and often appears in murine glycoproteins as 
terminal residue. However, NeuGc is almost non-detectable within adult humans. 
 
Figure 4.30: Deconvoluted and annotated full MS spectrum (m/z 2920-4760) of the 
glycopeptide (K)NISLGPQNVF(C) derived from human PAPP-A1 that was 
recombinantly expressed in a murine cell line. The glycoform identified at m/z 3531.4396 
is classified as a bi-antennary, complex glycan with core fucosylation (m/z 4247.8412) but, 




























Figure 4.31: Deconvoluted and annotated full MS spectrum (m/z 2660-3760)  of the 
glycopeptide (K)NISLGPQNVF(C) derived from recombinant PAPP-A1. The identified 
glycoform at m/z 3710.5058 in this spectrum is classified as tri-antennary complex glycan 





f) Amino acid asparagine-946 
The (glyco)peptide (W)ASNASVSHQDQQCPGW(V) was predicted after a combined 
in silico digest with trypsin and chymotrypsin with the programme PeptideCutter for 
the area around the sequon NASV at asparagine 946 (N946) for human recombinant 
PAPP-A1. The detected glycopeptide had the amino acid sequence 
(Y)TPQGFLDQWASNASVSHQDQ(Q), which represents two missed cleavages by 
chymotrypsin before phenylalanine-939 as well as tryptophan-943. However, an 
unpredicted cleavage occurred between glutamine-954 and glutamine-955. 
The glycosylation site at N946 was found to be occupied with a tetra-antennary 
glycoform of the complex type at m/z 5467.1779 with fucosylation of the glycan core, 
as depicted in figure 4.32.  









Figure 4.32: Deconvoluted and annotated full MS spectrum (m/z 2950-5475) of the 
glycopeptide (Y)TPQGFLDQWASNASVSHQDQ(Q) derived from human recombinant 
PAPP-A1 via nanoLC-NSI-MS/MS. The identified glycoform in this spectrum is 





4.4.1.2 Conclusions from the glycoproteomic analysis of 
the human recombinant PAPP-A1 
The glycoproteomic site analysis of the recombinant PAPP-A1 showed that the 
asparagine residues N349 (NHTL), N400 (NVTQ), N521 (NDTN), N539 (NDTC), 
N745 (NISL), and N946 (NASV) were glycosylated. The peptides carrying the 
sequons N310 (NISW), N322 (NSSL) and N645 (NASS) were not covered and no 
assumption can be made. As expected, the two sequons with a proline (N-P-S/T) did 
not carry glycan structures, which is in line with the existing criterion for N-linked 
glycosylation sequons. 
The analysis and characterisation of the glycan structures revealed that the 
recombinant PAPP-A1 is modified with glycoforms of the high-mannose, hybrid and 
complex type, respectively. Only asparagine-349 was partially occupied with 
glycoforms of the high-mannose and hybrid type. All other sequons revealed a 
modification with complex type glycans. No bisected complex carbohydrate 
structures were identified. Overall, the steric availability of mannose core structures 
(no bisection with a single GlcNAc) as well as a partial occupation with high-
mannose glycoforms prefigure an interaction between the N-linked glycans attached 
to the investigated sample of human recombinant PAPP-A1 and the CRD of 
DC-SIGN. The carbohydrate recognition domain of DC-SIGNR might recognise the 
recombinant PAPP-A1 either with low affinity or not at all, given the low accessibility 
of mannose residues for binding. 
Most sequons showed only a single glycoform attached. A summary of the findings 
is gathered in table 18.  
One glycoform on asparagine-745 showed a sugar moiety that is present in 
abundance in mice but not adult humans. It is noteworthy that mice have a similar, 
but not identical glycosylation pattern to that of humans. In particular, N-glycolyl-
neuraminic acid (NeuGc) is a common glycan moiety in murine glycoproteins. 
However, NeuGc is present only in traces within fully developed humans. It triggers 
an immune response when presented in abundance to the human immune system in 
postnatal phases (Varki, 2001). Remarkably, no terminal sialic acids residues (NeuAc) 
were identified in any of the glycoforms present on this recombinant human 
PAPP-A1 sample expressed in murine cells. 




Table 18: Summary of the glycoproteomic analysis of N-linked glycans identified in recombinantly expressed PAPP-A1 (amino acid sequence(s) 82/84-
1214). Out of the 9 N-glycan sequons (N-X-S/T, X not P; asparagine putatively linked to glycan is highlighted in red [N]), 6 have been found 
glycosylated including (partially fucosylated) glycoforms of the high-mannose, hybrid, and the complex type, respectively. However, 3 putative 
glycopeptides (sequons around N310, N322, N645) have not been covered by data. 




Glycosylation sequon FASTA peptide sequence Type of N-glycosylation 
310 NISW NISW‡ peptide not covered 
322 NSSL ELDVLEVSNSSLR‡ peptide not covered 
349 NHTL IGDENCDPECNHTLTGHDGGDCR 
High-mannose, Hybrid, 
Complex [fucosylated] 
400 NVTQ FNFDGGECCDPEITNVTQTCFDPDSPHR Complex [fucosylated] 
521 NDTN GISEIQSCSDPCMETEPSFETGDLCNDTNPAPK Complex 
539 NDTC SCGDPGPGNDTCGF Complex [fucosylated] 
645 NASS ASNASSPMPCSPSGHW‡ peptide not covered 
745 NISL NISLGPQNVF Complex [fucosylated] 












  Human native PAPP-A1/proMBP-
complex 
This part of the research project was carried out at the Analytical Services and 
Training Laboratory at the Complex Carbohydrate Research Center and partly 
supported by the National Institutes of Health grants 1S10OD018530 and 
P41GM10349010. The laboratory work was conducted by Dr Ganapati Bhat and Dr 
Nitin Supekar. 
The proMBP/PAPP-A1-complex was separated via SDS-PAGE (4-15 % 
polyacrylamide gel) under reducing conditions by the chemical DTT (figure 4.33). 
From each of the three lanes carrying 66.67 µg protein, the 200 kDa band was excised, 
which corresponds to the PAPP-A1 monomer. The sample was processed with 
trypsin and chymotrypsin for proteolytic digestion. A part of the sample was further 
treated with PNGase F, which released the N-glycans from the PAPP-A1 peptides. 
Released N-glycans were permethylated and analysed by MALDI-ToF-MS and NSI-
























4-15 % SDS-PAGE gel 
200 kDa, PAPP-A1 monomer 
Figure 4.33: SDS-PAGE gel of the human native proMBP/PAPP-A1 complex. The gel ran 
under reducing conditions and lane 1-3 were loaded with 66.67 µg protein, respectively. 
The 200 kDa band of each lane was cut out and processed further for MS investigation of 





The PAPP-A1 peptides after the PNGase F treatment were processed and analysed 
for O-glycopeptides. However, no O-glycans were detected. This finding is in 
agreement with the information available for PAPP-A1 (protein ID Q13219) from the 
established database Uniprot (The UniProt Consortium, 2001). 
4.5.1 Glycomic analysis of the human native 
PAPP-A1/proMBP-complex 
4.5.1.1 MALDI-ToF-MS analysis of released, per-
methylated N-linked glycans 
Matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry data 
was acquired for permethylated N-glycans, which were released from native human 
proMBP/PAPP-A1-complex after extraction of the 200 kDa band from SDS-PAGE 
gel.  
 
A representative MALDI-TOF spectrum of the permethylated N-glycans is shown in 
figure 4.34. The profile was obtained from the wash fraction of the C18 SPE cartridge 
as stated in section 2.3.1.3 a. The spectrum shows a very good signal-to-noise ratio 
(S/N) for the glycans, which is reflected in the clear distinction between signal peaks 
and the baseline. The baseline is caused by background ions that do not derive from 
the analytes, and is referred to as ‘noise’ (Krutchinsky and Chait, 2002). The spectrum 
was acquired with a maximum intensity of 2013.8 for the most abundant peak. 
Molecular ions were detected between m/z 1500-3900. Putative structures were 
based on the acquired data, the molecular weight, and on principles of the human N-
glycan biosynthesis pathway (Kornfeld and Kornfeld, 1985). Through MALDI-ToF 
analysis, 13 different N-glycoforms were observed at m/z 1579.7441, 1783.8208, 
1981.8928, 2028.9325, 2155.9700, 2185.9854, 2191.9919, 2390.0771, 2396.1822, 
2792.2019, 2966.2622, 3602.4958 and 3776.5410 for human native PAPP-A1. The 
annotated data show that primarily high-mannose and also complex sialylated 






Since the MALDI technique transfers a higher degree of energy to the ions during the 
ionisation phase, false fragmentation of fragile glycan substituents can occur. This 
includes labile sialic acid and fucose residues and could be a reason for the observed 
abundance of high-mannose, non-fucosylated, non-sialylated N-glycans. All detected 





















Figure 4.34: Annotated MALDI-TOF-MS spectrum (m/z 1500-3900) of permethylated N-glycans enzymatically released from the human native 
PAPP-A1, which was extracted from the 200 kDa band of a SDS-PAGE gel. The structures are based on the molecular weight, MS data and follow 
the principle of the N-glycan biosynthesis pathway in humans. Mainly bi- and tri-antennary high mannose and complex sialylated glycans are present 





















































































































4.5.1.2 NSI-MS analysis of released, permethylated 
N-linked Glycans  
Nanospray ionisation (NSI)-mass spectrometry was used for the acquisition of data 
for released and permethylated N-glycans. These derived from the native human 
proMBP/PAPP-A1-complex after extraction of the 200 kDa band, which corresponds 
to the PAPP-A1 polypeptide monomer, from the reducing SDS-PAGE gel.  
A representative NSI-MS spectrum of the permethylated N-glycans is shown in 
Figure 4.35. As stated in section 2.3.1.3 a, the profile was obtained from the wash 
fraction of the processing via the C18 SPE cartridge. The spectrum shows a good 
signal-to-noise ratio (S/N) for the glycans, based on the distinguishable analyte 
peaks. Since the NSI-MS technique is much more sensitive, more ions were visible in 
the overall spectrum. Molecular ions were detected between m/z 720–2000. Based on 
the molecular weight, the acquired data and principles of the human N-glycan 
biosynthesis pathway, putative structures were assigned. 
The data complements the information revealed through MALDI-ToF-MS (see 
section ‘4.5.1.1 MALDI-ToF-MS analysis of released, per-methylated N-linked 
glycans’). Moreover, due to a lower amount of unintended fragmentation for the full 
MS data acquisition, more glycoforms were assignable. In detail, four more glycan 
structures were assigned, which totals in 17 detectable glycoforms via NSI-MS. The 
N-glycan peaks were observed at the m/z values of 801.3861, 903.4360, 1002.4863, 
1025.9991, 1089.5307, 1104.5367, 1107.0372, 1206.0875, 1209.5851, 1407.6860, 
1422.6904, 1487.7216, 1494.73013, 1582.2750 for ions with a charge state z=2. Three 
more N-glycans ionised with a charge state z=3 are resolved at m/z values of 
1216.5883, 1274.9522, and 1332.9536 (depicted in figure 4.35). The charge states are 
caused by the comparatively slow evaporation of the droplet solvent during the NSI 
ionisation process. The additional glycoforms, which weren’t evident in the MALDI-
ToF-MS spectrum, carry more fragile glycan substituents, such as sialic acid and 
fucose residues. This finding is consistent with the literature as well as empirical data 
(Zaia, 2010, Shajahan et al., 2017a). 
The analysis and interpretation of the MS data confirmed that high mannose and 
multi-antennary, sialylated complex glycans are mainly present on human native 

























Figure 4.35: Annotated NSI-MS spectrum (m/z 720-2000) of permethylated N-glycans, which were enzymatically released from the human native 
PAPP-A1. PAPP-A1 was extracted from SDS-PAGE gel (200 kDa band). Annotated structures are based on the molecular weight, MS data and the 
human N-glycan biosynthesis pathway. High mannose and complex sialylated glycans with and without fucosylation are found to be present on 




4.5.2 Glycoproteomic analysis of N-linked 
glycans on human native PAPP-A1/proMBP-
complex 
For the glycoproteomic approach, the technique of liquid chromatography tandem 
MS (LC-MS/MS) was the method of choice. MALDI-ToF was not applied since the 
energy is favourably absorbed by glycosidic bonds, which subsequently leads to a 
higher degree of glycosidic cleavages. The aim was to obtain site-specific information, 
such as the specific asparagine residues of the glycan attachment and also the 
prevalent glycoforms present at each site. Therefore, a MS technique that favours the 
cleavage of peptide bonds was required, such as NSI-MS. The site mapping was 
performed first, as the acquired data helped the following glycopeptide analysis. NSI-
MS further allows for tandem MS (MS/MS or MS2) fragmentation methods and can 
be refined through a prior liquid chromatography (LC) step, referred to as liquid 
chromatography-MSn (LC-MSn). The LC-NSI-MS/MS method is able to separate 
isobaric glycans, which have the same mass but different sugar compositions and/or 
conformations (Costello et al., 2007, Shajahan et al., 2017a). 
As explicitly stated in ‘2.6 Methods for Mass Spectrometry’, the fragmentation 
methods of higher-energy collisional dissociation (HCD) and subsequent, HCD-
triggered collision–induced dissociation (CID) were used for analysis of 
(glyco)peptides derived from native human PAPP-A1. The database Uniprot lists the 
full FASTA peptide sequence of human PAPP-A1 with 1627 amino acids, including 
the signal peptide (aa 1-22) and the propeptide (aa 23-80) (The UniProt Consortium, 
2001), as shown in figure 4.36.  
The PAPP-A1/proMBP-complex was sourced from human retroplacental blood. 
Given the native state of the protein, the full human sequence and subsequent 
processing was expected, i.e. removal of the signal and propeptide. The remaining 
amino acid sequence of 1547 aa had been confirmed present - via proteomic analysis 
by mass spectrometry - prior to the glycan analysis. 
All forthcoming references to amino acids represent the mature FASTA peptide 




identification, the sequons of N-glycosylation sites will be presented in a peptide 






MRLWSWVLHL GLLSAALGCG LAERPRRARR DPRAGRPPRP AAGPATCATR AARGRRASPP 
PPPPPGGAWE AVRVPRRRQQ REARGATEEP SPPSRALYFS GRGEQLRLRA DLELPRDAFT 
LQVWLRAEGG QRSPAVITGL YDKCSYISRD RGWVVGIHTI SDQDNKDPRY FFSLKTDRAR 
QVTTINAHRS YLPGQWVYLA ATYDGQFMKL YVNGAQVATS GEQVGGIFSP LTQKCKVLML 
GGSALNHNYR GYIEHFSLWK VARTQREILS DMETHGAHTA LPQLLLQENW DNVKHAWSPM 
KDGSSPKVEF SNAHGFLLDT SLEPPLCGQT LCDNTEVIAS YNQLSSFRQP KVVRYRVVNL 
YEDDHKNPTV TREQVDFQHH QLAEAFKQYN ISWELDVLEV SNSSLRRRLI LANCDISKIG 
DENCDPECNH TLTGHDGGDC RHLRHPAFVK KQHNGVCDMD CNYERFNFDG GECCDPEITN 
VTQTCFDPDS PHRAYLDVNE LKNILKLDGS THLNIFFAKS SEEELAGVAT WPWDKEALMH 
LGGIVLNPSF YGMPGHTHTM IHEIGHSLGL YHVFRGISEI QSCSDPCMET EPSFETGDLC 
NDTNPAPKHK SCGDPGPGND TCGFHSFFNT PYNNFMSYAD DDCTDSFTPN QVARMHCYLD 
LVYQGWQPSR KPAPVALAPQ VLGHTTDSVT LEWFPPIDGH FFERELGSAC HLCLEGRILV 
QYASNASSPM PCSPSGHWSP REAEGHPDVE QPCKSSVRTW SPNSAVNPHT VPPACPEPQG 
CYLELEFLYP LVPESLTIWV TFVSTDWDSS GAVNDIKLLA VSGKNISLGP QNVFCDVPLT 
IRLWDVGEEV YGIQIYTLDE HLEIDAAMLT STADTPLCLQ CKPLKYKVVR DPPLQMDVAS 
ILHLNRKFVD MDLNLGSVYQ YWVITISGTE ESEPSPAVTY IHGSGYCGDG IIQKDQGEQC 
DDMNKINGDG CSLFCRQEVS FNCIDEPSRC YFHDGDGVCE EFEQKTSIKD CGVYTPQGFL 
DQWASNASVS HQDQQCPGWV IIGQPAASQV CRTKVIDLSE GISQHAWYPC TISYPYSQLA 
QTTFWLRAYF SQPMVAAAVI VHLVTDGTYY GDQKQETISV QLLDTKDQSH DLGLHVLSCR 
NNPLIIPVVH DLSQPFYHSQ AVRVSFSSPL VAISGVALRS FDNFDPVTLS SCQRGETYSP  
AEQSCVHFAC EKTDCPELAV ENASLNCSSS DRYHGAQCTV SCRTGYVLQI RRDDELIKSQ 
TGPSVTVTCT EGKWNKQVAC EPVDCSIPDH HQVYAASFSC PEGTTFGSQC SFQCRHPAQL 
KGNNSLLTCM EDGLWSFPEA LCELMCLAPP PVPNADLQTA RCRENKHKVG SFCKYKCKPG 
YHVPGSSRKS KKRAFKTQCT QDGSWQEGAC VPVTCDPPPP KFHGLYQCTN GFQFNSECRI 
KCEDSDASQG LGSNVIHCRK DGTWNGSFHV CQEMQGQCSV PNELNSNLKL QCPDGYAIGS  
ECATSCLDHN SESIILPMNV TVRDIPHWLN PTRVERVVCT AGLKWYPHPA LIHCVKGCEP 
FMGDNYCDAI NNRAFCNYDG GDCCTSTVKT KKVTPFPMSC DLQGDCACRD PQAQEHSRKD 
LRGYSHG 
 
Figure 4.36: FASTA peptide sequence of human native PAPP-A1. The sequence includes the 
signal peptide sequence (aa 1-22; highlighted in light grey) and the propeptide sequence (aa 23-
80; highlighted in dark grey). The mature PAPP-A1 protein consists of 1547 aa with 14 
potential N-glycosylation sites (sequon N-X-S/T, X not P [valid sequons highlighted in yellow; 
sequons N-P-S/T are not glycosylated and highlighted in cyan]). Only 11 of the sites have been 
found to be occupied by Overgaard et al. (2003). The five complement control protein (CCP) 
modules, also called sushi domains, present in the native PAPP-A1 are highlighted in dark 
green (Sushi 1 aa 1213-1282, Sushi 2 aa 1283-1344, Sushi 3 aa 1345-1412, Sushi 4 aa 1413-




4.5.2.1 nLC-NSI-MS/MS analysis of N-linked glycoforms 
on glycopeptides from human native PAPP-A1  
For the glycoproteomic analysis, an enzymatic digest was required to detect 
glycopeptides with the nanoLC-MS2 technique. Per in silico digest, the proteases 
trypsin and chymotrypsin were chosen, since they yielded the best theoretical 
peptide coverage for mass spectrometry. Ideally, peptides are required to have a 
length between 5-30 aa to lie within the detection limit, and 113 of the 253 predicted 
peptides did match this criterion. More importantly, most peptides carrying an 
N-glycosylation sequon lay within this range, except for NISW (aa 310-313) and 
NGSF (aa 1385-1388). 
Trypsin as well as chymotrypsin cleave before the substrate from the C-terminal side, 
i.e. the amino acid that served as proteolytic substrate is the last amino acid of the 
sequence in FASTA format. Trypsin cleaves from the C-terminus before amino acids 
with a positive charge, such as lysine (K) or arginine (R), if not followed by a proline. 
Chymotrypsin cleaves before C-terminal and bulky hydrophobic amino acids, e.g. 
tyrosine (Y), tryptophan (W), and phenylalanine (F). However, cleavage after smaller 
hydrophobic amino acids, such as methionine (M) and leucine (L), have also been 
described, but with slower rates of catalytic efficiency (Perona and Craik, 1995, Baird 
and Craik, 2013, Gráf et al., 2013). 
Overgaard et al. (2003) published, on basis of liquid chromatography and N-terminal 
sequence analysis of (glyco)peptides, the occupation of 11 sequons within PAPP-A1. 
However, the publication clearly states that “[m]ass spectrometry of peptides 
substituted with carbohydrate was not attempted”. The asparagine residues 
elucidated to carry N-linked glycosylation were N322 (NSSL), N349 (NHTL), N400 
(NVTQ), N521 (NDTN), N539 (NDTC), N645 (NASS), N745 (NISL), N946 (NASV), 
N1146 (NCSS), N1243 (NNSL), and N1439 (NVTV) (Overgaard et al., 2003). This 
leaves the asparagine residues N310 (NISW), N1142 (NASL), and N1405 (NGSF) to 
be excluded from glycosylation within their study from 2003. Furthermore, no 
analysis of the types of carbohydrates attached to PAPP-A1 was undertaken at the 
time. 
The following subchapters present the glycoforms identified on the confirmed 




glycan structure based on the mass, the pathway of synthesis of N- linked glycans, 
and the species-specific glycosylation pattern for humans. The data was confirmed 
by HCD MS2 data as well as CID MS2 data (not shown). 
 The spectra do not contain information about linkages between the sugar moieties, 
since linkage information was not part of the analysis and requires additional 
methods. For a clearer arrangement of the annotated spectra, the peptide part of the 
glycoform is referred to as “peptide” in cases of shortage of space. Amino acids 
highlighted in red indicate a modification of the amino acid, i.e. glycan modifications 







a) Amino acid asparagine-349  
The programme PeptideCutter was used to predict the potential cleavage sites 
around the sequon NHTL at asparagine-349 (N349) for mature human PAPP-A1. This 
resulted in the (glyco)peptide (K)IGDENCDPECNHTLTGHDGGDCR(H) for a 
combined in silico digestion with trypsin and chymotrypsin. The glycopeptide was 
identified and verified via b- and y-ions in the HCD MS2 spectrum (data not shown). 
The peptide mass matched with all three cysteines being modified via 
carbamidomethylation (highlighted in red in figure 4.37). 
Figure 4.37 shows the glycoforms that were determined for the glycosylation at site 
N349: Eights glycan structures were found in total - including three structures that 
are classified as high-mannose type (m/z 3845.4446, m/z 4007.4922, m/z 4169.5402), 
and five structures that belong to the hybrid type with sialylation (m/z 4177.5563, 
m/z 4339.6074, m/z 4501.6603) or without (m/z 4048.5121, m/z 4210.5662). The 
glycoforms possess either a bi-antennary or a tri-antennary structure. 
The data was obtained via on-line nano-LC-MS/MS and figure 4.37 shows a 

















Figure 4.37: Deconvoluted and annotated full MS spectrum (m/z 3820-4730) of glycopeptide (K)IGDENCDPECNHTLTGHDGGDCR(H) derived from 
human native PAPP-A1 via nanoLC-NSI-MS/MS. Glycoforms identified and shown in this spectrum are glycan structures classified as either high-mannose 




b) Amino acid asparagine-400 
The predicted (glyco)peptide, after in silico digestion with the programme 
PeptideCutter around the sequon NVTQ at asparagine-400 for the mature human 
PAPP-A1, was (R)FNFDGGECCDPEITNVTQTCFDPDSPHR(A). This finding 
matched with the identified sequence.  
The glycosylation site at asparagine-400 was found to be occupied with two 
glycoforms of the bi-antennary complex glycan type (m/z 5520.1132, m/z 5666.1632), 
both carrying terminal sialyl moieties (figure 4.38.). The glycoform at m/z value of 
5666.1632 was found to carry a core fucosylation.  











Figure 4.38: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)FNFDGGECCDPEITNVTQTCFDPDSPHR(A) (m/z 4950-5780) derived from human 
native PAPP-A1 via nanoLC-NSI-MS/MS. Glycoforms identified in this spectrum are glycan 







c) Amino acid asparagine-521 
The predicted (glyco)peptides around the sequon NDTN at asparagine-521 for the 
mature human PAPP-A1 were calculated as (R)GISEIQSCSDPCMETEPSF(E) and 
(F)ETGDLCNDTNPAPK(H) via an in silico digestion with both, trypsin and 
chymotrypsin. The glycopeptide found was (R)GISEIQSCSDPCMETEPSF-
ETGDLCNDTNPAPK(H) for all glycopeptides. Considering the proline in proximity 
to the predicted cleavage site, a change in the secondary structure might have 
prevented chymotrypsin from cleavage before the amino acid phenylalanine-514, 
leading to the combined peptide species.  
The glycopeptide was found to carry three glycoforms. Figure 4.39 depicts hybrid 
type glycans at m/z 5122.0259 (with fucosylation) and m/z 5154.0586 (without 
fucosylation), which were identified in a full MS spectrum from nano-LC-MS/MS. 













Figure 4.39: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(R)GISEIQSCSDPCMETEPSFETGDLCNDTNPAPK(H) (m/z 4980-5510) derived from 
human native PAPP-A1 via nanoLC-NSI-MS/MS. The glycoforms identified at m/z 
5122.0259 (with fucosylation) and m/z 5154.0586 classify as hybrid type and the glycoform 




d) Amino acid asparagine-539 
After in silico digestion with trypsin and chymotrypsin, respectively, the programme 
PeptideCutter predicted the (glyco)peptide (K)SCGDPGPGNDTCGF(H) around the 
sequon NDTC at asparagine-539 (N539) for the mature human PAPP-A1. However, 
the identified sequence matched with (K)SCGDPGPGNDTCGFHSFFN(T), indicating 
that chymotrypsin did not cleave as predicted before the amino acid phenyl-
alanine-547.  
The glycosylation site at N539 was found to be occupied with two glycoforms of the 
high-mannose glycan type with m/z 3499.2822 and m/z 3661.335, as annotated in 
figure 4.40. 
The data was retrieved from a full MS scan by on-line nano-LC-MS/MS and 






Figure 4.40: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(K)SCGDPGPGNDTCGFHSFFN(T) (m/z 3250-3750) derived from human native PAPP-
A1 via nanoLC-NSI-MS/MS. The identified glycoforms at m/z 3499.2822 and m/z 3661.335 




e) Amino acid asparagine-645 
Via the programme PeptideCutter, the potential cleavage sites around the sequon 
NASS at asparagine-645 (N645) were predicted for mature human PAPP-A1. This 
resulted in the theoretical (glyco)peptide (Y)ASNASSPMPCSPSGHW(S) for a 
combined in silico digestion with trypsin and chymotrypsin. However, the identified 
glycopeptide had the aa sequence (Y)ASNASSPMPCSPSGHWSPR(E). The chymo-
trypsin did not cleave before the tryptophan-658 for the yielded glycopeptide. The 
peptide mass matched with a modification of the cysteine residue via carb-
amidomethylation. 
The glycosylation site at N645 was found to be occupied with four glycoforms, of 
which two belong to the high-mannose type (m/z 3067.2395, m/z 3229.2937) and two 
are of the complex glycan type (m/z 4217.6449, m/z 4234.63650) with sialylation of 
the antennae (figure 4.41).  














Figure 4.41: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(Y)ASNASSPMPCSPSGHWSPR(E) (m/z 2900-4380) derived from human native 
PAPP-A1 via nanoLC-NSI-MS/MS. The identified glycoforms in this spectrum belong 
either to the high-mannose type (m/z 3067.2395, m/z 3229.2937) or to the bi-antennary, 





f) Amino acid asparagine-745 
The predicted (glyco)peptide after in silico digestion with the programme 
PeptideCutter was (K)NISLGPQNVF(C) for the area around the sequon NISL at 
asparagine-745 (N745) for the mature human PAPP-A1. The identified and verified 
(glyco)peptide sequences were (K)NISLGPQNVF(C) and (K)NISLGPQNVF-
CDVPLTIR(L), respectively. For the latter sequence, chymotrypsin did not cleave 
after the amino acid phenylalanine-754. 
Four out of the five occupying glycoforms found at asparagine-745 were classified as 
complex type with terminal sialyl residues only (m/z 3949.606 in figure 4.44 and 
m/z 4247.8412 in figure 4.43), or core fucosylation as well as sialyl residues on 
terminal ends of the glycan structures (m/z  4095.656 in figure 4.44., m/z 4393.8912 
in figure 4.43.). A glycan of the hybrid type with core fucosylation and terminal 
sialylation is shown in figure 4.42 at m/z 2783.176.  


















Figure 4.42: Deconvoluted and annotated full MS spectrum (m/z 2440-3290)  of the 
glycopeptide (K)NISLGPQNVF(C) derived from human native PAPP-A1 via nanoLC-
NSI-MS/MS. The identified glycoform at m/z 2783.176 in this spectrum (m/z 2440-3280) 


































Figure 4.44: Deconvoluted and annotated full MS spectrum (m/z 3150-4800) of the 
glycopeptide (K)NISLGPQNVF(C) derived from human native PAPP-A1 via nanoLC-
NSI-MS/MS. The identified glycoforms in this spectrum (m/z 3050-4800) are classified 
as tri-antennary complex glycans with terminal with core fucosylation (m/z 4095.656) 
and without fucose residues (m/z 3949.606), respectively.  
Figure 4.43: Deconvoluted and annotated full MS spectrum (m/z 3510-4990)  of the 
glycopeptide (K)NISLGPQNVFCDVPLTIR(L) (cysteine-755 carbamidomethylated) 
derived from human native PAPP-A1 via nanoLC-NSI-MS/MS. The identified glycoforms 
in this spectrum (m/z 3510-5000) are classified as bi-antennary, sialylated complex glycans 





g) Amino acid asparagine-946 
Via the programme PeptideCutter, the potential cleavage sites around the sequon 
NASV at asparagine-946 (N946) were elucidated for mature human PAPP-A1. The 
(glyco)peptide (W)ASNASVSHQDQQCPGW(V) was predicted for a combined in 
silico digest with trypsin and chymotrypsin. The detected glycopeptide had the amino 
acid sequence (Y)TPQGFLDQWASNASVSHQDQQCPGW(V), which represents two 
missed cleavages by chymotrypsin before phenylalanine-939 as well as tryptophan-
943. Furthermore, the cysteine-956 was found to be carbamidomethylated. 
The glycosylation site at N946 was found to be occupied with a bi-antennary glycan 
structure of the complex type at m/z 5195.07209 with fucosylation of the core and 
sialylation of the antennae (figure 4.45.). The data was retrieved via on-line nano-LC-




















Figure 4.45: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(Y)TPQGFLDQWASNASVSHQDQQCPGW(V) (carbamidomethylated cysteine-956) 
derived from human native PAPP-A1 via nanoLC-NSI-MS/MS. The identified 
glycoform in this spectrum (m/z 4520-5360) is classified as sialylated glycan of the 




h) Amino acids asparagine-1142 and asparagine-1146 
The programme PeptideCutter was used to predict the potential cleavage sites 
around the sequon NASL at asparagine-1142 (N1142) and NCSS at asparagine-1146 
(N1146) for mature human PAPP-A1. The (glyco)peptide (K)TDCPELAVE-
NASLNCSSSDR(Y) was expected for a combined in silico digest with trypsin and 
chymotrypsin. The predicted (glyco)peptide sequence was confirmed and carries two 
N-glycosylation sequons: NASL and NCSS. Therefore, it is not possible to confidently 
assign the glycoforms on each site but determine the glycoforms that are found on 
the glycopeptide with the two N-glycosylation motifs.  
The peptide mass matched with modifications (both are highlighted in red in figure 
4.46) of both cysteine residues: One has been found to be modified via carb-
amidomethylation and the other via propionamidylation. The propionamide is an 
artefact from the SDS-PAGE (see section 4.5).  
The glycopeptide - carrying the glycosylation sites N1142 and N1146 - was found to 
be occupied with sialylated glycoforms of the complex type (figure 4.46). Complex, 
bi-antennary and sialylated glycan structures with core fucosylation (m/z 4589.7950) 
or without core fucosylation (m/z 4152.6417, m/z 4443.73715) were identified. 
Furthermore, tri-antennary glycans of the complex type with sialylation of the 
antennae (m/z 5099.9647) and additional core fucosylation (m/z 5246.0226), 
respectively, were assigned. 


















Figure 4.46: Deconvoluted and annotated full MS spectrum of the glycopeptide (K)TDCPELAVENASLNCSSSDR(Y) derived from human native PAPP-A1 
via nanoLC-NSI-MS/MS. Both cysteine residues were identified as modified – one via carbamidomethylation and one via propionamidylation. The identified 
glycoforms in this spectrum (m/z 4130-5300) are classified as sialylated glycans of the complex type with fucosyl residues at the core (m/z 4589.7950,  




i) Amino acid asparagine-1243 
Via the programme PeptideCutter, the potential cleavage sites around the sequon 
NSLL at asparagine-1243 (N1243) were predicted for mature human PAPP-A1. The 
theoretical (glyco)peptide (K)GNNSLLTCMEDGLW(S) for a combined in silico 
enzymatic digest with trypsin and chymotrypsin was calculated. However, the 
identified glycopeptide had the aa sequences (K)GNNSLL(T). Interestingly, 
PeptideCutter did predict the cleavage site before amino acid threonine-148 for a 
chymotryptic digest only, but not for the combined digestion.   
The glycosylation site at N1243 was found to be occupied with a bi-antennary 
complex glycan type that possesses terminal sialic acid residues as well as a core 
fucose (m/z 2968.14728), as depicted in the full MS spectrum in figure 4.47. The data 











Figure 4.47: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(K)GNNSLL(T) derived from human native PAPP-A1 via nanoLC-NSI-MS/MS. The 
identified glycoform in this spectrum (m/z 2590-3340) is classified as bi-antennary, 
sialylated glycan of the complex type with a fucosyl residue attached to the core structure 




j) Amino acid asparagine-1439 
The predicted (glyco)peptide after in silico digestion with the programme 
PeptideCutter was (Y)AIGSECATSCLDHNSESIILPMNVTVR(D) for the area around 
the sequon NVTV at asparagine-1439 (N1439) for the mature human PAPP-A1. The 
(glyco)peptide sequence found was (M)NVTVR(D) instead. Even though methionine 
has been reported as a rare cleavage site for chymotrypsin, PeptideCutter did not 
predict it for the amino acid methionine-1438.  
The glycoform found at asparagine-1439 was classified as bi-antennary complex type 
with sialylation and core-fucosylation (m/z 2939.1787), as shown in the full MS 
spectrum in figure 4.48.  















Figure 4.48: Deconvoluted and annotated full MS spectrum of the glycopeptide 
(M)NVTVR(D) derived from human native PAPP-A1 via nanoLC-NSI-MS/MS. The 
identified glycoform in this spectrum (m/z 2460-3090) is classified as bi-antennary, 




4.5.3 Conclusions from the glycomic and 
glycoproteomic analyses of the human 
native PAPP-A1/proMBP-complex 
The glycoproteomic site analysis of the glycopeptides derived from human native 
PAPP-A1 revealed that the asparagine residues N349 (NHTL), N400 (NVTQ), N521 
(NDTN), N539 (NDTC), N645 (NASS), N745 (NISL), N946 (NASV), N1142 (NASL), 
N1146 (NCSS), N1243 (NNSL), and N1439 (NVTV) were modified by glycosylation. 
Hence, the asparagine residues N310 (NISW), N322 (NSSL), and N1405 (NGSF) were 
found without glycan modifications. As expected, all three sequons with a proline 
(N-P-S/T) did not carry glycan structures, which confirms the existing criterion for 
N-linked glycosylation sequons. In summary, 11 out of 14 putative N-glycosylation 
sites were found to be occupied with N-linked complex carbohydrate structures in 
this study. 
The analysis and characterisation of the glycan structure revealed that PAPP-A1 is 
modified with glycoforms of the high-mannose, hybrid, and complex type, 
respectively; whereby most sequons showed multiple glycoforms attached. A 
summary of the findings is gathered in table 19.  
It is important to point out that the glycoproteomic data obtained with nLC-NIS-
MS/MS data (section 4.5.2.) matched with the glycomic data that was acquired via 
MALDI-ToF-MS and is presented in section 4.5.1. in this chapter. 
The human native PAPP-A1 is primarily modified with high-mannose glycans but 
also complex sialylated glycans with heterogeneous multi-antennary structures. 
Bisection of the complex glycans is not prevalent and, therefore, the core mannose 
residues of the glycans theoretically without steric hindrance. An interaction between 
the glycan structures present on the native human PAPP-A1 and the CRD of 
DC-SIGN as well as DC-SIGNR is very likely, given their binding prevalence for 
mannose-type sugars. 
 
No O-linked glycosylation was detected for this sample of human native PAPP-A1, 




Table 19: Summary of the glycoproteomic analysis of N-linked glycans identified on human native PAPP-A1. Out of the 14 N-glycan sequons, 11 
have been found glycosylated including (partially fucosylated/sialylated) glycoforms of the high-mannose, hybrid, and complex type, respectively. The 




Glycosylation sequon FASTA peptide sequence Type of N-glycosylation 
310 NISW NISW Not glycosylated 
322 NSSL ELDVLEVSNSSLR Not glycosylated 
349 NHTL IGDENCDPECNHTLTGHDGGDCR High-mannose, Hybrid [sialylated] 
400 NVTQ FNFDGGECCDPEITNVTQTCFDPDSPHR Complex [sialylated, fucosylated] 
521 NDTN GISEIQSCSDPCMETEPSFETGDLCNDTNPAPK Hybrid [fucosylated]  
539 NDTC SCGDPGPGNDTCGFHSFFN High-mannose 
645 NASS ASNASSPMPCSPSGHWSPR  High-mannose,  
Complex [fucosylated, sialylated] 
745 NISL NISLGPQNVFCDVPLTIR 
NISLGPQNVF 
Hybrid [fucosylated, sialylated], 
Complex [fucosylated, sialylated] 








Complex [fucosylated, sialylated] 
1243 NNSL GNNSLL Complex [fucosylated, sialylated] 
1405 NGSF DGTWNGSFHVCQEMQGQCSVPNELNSNLK Not glycosylated 





 Comparison of the mass spectrometric 
analyses of complex-carbohydrate 
structures on recombinant proMBP, 
recombinant PAPP-A1 and native 
PAPP-A1 from the proMBP/ PAPP-A1-
complex  
 
The samples with the human protein sequences of recombinant proMBP, 
recombinant PAPP-A1, as well as native PAPP-A1 (derived from the human 
proMBP/PAPP-A1 complex) were investigated for their glycosylation patterns by 
the use of glyco(proteo)mic mass spectrometric approaches. 
 
The sample of recombinant proMBP (expressed by human cells; cell line undisclosed) 
did not display any high-mannose type N-linked glycoforms. Furthermore, half of 
the glycoforms of the presented complex type N-glycans carried a bisecting GalNAc 
residue. This finding might indicate an exclusion of any high affinity and specific 
interactions with the CRDs of mannose-type binding C-type lectins, such as DC-SIGN 
and DC-SIGNR.  
Since DC-SIGN is also known to bind fucosylated Lewis-type antigens, the 
O-glycosylation of the recombinant proMBP was also of interest. However, only 
O-glycans of the core 1 and 3 type (including extension and branching) were detected. 
Therefore, the O-glycans on proMBP are not likely to contribute any high affinity 
binding epitopes for the CRD of DC-SIGN. 
 
The sample of human recombinant PAPP-A1, which was expressed in a murine 
myeloma cell line, was found to be modified with N-linked glycoforms of all types: 
high-mannose, hybrid and complex glycans. Unfortunately, not all of the putatively 




bisected complex glycans were found and only a fractional occupation with high-
mannose glycoforms was determined. Therefore, it is expected that DC-SIGN and 
DC-SIGNR binding to this preparation of recombinant PAPP-A1 will be reduced 
compared to native PAPP-A1, which has been shown to display multiple high-
mannose N-glycans. 
The discovery of a NeuGc residue in one glycoform, which is very rare in human 
adults but abundant in murine glycosylation patterns, reflects the importance of 
species-specific investigations within the field of glycobiology. 
In line with past studies, no O-linked glycosylation was found. 
 
The human native PAPP-A1 sample (derived from human retroplacental blood) was 
found to be post-translationally modified with a great range of high-mannose, hybrid 
and complex type glycan structures on 11 out of the 14 putative N-glycosylation sites. 
Overgaard et al. (2003) found asparagine-310, asparagine-1142 and asparagine-1405 
were not glycosylated; whereby the analysis of MS data within this study revealed 
no glycosylation at asparagine-310, asparagine-322 and asparagine-1405 for the 
native PAPP-A1 sample. The prevalence of high-mannose structures as well as a great 
proportion of complex type N-glycans, provides, theoretically, numerous high 
affinity binding epitopes for the CRDs of DC-SIGN and DC-SIGNR in the presence 
of calcium. 
In this study, no O-linked glycosylation was found attached to human native 
PAPP-A1, which confirms the findings of past studies. 
 
The analysis of the MS data showed that the pattern of glycosylation between all three 
glycoproteins differed and supports the determination of varying binding affinities 
for these three glycoproteins and the extracellular domains of DC-SIGN and 
DC-SIGNR.  
From the MS data as well as kinetic data (chapter 3), the mannose-type binding 
carbohydrate recognition domains of DC-SIGN and DC-SIGNR are very likely to 
show the highest affinity of interaction with the human native PAPP-A1 




PAPP-A1 presents the most mannose-binding epitopes within its pattern of 
glycosylation, from which the most likely binding contacts will be positioned for the 
















5 RESULTS AND DISCUSSION (III)      
BIOPHYSICAL INTERACTION STUDIES 
BETWEEN HUMAN C-TYPE LECTIN DC-SIGN 






Specific carbohydrate patterns are recognised by the CRDs of C-type lectin receptors 
(CLRs), depending on their sugar-binding specificity and the clustering of CRDs 
within oligomers. These carbohydrate patterns enable the host to differentiate 
between foreign structures, which could indicate contact with a harmful pathogen, 
and self/host structures via interactions with a range of lectins. The recognition of 
foreign structures via immune-related C-type lectins triggers immune responses, 
which can be of a pro-inflammatory or anti-inflammatory nature. Specifically 
designed ligands, such as synthetic glycopolymers, play not only a crucial role for a 
better understanding of the mechanisms and principles behind the recognition of 
ligands via CRDs, but also have the potential to lead towards the development of 
either anti-pathogen agents or immune-regulating drugs. 
 
For the characterisation of interactions between synthetic, well-defined glyco-
polymers and DC-SIGN, binding studies were carried out via surface plasmon 
resonance (SPR) spectroscopy.  
The three types of mannose glycopolymers that were investigated had a defined 
shape and a conserved molecular weight of 25 kDa. The glycopolymer analytes for 
the binding studies were designed as either star-shaped - in the case of the 5-arm and 
8-arm glycopolymers - or linear - as for the DP58 glycopolymer. The structures are 
depicted in figure 5.1. 
 
Figure 5.1: Representative chemical structures of the mannose glycopolymers. R= Br in the 






The glycopolymers were synthesised through living radical polymerisation and 
reflecting architectures of either a star of five or eight arms radiating from a 
multivalent initiator structure (5-arm, 8-arm) or a simple linear polymer of set degree 
of polymerisation (DP58, containing 58 mannose units). 
The glycopolymer synthesis was carried out by the group of Dr Remzi Becer at the 
School of Engineering and Materials Science, Queen Mary University of London. 
 
The data has been presented within the scope of a presentation as well as a report for 
the Upgrading from MPhil to PhD candidate in October 2015 for this specific degree 
at the University of Warwick.  
 
A part of the study has been successfully published as a peer-reviewed scientific 
article in the journal of Chemical Science by the Royal Society of Chemistry [please see 






  Biophysical interaction studies with 
synthetic glycopolymers and DC-SIGN 
The interaction between the soluble, extracellular domain of the C-type lectin 
DC-SIGN and the glycopolymers 5-arm, 8-arm and DP58 were investigated. The 
concentration-dependent testing of the ligands was carried out in the presence of 
calcium.  
The recombinant soluble DC-SIGN protein was immobilised (0.02 mg/mL; loading 
buffer 10 mM HEPES pH 5.0, 150 mM NaCl) as ligand on a 6-channel GLM sensor 
chip, which uses the chemistry of amine-coupling for binding. The experimental 
setup for the interaction study included a baseline step with assay buffer (10 mM 
HEPES pH 7.4, 150mM NaCl, 5mMCaCl2, 0.01% (v/v) Tween-20, 0.01% (w/v) NaN3) 
for 250 sec, an association step with the analyte for 900 s, and a dissociation step with 
assay buffer for 600 s. Each polymer was run (flow rate 25 µL/min; buffer 10 mM 
HEPES pH 7.4, 150mM NaCl, 5mMCaCl2, 0.01% (v/v) Tween-20, 0.01% (w/v) NaN3) 
in a 1:2-dilution series from 500 nM to 244 pM during the association step. The 
software programme ProteOn Manager was used for data presentation and analysis. 
 
              CaCl2                 EDTA                  CaCl2                 EDTA 
Figure 5.2: Representative sensorgram of the nature of the interaction between the mannose 
glycopolymers, depicted is DP58, and C-type lectin DC-SIGN. All interactions were 
specific, given that no signal was detectable in the absence of calcium and presence of the ion 
chelator EDTA. In fact, assay buffer with EDTA was used for regeneration of the GLM chip 




The SPR approach allowed for the identification of the putative interactions between 
the CRD of DC-SIGN and the glycopolymers. Furthermore, binding kinetics of the 
interaction were determined. The data is presented in the following subchapters.  
The specificity of the interactions between the CRD of DC-SIGN and the 
glycopolymers was tested and confirmed, since interaction signals (in response units 
[RU]) were only detectable in the presence of 5 mM calcium, but not 5 mM EDTA (see 
figure 5.2). 
5.2.1 Star-shaped 5-arm glycopolymer 
Interaction between the star-shaped 5-arm glycopolymer and the extracellular 
domain of DC-SIGN was investigated via surface plasmon resonance (SPR). The 
5-arm glycopolymer showed a concentration-dependent binding to DC-SIGN within 
a serial dilution ranging from 500 nM to 0.244 nM. The representative sensorgrams, 
depicted in figure 5.5 and 5.6, were analysed and enabled the determination of the 
kinetic parameters of the interaction.  
Binding kinetics of the interaction between the polymers and the human recombinant 
DC-SIGN extracellular domain were obtained via the analysis of association rate kon 
and dissociation rate koff of the detected interactions. The overview of the acquired 







Figure 5.3: Representative sensorgram of the binding study between the 5-arm glycopolymer 
in the lower concentration range (between 0.244 nM and 7.81 nM) and DC-SIGN. Binding 
kinetics of the interaction between the polymers and the human recombinant DC-SIGN 






Table 20: Overview of the kinetic parameters obtained from the binding studies between the 
glycopolymer 5-arm and the extracellular domain of DC-SIGN. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
5-arm polymer run1 1.01E6 7.33E-5 7.25E-11 
5-arm polymer run2 1.01E6 7.04E-5 7.00E-11 
5-arm polymer set2 run1 7.97E5 7.37E-5 9.25E-11 
5-arm polymer set2 run2 7.93E5 7.01E-5 8.84E-11 
  
 
The average dissociation constant of the 5-arm glycopolymers was calculated with 
KD=80.8 pM. This reflects a comparatively very high affinity interaction, since most 









Figure 5.4: Representative sensorgram of the binding study between the 5-arm glycopolymer 
in the higher concentration range (between 15.62 nM and 500 nM) and soluble DC-SIGN. 





5.2.2 Star-shaped 8-arm glycopolymer 
The 8-arm star-shaped glycopolymer was investigated for its binding affinity to the 
extracellular domain of DC-SIGN.   
The polymer with a measured molecular weight of 25 kDa showed binding to DC-
SIGN (figure 5.7 and figure 5.8). The kinetic analysis was based on the acquired 
association rate kon and dissociation rate koff of the detected interaction, which is 











Figure 5.5: Representative SPR sensorgram of the interaction between DC-SIGN and the 
glycopolymer 8-arm within a concentration range between 0.244 nM and 7.81 nM (see 









Figure 5.6: Representative SPR sensorgram of higher concentrations of the 8-arm 
glycopolymer (500 nM-15.62 nM) and soluble DC-SIGN (see legend for annotation). The 











Table 21: Overview of the kinetic parameters obtained from the binding studies between the 
8-arm glycopolymer and the soluble polypeptide that encodes the extracellular domain of 
DC-SIGN. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
8-arm polymer run1 9.27E5 6.03E-5 6.51E-11 
8-arm polymer run2 9.29E5 5.18E-5 5.58E-11 
8-arm polymer set2 run1 7.19E5 6.10E-5 8.47E-11 
8-arm polymer set2 run2 7.27E5 5.19E-5 7.14E-11 
 
Specifically, the average dissociation constants for the 8-arm glycopolymer was 









5.2.3 Linear DP58 glycopolymer 
A glycopolymer with a degree of polymerisation (DP) value of 58 (DP58) of mannose 
units was tested as binding partner for DC-SIGN. DP58 has a measured molecular 
weight of 25 kDa and was able to bind to DC-SIGN with a very high affinity of 
KD= 114 pM (figure 5.9 and figure 5.10). The calculated kinetic data is shown in table 

















Figure 5.7: Representative SPR sensorgram of the interaction between DC-SIGN and the 
glycopolymer DP58 within a concentration range between 0.244 nM and 7.81 nM, as 
annotated in the legend. The kinetic analysis was based on the acquired data and revealed a 







Figure 5.8: Representative SPR sensorgram of the interaction between DC-SIGN and the 
glycopolymer DP58 within a concentration range between 500 nM and 15.62 nM, as 
annotated in the legend. The kinetic analysis was based on the acquired data. The calculated 







Table 22: Overview of the kinetic parameters obtained from the binding studies between the 
glycopolymer DP58 and the soluble DC-SIGN, which consists of the extracellular domain. 
Experiment kon (M-1 s-1) koff (s-1) KD (M) 
DP58 polymer run1   1.24E6 1.34E-4 1.08E-10 
DP58 polymer run2  1.27E6 1.37E-4 1.08E-10 
DP58 polymer set2 run1 1.04E6 1.35E-4 1.30E-10 
DP58 polymer set2 run2 9.52E5 1.04E-4 1.09E-10 
 
The calculated average dissociation constant of the DP58 glycopolymer showed a 














  Conclusion of the interaction studies 
between C-type lectins and synthetic 
glycopolymers  
The binding studies, conducted via the biophysical method of SPR technique, clearly 
showed that the glycopolymers 5-arm, 8-arm and DP58 bound specifically to the CRD 
of DC-SIGN, i.e. only in the presence of calcium.  
The tetramer of DC-SIGN is known to interact with most of its test ligands within the 
submillimolar range. However, the dissociation constants of the glycopolymers were 
determined to lie in the picomolar range (KD5arm=80.8 pM, KD8arm=69.3 pM, 
KDDP58=114 pM), which can be classified as very high affinity interaction. The star-
shaped glycopolymers bound with an even higher affinity than the linear DP58 
polymer; suggesting that the clustering of mannose units – realised by the star 
arrangement – increases the favourability of the interaction. Furthermore, these 
polymers are capable of disrupting interactions between DC-SIGN and other ligands, 
such as HIV gp120. 
 
The principle would be particularly interesting for deeper study of immune-
pathology and autoimmunity, where advanced glycopolymers could lead to the 
generation of drug-like materials for immune modulation via crosstalk with other 
pattern recognition receptors, which are present on dendritic cell (DC) and 
macrophage surfaces. The opportunity of triggering anti-inflammatory responses in 
immune cells expressing DC-SIGN has potential to lead to treat conditions, such as 
rheumatoid arthritis, or provide probes for the translational investigation of the 
processes of inflammation. 
 
The same glycopolymer sets were used in dendritic cell analysis by Dr Shan Herath 
and Dr Steve Patterson at Imperial College London. The glycopolymers were shown 
to invoke elevated interleukin-10 and reduced interleukin-12p70 production, when 
co-incubated with LPS (Mitchell et al., 2017). This cytokine profile is a signature of 





These findings were part of a study that was published as a peer-reviewed scientific 
article (please see the appendix) in the journal of Chemical Science by the Royal Society 
of Chemistry: 
MITCHELL, D. A., ZHANG, Q., VOORHAAR, L., HADDLETON, D. M., HERATH, 
S., GLEINICH, A. S., RANDEVA, H. S., CRISPIN, M., LEHNERT, H., WALLIS, R., 
PATTERSON, S. & BECER, C. R. 2017. Manipulation of cytokine secretion in human 
dendritic cells using glycopolymers with picomolar affinity for DC-SIGN. Chemical 





















Here, I would like to address the accomplished Thesis Aims set out in Chapter 1:  
 
AIM ONE - To detect and quantify interactions between C-type 
lectins, such as DC-SIGN, DC-SIGNR and MMR, and candidate 
secreted human glycoproteins 
 
Results described in Chapter 3, using biolayer interferometry, showed successful 
detection and quantification of calcium-dependent interactions between the human 
C-type lectin DC-SIGN and the candidate human glycoprotein PAPP-A1. For this 
interaction, the dissociation constant was determined as being in the low nanomolar 
range and, therefore, lies well within the physiologically-relevant range, which 
strengthens the hypothesis that PAPP-A1 serves as a novel, soluble endogenous 
ligand for DC-SIGN. Evidence of DC-SIGN binding to recombinant human PAPP-A1 
was also shown, although the interaction was determined to be of lower affinity, 
suggesting that the glycosylation profile of this preparation is different to the native 
form. 
Binding responses for two other C-type lectins, namely DC-SIGNR and MMR, were 
either comparatively low or inconclusive. Whilst further development of the BLI 
platform may reveal a level of PAPP-A1 binding to these molecules, the overall data 
support the hypothesis that PAPP-A1 is a much more specific ligand for DC-SIGN. 
This evidence of greater discrimination demonstrates the fundamental importance of 
higher-order lectin structure in defining physiologically relevant lectin-glycoprotein 
couplings. 
 
AIM TWO - To characterise and assign the glycans of the PAPP-
A1/proMBP-complex – a secreted ligand for the extracellular CRD 
of human DC-SIGN 
 
The data presented in Chapter 4 demonstrate the ability of powerful and sensitive 
mass spectrometric methods, incorporating on-line nano-scale chromatography, to 




human recombinant proMBP and human native PAPP-A1. N-glycosylation site 
assignment was also accomplished in these studies. The identified N-linked glycan 
types in these samples confirm the presence of complex carbohydrates favourable for 
DC-SIGN interactions and illustrate with great clarity the structural basis for 
measured differences in DC-SIGN binding affinities for native and recombinant 
forms of PAPP-A1. The data also represent pioneering work in understanding the 
structure and function of PAPP-A1 – an important protein in pregnancy and 
cardiovascular disease diagnostics. 
  
AIM THREE - To characterise advanced synthetic glycoconjugate-
ligand interactions with the C-type lectin DC-SIGN and relate them 
to natural ligands 
 
The data presented in Chapter 5 show novel glycopolymer interactions with very 
high affinity for DC-SIGN via SPR. Remarkably, the dissociation constants were 
determined as lying in the picomolar range (KD5arm=80.8 pM, KD8arm=69.3 pM, 
KDDP58=114 pM), which - at the time of writing this thesis - are the highest affinity 
values obtained to date for DC-SIGN ligands. These glycopolymers will be 
particularly useful for further studies of mechanisms and principles behind the 
recognition of specific glycan arrangements via the multiple CRDs within the 
tetrameric DC-SIGN molecule arrangement.  
Moreover, the glycopolymer sets were used in dendritic cell analysis by Dr Shan 
Herath and Dr Steve Patterson at Imperial College London. As the peer-review 
publication that I co-authored states, the glycopolymers triggered elevated 
interleukin-10 and reduced interleukin-12p70 production during dendritic cell 
activation with LPS (Mitchell et al., 2017)]. This cytokine profile is known to represent 
the phenotype of wound healing of the host via DCs and macrophages, raising the 
exciting possibility that glycopolymers of this kind could be adapted for therapeutic 






PAPP-A1 (Pregnancy-associated Plasma Protein A1; also Pappalysin-1) inspired in-
depth glycoproteomic investigation following its novel detection in an affinity 
chromatography screen using immobilised DC-SIGN and solubilised placental 
extract (Ilyas, 2010). 
PAPP-A1 was originally discovered in the 1970s within studies to detect pregnancy-
specific antigens in the maternal plasma. The protein is abundant in pregnant women 
– appearing early in pregnancy and peaking at term at concentrations of about 85 nM 
(Gall and Halbert, 1972, Lin et al., 1974). Non-pregnant, healthy males and females 
usually have a plasma level of PAPP-A1 between 0-0.8 nM.  
PAPP-A1 itself is a metalloprotease of the metzincin superfamily with an intrinsic 
proteolytic function. The protease is secreted by fibroblasts from a wide range of 
tissues and is involved in the insulin-like growth factor (IGF) regulation cascade by 
cleaving IGF-binding proteins (IGFBP) 4 and 5 via its zinc-binding catalytic motif 
(Lawrence et al., 1999), which subsequently increases IGF bioavailability. These 
cleavage events are significant in aspects of healthcare - IGFBP4 and IGFBP5 are 
considered to inhibit cancer cell growth, wherein free IGF-1 can trigger oncogenic 
pathways. Therefore, PAPP-A1 has been described as a pro-oncogenic factor (Guo et 
al., 2018). 
Within the last decade, free serum PAPP-A1 has been positively associated with 
elevated risk of acute coronary syndromes and complications associated with 
patients requiring haemodialysis in both, males and non-pregnant females (Bayes-
Genis et al., 2001, Gururajan et al., 2012). In the context of cardiovascular diseases, 
PAPP-A1 is proteolytically fully active and, therefore, presumably involved in 
driving the IGF cascade, which appears to contribute to atherosclerosis cardiac 
hypertrophy.  
It has been found that a decreased availability of IGF, resulting from a depletion of 
the enzymatic function of PAPP-A1 in gene-targeted PAPP-A1 knockout mice, is 
linked to a prolonged life span and, thus, slower aging (Conover and Oxvig, 2017). 
Within these pathways, it is reasoned that future research could promise a new 
approach to understanding the processes of aging, which includes the treatment and 




and neurodegeneration. It is fascinating to contemplate the involvement of PAPP-A1 
glycosylation and lectin interactions in this high-profile field of study. 
Conversely, the proteolytic site of PAPP-A1 is almost exclusively inhibited by 
formation of a complex with the proform of eosinophil major basic protein (proMBP) 
during pregnancy (Oxvig et al., 1993). This complex was identified as a 
heterotetramer, i.e. 2:2-PAPP-A1/proMBP-complex, covalently bound via disulfide 
bonds (Christiansen et al., 2000, Overgaard et al., 2003). PAPP-A1 has been used for 
decades as a reliable biomarker marker in first-trimester screening for chromosomal 
abnormalities such as Down’s Syndrome, preterm labour, intrauterine growth 
retardation, pre-eclampsia, and miscarriage/stillbirth. However, the underlying 
mechanisms behind the correlation of low plasma levels seen in pathologies of 
pregnancy are not fully understood (Kirkegaard et al., 2010). Considering that the 
proteolytic function of PAPP-A1 is believed to be inhibited by proMBP in the 
maternal form, it is still unclear why its plasma level increases dramatically (up to 
100x) during pregnancy. The confirmation that PAPP-A1 binds to DC-SIGN, a 
receptor that is heavily expressed on both placental and uterine macrophages with 
known anti-inflammatory functions, raises the possibility that it is a component of 
establishing and maintaining a foeto-maternal immunological tolerance. 
 
It is well-known that PAPP-A1 as well as proMBP are glycoproteins. The group of 
Claus Oxvig investigated the carbohydrate attachment sites around 15 years ago with 
the methods available. Such methods were insufficient for determination of the 
glycan structures at the time; however, they did identify glycan attachment in 11 out 
of the 13 potential N-linked glycosylation sites (Overgaard et al., 2003). Within this 
thesis, the occupation of these glycan attachment sites was confirmed and taken 
further with new insights into the precise nature of the PAPP-A1 and proMBP 
N-glycosylation patterns. 
Shortly after the discovery of PAPP-A1, Bischof and colleagues showed that 
proteolytically active PAPP-A1 “markedly inhibits the haemolytic activity of 
complement” (Bischof, 1981). Since the PAPP-A1 gene also encodes for five 
complement control protein modules, a close association with the complement 




over the last two decades. It would therefore be of great interest to revive this research 
using the sensitive technologies now available, especially since the findings here 
illuminate a potential role for PAPP-A1 in immune regulation. 
 
A holistic insight into the functional integration of PAPP-A1 throughout the human 
body – enzymatically active and inactive - is still pending. The discovery of the 
involvement of PAPP-A1 in the most diverse biological contexts has led to the 
development of exciting hypotheses above.  
 
Importantly, the clearance mechanisms for PAPP-A1 are largely unknown and the 
failure to clear PAPP-A1 efficiently could accelerate life-threatening conditions such 
as cancer and cardiovascular disease. It is very tempting to hypothesise that the 
nature of the interaction with DC-SIGN, which is highly endocytic and expressed on 
resident M2 macrophages and hepatic sinusoidal endothelium, provides a 








One detail of PAPP-A1 as a ligand for DC-SIGN is that it is a soluble, endogenous, 
secreted glycoprotein. This is significant, as the full DC-SIGN molecule possesses 
cytoplasmic motifs that are strongly associated with endocytosis into clathrin-coated 
pits that are well-suited to the cellular uptake and processing of soluble factors. In 
contrast, many biological DC-SIGN ligands that have been reported in the literature 
are membrane-bound molecules, such as viral envelope glycoproteins, human 
CEACAM1 (Bogoevska et al., 2006) and human CD11b/CD18 (van Gisbergen et al., 
2005). 
 
Reports have been published suggesting that a specific, di-sialylated glycoform of 
human IgG is able to interact with DC-SIGN (Anthony et al., 2008)  and invoke the 
anti-inflammatory effects of therapeutic intravenous immunoglobulin (IVIG). 
However, this work has been carried out using mouse systems in combination with 
human IgG1 fragments and there are significant differences between the mouse and 
human DC-SIGN orthologues (Powlesland et al., 2006). Furthermore, measurement 
of binding affinities between purified human DC-SIGN and isolated glycoforms of 
human IgG1 showed that all the high-mannose IgG1 glycoforms bound to DC-SIGN, 
compared with none of the sialylated IgG1 glycoforms (Yu et al., 2013) . In addition, 
high field heteronuclear NMR has been used to investigate interactions between 
13C-labelled di-sialylated IgG1-Fc and 15N-labelled DC-SIGN CRD without success 
(personal communication from Prof J Prestegard, Complex Carbohydrate Research 
Center, University of Georgia, USA). Therefore, this proposed ligand partner for 
DC-SIGN, including a subsequent biological role, is highly debatable.  
However, the clear BLI binding data with encouraging affinity values - together with 
the determination of its high mannose N-glycans - makes human native PAPP-A1 a 







In conclusion, through the combination of these three project themes with cutting-
edge analytical and structural techniques, this thesis has made contributions to 
several new areas within the fields of glycobiology and immunology: 
 
1.  First time reporting of the high affinity interaction between the soluble human 
glycoprotein – the native PAPP-A1/proMBP-complex - and the human 
C-type lectin DC-SIGN within the physiologically relevant range, suggesting 
a viable biological connection between these molecules. This has also 
demonstrated pioneering use of dip-and-read BLI technology to measure 
human glycoprotein-lectin interactions in real time, with major implications 
in the future for quantitative evaluation of functional glycomics where sample 
scarcity has previously been a major challenge. 
 
2.  The determination of the glycosylation profile of the native PAPP-A1, which 
derived from human retroplacental blood. The reported N-glycan profile, 
illustrating both the specific glycan structures and their sites of attachment, is 
a novel contribution to the field of pregnancy biology and also provides 
crucial insights into the basis of the elucidated interaction with DC-SIGN. It 
is also the first report of comparative N-glycan profiling of recombinant and 
native human PAPP-A1 and this emphasises the importance of 
understanding the glycosylation state of glycoproteins used in the research 
laboratory as well as pharmaceutical industry. 
 
3. The interaction studies with star-shaped glycopolymers and DC-SIGN have 
pushed the fields of polymer chemistry and advanced materials further into 
the domain of immunology, whilst convincingly achieving picomolar affinity 









The results from this thesis highlight new territories within glycobiology and the 
immune system, in addition to potential implications in endocrinology and growth 
factor control. From here, a number of key future projects could be developed: 
 
a) Cellular immunology work 
Experiments to test PAPP-A1/proMBP interactions with DC-SIGN in cellular 
environments to assess the hypothesis further and apply translational approaches: 
Strategies would include the investigation of PAPP-A1/proMBP binding to 
DC-SIGN+ cells using biotinylated hnPAPP-A1/proMBP and functional cell types, 
such as differentiated macrophages and DCs. Fluorophore-labelled streptavidin 
probes would facilitate PAPP-A1/proMBP detection via flow cytometry and also 
investigate phenomena such as glycoprotein uptake. Cytokine secretion and gene 
expression responses would also be possible to study the impact of PAPP-
A1/proMBP on immune cells. Together with further glycopolymer investigations, 
including the analysis of fucose glycopolymers, it would also be valuable to use 
PAPP-A1 to probe the mannose and fucose signalosomes activated by cellular 
engagement of DC-SIGN. 
Furthermore, an exciting possibility presents itself with PAPP-A1 being a soluble 
glycoprotein favoured by DC-SIGN: It is feasible to conjugate human PAPP-A1 to 
molecules of interest, such as vaccine preparations or siRNA oligonucleotides, in 
order to facilitate their putative uptake by human DCs without the risk of invoking 
immune responses or needing synthetic polymer components. 
 
b) Further biophysical analysis 
This would include deeper mass spectrometry analysis, including ion mobility MS to 
define full sugar-linkage of the glycoforms, and also complete the investigation of 




Furthermore, opportunities for translational work could arise through 
characterisation of glycosylation patterns for PAPP-A1/proMBP, e.g. in mothers that 
develop pregnancy complications, such as pre-eclampsia and foetal growth 
restriction (via collaboration with Dr Manu Vatish, Nuffield Department of Obstetrics 
& Gynaecology, Oxford), and also in individuals at risk of acute coronary syndromes. 
 
 
Additional structural work via techniques such as Cryo-Electron Microscopy could 
provide fundamental data on the nature of how the DC-SIGN/PAPP-A1-proMBP 
complex assembly is formed in three dimensions. Closely aligned with this would be 
ongoing collaborations with Prof Russell Wallis (University of Leicester, UK) 
involving co-crystallisation studies with the extracellular domain of DC-SIGN. 
The feasibility of BLI as a technique for resolving lectin-glycoprotein interactions 
opens up opportunities for extracting crucial data from low abundance samples. In 
Coventry, we are fortunate to be near the Arden Tissue Bank based at the University 
Hospital Coventry & Warwickshire. This is a major source of a wide range of human 
tissue and blood samples collected from a broad range of patient groups. Together 
with the growing availability of native and recombinant human lectins in quantities 
amenable to the BLI platform, significant potential opens up to broaden the 
identification and characterisation of novel glycomic networks. This could 
incorporate other important human lectins such as the Siglec family and galectins, in 
addition to glycoproteins recovered from selected tissue and blood samples relating 
to specific disease states. 
 
c) Exploring the Immune-Endocrine interface 
Confirmation of PAPP-A1 as a feasible ligand for DC-SIGN raises the possibility of 
new links between growth factor endocrinology and the immune system. In addition 
to DC and macrophage studies above, it would be valuable to investigate whether 
PAPP-A1 connects fibroblast function in localised tissue growth and homeostasis 
with immune surveillance using fibroblast-DC/macrophage co-cultures. It is 




PAPP-A1 in tissues and blood vessels has negative implications in atherosclerotic 
plaque and tumour development. The proximity of the Arden Tissue Bank and 
Pathology Services in Coventry also raises the possibility of visualising potential 
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Glyconanoparticles with controlled morphologies
and their interactions with a dendritic cell lectin†
Gokhan Yilmaz,a,b,c Lea Messager,d Anne S. Gleinich,e Daniel A. Mitchell,e
Giuseppe Battaglia*d and C. Remzi Becer*c
Well-defined amphiphilic block glycopolymers with equal
mannose content have been self-assembled in aqueous solution to
form glyconanoparticles with different morphologies. The size and
shape of nanoparticles have significant effects on the interactions
with the dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN; CD209), characterized using a
surface plasmon resonance spectrometer (SPR).
Protein–carbohydrate interactions play an important role in
many biological processes including cell interactions with
immune systems, tumor metastasis, adhesion of infectious
agents to host cells and many more.1 Proteins involved in
these signaling and processing pathways are known as
lectins.2 These carbohydrate binding proteins are wide-spread
in nature and they differ from antibodies or enzymes entities.3
For example, it has been shown that some viruses such as HIV
express many carbohydrate entities at their surface, which
enable them to bind to these lectins on the cell surface in the
immune system. Therefore, one of the promising strategies for
fighting against infectious diseases would be to design com-
peting systems with higher lectin affinity than pathogens, thus
preventing their adhesion.
Recent and elegant synthetic routes have allowed polymer
chemists to prepare a wide range of glyco-polymers/particles
that provide strong and selective recognition properties
towards lectins.4–8 In particular, amphiphilic block glycopoly-
mers (GPs) have attracted a great attention in terms of their
ability to form various types of glyconanoparticles. These
amphiphilic GPs are generally composed of biocompatible,
biodegradable hydrophobic polymer blocks covalently bonded
to a biocompatible hydrophilic block.9–11 Some recent studies
have shown that amphiphilic block glycopolymers with
different carbohydrate compositions were used to produce
nanoparticles, such as micelles, nanospheres, core–shell nano-
particles, micelle-like nanoparticles, crew cut micelles, nano-
capsules and polymersomes.12–16 These studies facilitate the
understanding and investigation of GP–lectin binding activi-
ties that are significantly influenced by GP architecture,
valency, size, and density of binding elements. Furthermore,
they offer a promising route for the creation of a broad variety
of bioactive self-assembled glyco-nanostructures for bio-
medical applications such as drug delivery, biomaterials, bio-
and nanotechnologies, and gene therapy.17–24 In the last few
years, the number of strategies devoted to prepare GPs via
single electron transfer living radical polymerization (SET-LRP)
polymerization technique has increased rapidly. Therefore,
SET-LRP was used in this study to synthesize several types of
amphiphilic block glycocopolymers bearing mannose moieties
by using methyl acrylate (MA) and a glycomonomer (ManAc)
and/or poly(ethylene glycol) (PEG) as a hydrophobic and a
hydrophilic block, respectively. Mannose glycomonomer was
prepared according to the procedure reported by Zhang et al.25
Poly(ethylene glycol) 2-bromoisobutyrate (PEG-Br) initiator was
used as an initiator to prepare amphiphilic triblock glycocopoly-
mer. The self-assembly behaviors of these well-defined amphi-
philic GPs were investigated in aqueous solution to obtain glyco-
nanostructures with various sizes and morphologies. The result-
ing glyconanoparticles (GNPs) were further investigated for their
binding affinity towards lectins, in particular with DC-SIGN,
which is a C-type human lectin present on both macrophages
and also dendritic cell subpopulations. DC-SIGN binds to micro-
organisms and host molecules by recognizing surfaces rich in
mannose containing glycans through multivalent glycan–
protein interactions and notably serves as a target molecule for
several viruses such as HIV and hepatitis C virus.26
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Here, we report the synthesis of well-defined amphiphilic
GPs using the SET-LRP technique, their spontaneous self-
assembly in aqueous solution, and binding studies of the
resulting glyconanoparticles with DC-SIGN.
A series of well-defined amphiphilic block GPs were pre-
pared via SET-LRP using EBiB or PEG-Br initiator. The molar
ratio of [MA]/[ManAc] has been varied to yield amphiphilic
block copolymers with increasing ratios between their hydro-
phobic and hydrophilic moieties. One-pot polymerization
approach has been employed to ensure well-defined block
copolymer formation. Initially, MA was polymerized up to high
conversion and subsequently; the chain extension with
mannose glycomonomer (DP = 15, dissolved and degassed in
1 mL of DMSO) to form the second block was carried out (ESI,
Fig. S7†). The monomer conversions were followed by 1H
NMR, which showed the disappearance of vinyl groups appar-
ent between 5.8–6.4 ppm. The purified glycopolymers were
further analyzed by GPC and 1H NMR (ESI, Fig. S9†). Based on
these results, it is evident that the copolymerization of MA and
ManAc has been achieved with a good control as indicated by
low polydispersity indices and increasing molecular weight of
the block copolymer. Analysis of all P((MA)m-b-(ManAc)n) poly-
mers (P1, P2, P3, and P4) are presented in Table 1. High chain
end fidelity of P((PEG)-b-(MA)) has been confirmed by chain
extension with MA prior to the synthesis of triblock glyco-
copolymer, P5, using the same approach in the presence of
PEG-Br initiator. GPC analysis (ESI, Fig. S10†) revealed a clear
baseline shift of elution traces after each monomer addition
with increasing molecular weight and final PDI of 1.17. No sig-
nificant tailing or shoulders have been observed in the GPC
throughout the polymerization. Moreover, the measured
Mn,GPC and the Mn,theo calculated from the monomer conver-
sions are in good agreement.
Nanoparticles of these amphiphilic GPs having PEG block
and/or carbohydrate bearing chains as hydrophilic block and
MA as hydrophobic one were prepared using a nanoprecipita-
tion method an the detailed conditions are summarized in the
ESI.† Slow-injection of water droplets into glycopolymer in
DMF solution ensures to obtain thermodynamically stable self-
assembled structures. The morphology and size of the result-
ing nanoparticles were systematically analyzed by TEM and
DLS.
Amphiphilic block copolymers P1, P2 and P3 yield well-
dispersed nanoparticles of around 25 nm. While P1 and P2
generated micelles with a regular spherical shape, P3 created
non-uniform micelles due to their non-regular spherical shape
according to TEM imaging and DLS measurements. These fea-
tures are typical of spherical micelles. Further TEM analysis
was conducted on each suspension measuring the average dia-
meter of more than 50 single particles. The majority of the par-
ticles display an average diameter of 20 nm, which is slightly
smaller than the values obtained by DLS, thus providing the
dry structure of these particles. Furthermore, TEM imaging
shows that most of the particles are not clustered, which is
promising, as micelles generally tend to cluster together.
Moreover, it was also observed that P2 and P3 yielded small
amount of larger aggregates, which could potentially be vesi-
cles. Increasing the hydrophobic content of the copolymer
revealed the formation of self-assembled nanoparticles with
larger hydrodynamic diameter. Indeed, the TEM image of P4
indicated the formation of vesicular structures and DLS
measurements showed a narrow size distribution centered at
380 nm.
According to TEM and DLS results, sizes of glyconanoparti-
cles are increasing with increasing of polymer length (ESI,
Table S2†). Depending on the increasing MA fraction in the
polymer, the existence region of nanoparticles has become
broader. This is possibly due to dependency on composition,
molecular geometry, relative block lengths of the constitutive
copolymers, and the preparation methods on the formation of
glyconanoparticles. Another attempt was conducted on P4 to
obtain a higher number of vesicular particles, decreasing the
injection rate of the aqueous solution.
The self-assembly of amphiphilic triblock GP, P5, has lower
hydrophilic fraction than P1–P4, P((MA)m-b-(ManAc)n), due to
the increasing molecular weight ratio of the hydrophobic
block. According to TEM measurement, the majority of nano-
particles were worm-like micelles but with a small fraction of
spherical micelles (Fig. 1). The length of these worm-like
micelles is in the range of 45 to 60 nm and their width is
24 nm, which is in agreement with unimer chain scaling.
Further increase of molar ratio of hydrophobic block (for P4
and P5) allowed fabricating different aggregates such as vesi-
cles and worm-like micelles.
Table 1 Summary of monomer conversions, number average molecular weight (Mn) and molecular weight distributions (Đ) of SET-LRP polymeriz-
ation of all amphiphilic block glycocopolymers
Run Polymer [MA] : [ManAc] : [I]a
Conv.b (%)
Mn,NMR
c (g mol−1) Mn,GPC
d (g mol−1) ĐMA ManAc
P1 P((MA)76-b-(ManAc)15) 80 : 15 : 1 96 98 11 850 12 400 1.16
P2 P((MA)103-b-(ManAc)15) 105 : 15 : 1 97 99 14 150 14 800 1.18
P3 P((MA)130-b-(ManAc)15) 135 : 15 : 1 96 99 16 400 17 600 1.17
P4 P((MA)206-b-(ManAc)15) 210 : 15 : 1 97 98 22 800 26 900 1.20
P5 P((PEG)45-b-(MA)172-b-(ManAc)15) 180 : 15 : 1 96 99 23 800 24 600 1.17
a Initial molar ratio of monomers to initiator. b Conversions obtained from 1H NMR analysis. c Calculated according to equation Mn,NMR = ([M]0/
[I] × NMR conv.% × MW of MA and ManAc) + MW of initiator. dDetermined by GPC (DMF as an eluent and relative to PMMA standards).
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The biological activity of these nanoparticles towards
lectins was measured via SPR. DC-SIGN, which is a human
lectin on cell surfaces that preferentially binds to N-linked
high-mannose oligosaccharides, was employed for binding
assays. DC-SIGN plays a critical role in human immuno-
deficiency virus (HIV) trafficking ability to interact with the
highly mannosylated gp120 glycoprotein present on the envel-
ope of HIV. In general, all glyconanoparticles showed strong
binding signal with DC-SIGN (Fig. 1).
As expected, the binding of nanoparticles to DC-SIGN
decreased at lower nanoparticle concentrations. All glyconano-
particles exhibited relatively high binding values at higher con-
centrations. Therefore, in order to compare the binding levels
of these glyconanoparticles, the nanoparticle concentration of
all nanoparticle solutions were kept constant to determine the
effect of particle size on DC-SIGN binding (Fig. 2). According
to the SPR data, vesicle structured nanoparticles P4 had a
much higher affinity in comparison to other GNPs.
Surprisingly, P1 showed the second highest binding level in
this series after P4. This may be due to the mannose groups
on the surface of P1 glyconanoparticles being more accessible
in order to mediate strong interactions with DC-SIGN. Another
interesting result is that the worm-like micelles P5 showed
higher level of interaction than P2 and P3. The possible expla-
nation for this can be that the formation of worm-like micelles
in clustered structures may enhance the binding capability of
nanoparticles with the natural oligomeric structure of
DC-SIGN. As a result, the small increase in the size of a nano-
Fig. 1 Characterization of glyconanoparticles and their respective binding with DC-SIGN. [a] Chemical structures of polymers; [b] TEM images of
glyconanoparticles in selected solvent condition; [c] zoomed in TEM images; [d] size of glyconanoparticles via DLS [e] DC-SIGN binding of glyco-
nanoparticles measured by SPR.
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particle showed a significant decrease on binding with
DC-SIGN.
Conclusions
In summary, several types of amphiphilic block co-glycopoly-
mers with optimal molecular weights and relatively narrow
molecular weight distributions were synthesized via SET-LRP
to prepare different glycopolymer nanostructures. These syn-
thesized amphiphilic glycopolymers with the same number of
mannose units self-assembled in water to generate glyconano-
particles with different morphologies such as spherical and
worm-like micelles as well as spherical vesicles. The shape and
size of these self-assembled glyconanoparticles were character-
ized via TEM and DLS. Finally, the interaction of these glyco-
nanoparticles of different size and shape with DC-SIGN was
monitored by SPR. The SPR results indicate that the size and
shape of nanoparticles have significant effect on the binding
level with DC-SIGN. According to the binding performance of
these glycopolymer nanostructures, they can be potentially uti-
lized in biomedical applications such as cell-targeted drug
delivery and inhibition of viral infection such as HIV.
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ABSTRACT: A range of glycopolymers composed of N-
acetylgalactosamine were prepared via sequential Cu(I)-medi-
ated polymerization and alkyne−azide click (CuAAC). The
resulting polymers were shown, via multichannel surface
plasmon resonance, to interact specifically with human macro-
phage galactose lectin (MGL; CD301) with high affinity (KD =
1.11 μM), but they did not bind to the mannose/fucose-selective
human lectin dendritic-cell-specific intercellular adhesion mole-
cule-3-grabbing nonintegrin (DC-SIGN; CD209). The effect of
sugar ligand valency on the binding (so-called “glycoside cluster
effect”) of poly(N-acetylgalactosamine) to MGL was inves-
tigated by varying first the polymer chain length (DP: 100, 64,
40, 23, 12) and then the architecture (4- and 8-arm star glycopolymers). The chain length did not have a significant effect on the
binding to MGL (KD = 0.17−0.52 μM); however, when compared to a hepatic C-type lectin of a similar monosaccharide
specificity, the asialoglycoprotein receptor (ASGPR), the binding affinity was more noticeably affected (KD = 0.37− 6.65 μM).
These data suggest that known differences in the specific configuration/orientation of the carbohydrate recognition domains of
MGL and ASGPR are responsible for the differences in binding observed between the different polymers of varied chain length
and architecture. In the future, this model has the potential to be employed for the development of tissue-selective delivery
systems.
■ INTRODUCTION
Carbohydrate recognition controls many biological processes
and is mediated through carbohydrate binding proteins termed
lectins.1 One of the most important classes of human lectins is
the C-type lectin class (CTLs),2−6 and these proteins mediate
selective and specific carbohydrate recognition and subse-
quently drive important functions such as endocytosis.7 A
number of major C-type lectins are expressed on the surfaces of
key immune cells such as macrophages and dendritic cells and
have been identified as a potential platform for targeted drug
delivery and synthetic vaccination.8,9 In general, all CTLs share
high sequence homology and tertiary structure, but the
carbohydrate specificity can be generalized into two broad
groups by tripeptide motifs in the carbohydrate recognition
domain (CRD) that engages calcium chelation and H-bonding
with the C3 and C4 hydroxyl groups of the target carbohydrate
subcomponent. CTLs such as DC-SIGN and macrophage
mannose receptor (MR; CD206) that contain the “Glu−Pro−
Asn” (EPN) motif in the CRD prefer to bind pyranose units
with C3/C4 hydroxyls at equatorial/equatorial positions; these
include mannose, L-fucose, and N-acetylglucosamine
(GlcNAc).10 Physiologically, these mannose-selective CTLs
are generally credited as pathogen pattern recognition
receptors.11 In contrast to the several members of EPN type
CTLs in humans, there are a small set of CTLs with the “Gln−
Pro−Asp” (QPD) motif in the CRD, and they have preferential
binding to galactose-based sugars with the C3/C4 pyranosyl
hydroxyls at an equatorial/axial position.12 For the two major
galactose-specific CTLs in the human body, ASGPR and MGL,
where the structure and function are not fully understood, there
have been no direct comparisons between their binding
activities to synthetic ligands. ASGPR is a hepatic CTL largely
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expressed on sinusoidal face of hepatocyte surfaces and is
responsible for vascular homeostatic regulations13 mediated by
recognition of terminal galactose/GalNAc residues found on
senescent desialylated glycan clusters found on circulating
glycoproteins and platelets.14 In contrast, MGL is an
immunological CTL, expressed on the surface of macrophages
and dendritic cells, implicated in stimulating T-cell signaling.3
Glycopolymers that interact with biological systems possess
considerable potential as novel therapeutics and molecular
probes. Recent discoveries have led to complex compositions
and architectures, attracting interest in various fields for
numerous applications such as biosensors,15 drug-delivery
components,16 cryopreservation, synthetic vaccines,9 immuno-
dulators,8 and cell culture matrices.17 However, the majority of
the literature focuses on interactions with plant derived lectins
such as Concanavalin A (ConA),18 Soybean Agglutinin
(SBA),19 Peanut Agglutinin (PNA)20 and Helix pomatia
Agglutinin (HPA).21 In the context of human drug delivery
and therapeutic applications, investigating human immuno-
logical C-type lectins such as MR, MGL, and DC-SIGN is of
much higher importance and relevance.
Historically, the synthesis of well-defined glycopolymers has
been a challenge because of the need for complex multistep
syntheses. Recently, however, this has been alleviated by the
development of methods whereby glycopolymers can be
synthesized by direct polymerization of glycomonomers. For
example, Davis et al. exploited chemoenzymatic reactions to
synthesize (meth)acrylate-22 and vinyl-ester-based23 glycomo-
nomers, which were subsequently polymerized by RAFT using
dithiocarbonate and xanthate chain transfer agents, respectively.
Cameron et al. polymerized α-GalNAc functionalized acryl-
amide by RAFT as a Tn-antigen mimic and coated gold
nanoparticles as potential candidates for synthetic, carbohy-
drate-based anticancer vaccines.24 Haddleton and co-workers,
reported sequence controlled glycopolymers synthesized by
single-electron transfer living radical polymerization (SET-
LRP) from a library of glycomonomers.25 Binding studies with
DC-SIGN26 and its competitive inhibition of the attachment of
HIV glycoprotein gp120 was also reported. Finally, De Coen
and co-workers used acetylated mannose to prepare a
mannose−arcylamide monomer in a single step.27
Postpolymerization modification of functional polymer
scaffolds is a complementary, efficient method for generating
libraries of glycopolymers, with well-defined scaffolds accessible
from commercially available or easily obtainable monomers.
Glycidyl (meth)acrylate has been shown to be a versatile
monomer, yielding scaffolds capable of undergoing thio-epoxy
ring opening in the presence of thio-sugars,28 as well as
sequential nucleophilic ring opening, by sodium azide, and
“click” with glycosyl alkynes.29 Activated esters such as
pentafluorophenyl and N-Hydroxysuccinimide (NHS) ester
activated polymers are interesting precursor scaffolds; however,
they are often hydrolytically unstable and do not necessary
yield quantitative conversions.30 Bertozzi reported a method
involving the attachment of nonfunctionalized sugar to
poly(acrylhydrazide) scaffolds via the reducing termini;21
however, grafting efficiency is reduced for N-acetylated
carbohydrates. “Click” chemistry is an attractive tool for
glycopolymer synthesis because of the inherent efficiency and
quantitative conversions associated with the reactions. In
particular, copper(I)-catalyzed azide alkyne cycloaddition
(CuAAC) has been employed over the past decade to generate
glycopolymers.31 Glycosyl azides/alkynes have been efficiently
coupled to well-defined alkyne/azide-functional scaffolds, which
can be synthesized by various radical polymerization protocols
including RAFT,32,33 ATRP,34 and cobalt-mediated CCTP.35
Herein we report the synthesis of N-acetyl galactosamine
glycopolymers and their specific/differential binding to
recombinant human MGL and ASPGR lectins. The difference
in binding with respect to the degree of polymerization (DPn)
and the molecular architecture is also reported.
■ EXPERIMENTAL SECTION
Materials and Methods. N-(Ethyl)-2-pyridylmethanimine and
trimethylsilyl propargyl methacrylate were synthesized according to
previously published work.36 Copper(I) bromide (98%, Sigma-
Aldrich) was treated with acetic acid and ethanol and dried under
vacuum prior to use. Amberlite IR120 (Sigma-Aldrich) was treated
with 1 M NaOH, deionized water and ethanol prior to use. 2-Chloro-
1,3-dimethylimdazolinium chloride (DMC) (>97%, Fluka), N-acetyl-
D-glucosamine GlcNAc (>98%, Alfa Aesar), GalNAc (99.6%, Dextra),
triethylamine (TEA) (Fisher scientific, > 99%) were used as received.
All the other reagents and solvents were obtained from Sigma-Aldrich
at the highest purity available and used without any further
purification. Dialysis tubing (1KDa MWCO) was supplied by
Spectrum Laboratories. Soluble recombinant, tetrameric extracellular
domains of DC-SIGN and DC-SIGNR were prepared as previously
described.37 Soluble recombinant Langerin trimeric extracellular
domain was obtained from Elicityl SA (Grenoble, France). Soluble
recombinant trimeric MGL extracellular domain and trimeric ASGPR
H1 extracellular domain proteins were obtained from R&D Systems
Inc. (Minneapolis, MN). All 1H NMR and 13C NMR spectra were
recorded on Bruker HD 300 or 400 MHz spectrometers. The chemical
shifts are reported in ppm with respect to the residual peaks of the
deutrated solvents used as internal standards and ACDLABS software
was used to analyze the data obtained. Infrared absorption spectra
were recorded on Bruker VECTOR-22 FT-IR spectrometer using a
Golden Gate diamond attenuated total reflection cell and OPUS
software was used to analyze the data. Mass spectra were recorded on
Bruker Esquire 2000 using ESI. SEC analysis was conducted on
Agilent 1260 Infinity Multi-Detector GPC Systems in DMF (1.06 g·
L−1 LiBr), calibrated with narrow PMMA standards (200−4.7 × 105 g
mol−1). The GPC data obtained were analyzed using Agilent
Technologies GPC/SEC software. Melting point was measured
using an Optimelt MPA100 system (Stanford Research Systems),
and the data was analyzed with Meltview v.1.108.
Synthesis. Representative spectra of the sugar azides and
glycopolymers synthesized can be found in the Supporting
Information.
Azido Sugars. 2-Chloro-1,3-dimethylimdazolinium chloride (4.6 g,
27.1 mmol, 3 equiv) was added to a mixture of H2O (45 mL), sodium
azide (5.9 g, 90.4 mmol, 10 equiv), triethylamine (9.2 g, 90.4 mmol, 10
equiv) and D-N-acetylgalactosamine/D-N-acetylglucosamine (2 g, 9.0
mmol, 1 equiv). The reaction was left stirring at 0 °C for 1 h and left
to stir overnight at ambient room temperature. The reaction mixture
was concentrated under reduced pressure. Ethanol (100 mL) was
added and passed through a short column of Amberlite IR-120. The
filtrate was concentrated under reduced pressure. H2O (10 mL) was
added and washed with dichloromethane (3 × 15 mL). The aqueous
layer was collected and freeze-dried. The resulting yellow solid was
redissolved in methanol (10 mL) and precipitated into dicholoro-
methane (100 mL) to yield the pure products β-N-acetylgalactosamine
azide (1.2 g, 4.9 mmol, 54%) and β-N-acetylglucosamine azide (1.0 g,
4.1 mmol, 45%) that were spectroscopically equivalent to those
previously reported in the literature.38
General Procedure for ATRP of Trimethylsilyl Propargyl
Methacrylate (Linear). N-(Ethyl)-2-pyridylmethanimine (34.2 mg,
255.0 μmol, 2 equiv), ethyl α-bromoisobutyrate (24.8 mg, 127.0 μmol,
1 equiv), trimethylsilyl propargyl methacrylate (2.0 g, 10.2 mmol, 80
equiv), and toluene (2 mL) were charged to a dry Schlenk tube. The
tube was sealed and subjected to seven freeze−pump−thaw cycles.
The resulting degassed mixture was transferred via cannula under
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nitrogen into a second Schlenk tube, previously evacuated and filled
with nitrogen, containing Cu(I)Br (18.3 mg, 127.0 μmol, 1 equiv) and
a magnetic stirrer. The reaction mixture was stirred at 70 °C for 6 h.
The conversion was measured by integrating the monomeric OCH2
(4.74 ppm) and emerging polymeric OCH2 (4.60 ppm) and
comparing it against the vinylic signals (6.16 and 5.58 ppm). The
polymerization was stopped at 70% conversion and terminated by
diluting reaction mixture with 10 mL of toluene before bubbling air for
2 h. The terminated mixture was passed through a short column of
alumina eluting with THF. The solvent was removed under pressure
and redissolved in THF (10 mL) prior to precipitation in petroleum
ether (200 mL). The precipitate was separated by centrifugation and
decanting the solvent to yield poly(trimethylsilyl propargyl meth-
acrylate) (1.1 g) as white solid.
For investigating the effect of chain length (DPn,th = 10, 20, 40, 60,
100), a benzyl functional initiator was employed for more accurate
determination of the DPn,NMR using the aromatic protons (7.28−7.38
ppm). The amount of monomer and solvent used was kept constant,
and the amount of initiator used was in accordance to eq 1. The
amount of copper and ligand used was adjusted with respect to the





ATRP of Trimethylsilyl Propargyl Methacrylate (4-Arm Star).
General procedure followed using a pentaerythritol based tetra-
initiator.39 The initiator concentration was calculated according to eq 1
by taking each bromine group as an effective initiator to calculate
effective initiator concentration to calculate target DPn per arm. A ratio
of [initiator]eff/[copper]/ligand] = 1:1:2 was employed.
ATRP of Trimethylsilyl Propargyl Methacrylate (8-Arm Star). The
general procedure used a lactose-based initiator40 under more dilute
conditions (25 wt % monomer) to limit the potential of star−star
coupling. The initiator concentration was calculated according to eq 1
taking each bromine group as an effective initiator to calculate effective
initiator concentration to calculate target DPn per arm. A ratio of
[initiator]eff/[copper]/[ligand] = 1:1:2 ratio was employed. The
reaction was terminated at 49% conversion, and the target DPn based
on eq 1 was used to estimate the final DP as the lactose core protons
were obscured and could not be used to determine DPn,NMR.
General Procedure for Deprotection. Poly(trimethylsilyl propargyl
methacrylate) (1.0 g) and acetic acid (460.0 mg, 1.5 eq mol/mol with
respect to the alkyne-trimethylsilyl groups) were dissolved in THF (60
mL) and sealed. The solution was bubbled with nitrogen for 20 min
and then cooled to −20 °C. A solution of 1 M tetrabutylammonium
fluoride hydrate (5 wt % water) in THF (2.3 mL, 1.5 eq mol/mol with
respect to the alkyne-trimethylsilyl groups) was added slowly into the
mixture via syringe. The resulting mixture was stirred at −20 °C for 30
min before being warmed to ambient temperature for 6 h. The
resulting mixture was passed through a short column of silica, using
THF as an eluent. The resulting filtrate was concentrated under
reduced pressure, and the polymer was precipitated in water (150
mL). The precipitate was separated by centrifugation and decanting
the water to yield poly(propargyl methacrylate) (834 mg) as white
solid.
General Procedure for the Synthesis N-Acetylated Glycopol-
ymers. Poly(propargyl methacrylate), sugar azide (1.2 eq mol/mol
with respect to the alkyne groups), 2,2′-bipyridine (0.2 eq mol/mol
with respect to the alkyne groups), and DMSO (5 mL) were charged
into a dry Schlenk tube. The tube was sealed and subjected to seven
freeze−pump−thaw cycles. The resulting degassed mixture was
transferred under nitrogen into a second Schlenk tube, previously
evacuated and filled with nitrogen, containing Cu(I)Br (1 eq mol/mol
with respect to the alkyne groups) and a magnetic stirrer. The reaction
mixture was stirred at room temperature for 36 h. The glycopolymer
was precipitated into THF. The precipitate was then dissolved in water
and treated with cuprisorb until the solution turned colorless. The
polymer solution was then dialyzed using 1KDa MWCO dialysis
tubing in deionized water for 2 days, changing the water at least twice a
day. The solution was then freeze-dried overnight to yield N-acetylated
glycopolymers as white solids.
Surface Plasmon Resonance (Amine Coupling Protein Surface
Immobilization). Sensorgrams were recording using the ProteOn
XPR36 instrument (BioRad Laboratories). Lectins were immobilized
on BioRad ProteOn GLC sensor chips via amine coupling at pH 5.0
using surfaces activated with sulfo-N-hydroxysuccinimide. After
blocking amine coupling sites with 1 M ethanolamine pH 8.0, chip
flowcells were equilibrated in running buffer (10 mM HEPES pH 7.4,
150 mM NaCl, 3 mM CaCl2, 0.01% NaN3, 0.005% Tween-20).
Glycopolymer analytes were prepared in running buffer and flowed
over the lectins at 25 °C and a flow rate of 25 μL/min with analyte
association times of 300−900 s.
Surface Plasmon Resonance (His-Tag Capture Protein Surface
Immobilization). Lectins were immobilized on BioRad ProteOn HTE
sensor chips via Histidine tag-capture, using 10 mM nickel sulfate to
activate the surface. Samples were run straight after lectin
immobilization with running buffer (10 mM HEPES pH 7.4, 150
mM NaCl, 3 mM CaCl2, 0.01% NaN3, 0.005% Tween-20) at 25 °C
and a flow rate of 25 μL/min for association time of 300 s. Running
buffer was flowed immediately afterward for dissociation phase of 375
s. The sensor chip was regenerated by complete removal of the lectins
with 300 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid (EGTA), in order to recoat the surface with new
lectins.
Numerical Fit. The models (eq 2, 3) were fitted numerically using
MATLAB, standard errors were gained for each parameter by
confidence bound of each fit. Response at equilibrium (Req) is
measured as the average response over the last 20 s of the association
phase (response as the sensorgram curve platos). Rmax and KD are










Scheme 1. Synthesis of PGalNAc Prepared by Sequential Cu(I)-Mediated Polymerization and Azide−alkyne Clicka
a(i) CuBr, N-(ethyl)-2-pyridylmethanimine, toluene, 70 °C; (ii) TBAF, AcOH, THF, −20 °C; (iii) CuBr, bipy, sugar azide, DMSO, RT.
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To obtain dissociation rate, a decay equation (eq 3) was fitted to the
dissociation phase (buffer flow). The response unit at the start of the
dissociation phase was taken as the initial response unit (R0):
= −R R k texp( )t 0 off (3)
Association rate (kon) was obtained from KD and koff according to





■ RESULTS AND DISCUSSION
Synthesis of the N-Acetylated Glycopolymers. Rever-
sible deactivation radical polymerization (RDRP) is a popular
method for the preparation of glycopolymers. This study was
initiated by the synthesis and polymerization of a protected
alkyne-functional monomer, trimethylsilyl propargyl methacry-
late (TMS-PgMA) in accordance with previous reports
(Scheme 1).34 Atom transfer radical polymerization (ATRP)
of TMS-PgMA was employed using ethyl α-bromoisobutyrate
(EBiB) as initiator and Cu(I)Br/N-(ethyl)-2-pyridylmethani-
mine (NEPI) as catalyst in toluene (50 wt %) at 70 °C ([TMS-
PgMA]: [EBiB]: [Cu(I)Br]: [NEPI] = [80]: [1]: [1]: [2]).
The polymerization was stopped before reaching full
conversion to reduce the occurrence of bimolecular termination
(ρ = 68%, DPn,NMR = 69, Mn,NMR = 13600 g mol
−1, Đ = 1.30,
Table 1, entry 1). Conversions were determined by monitoring
the disappearance of vinylic protons at δ = 6.11−5.56 ppm,
relative to residual CHCl3 (7.26 ppm) and the degree of
polymerization (DPn) and number-average molecular weight
(Mn,NMR) were determined by comparing the methylene signal
present in the initiator end group (δ = 4.09 ppm) with a
methylene signal in the polymer side chain at purification (δ =
4.60 ppm, Figure S1). The trimethylsilyl protecting groups
were cleaved using tetra-N-butylammonium fluoride (TBAF)
and acetic acid to afford an alkyne-functional polymer scaffold
(Mn,NMR = 8700 g mol
−1, Đ = 1.40, Table 1, entry 2) as
indicated by the disappearance of the TMS signal in 1H NMR
(δ = 0.2 ppm) which coincided with the appearance of a signal
for the alkyne proton (δ = 2.5 ppm, Figure S2). Anomerically
pure β-glycosyl azides of N-acetyl galactosamine (GalNAc) and
N-acetyl glucosamine (GlcNAc), prepared via the one-step
procedure of S. Shoda et al.41−43 (Figure S3−6), were then
“clicked” onto the pendant alkyne groups according to a
literature procedure28 using Cu(I)Br and bypyridine to furnish
GalNAc (GP1, Table 1, entry 3) and GlcNAc (GP2, Table 1,
entry 4) functional glycopolymers from a single polymer
scaffold. The success of the cycloaddition reaction was
confirmed by FT-IR, with the disappearance of the alkyne
peak (ν(C−H): 3286 cm−1 and ν(CC): 2129 cm−1, Figure
S7) and 1H NMR with the appearance of a signal
corresponding to the triazole hydrogen (δ = 8.30 ppm, Figure
S8−9).
Investigating Binding Interactions of MGL with N-
Acetylated Glycopolymers (GP1−GP2). MGL has only
been reported to be expressed in subtypes of macrophages and
dendritic cells as a scavenger receptor that facilitates antigen
presentation of nonself-antigens.44 MGL expression is
implicated in cancer progression and binds to GalNAc based
tumor-associated carbohydrate (Tn-antigen) on the mucin
molecule MUC145 expressed by malignant cells.46 Binding to
MGL is reported to drive Th2-mediated responses via the
MHC class II processing and presentation pathway,47 as
opposed to tumorcidal Th1 responses.48 Although the
engagement of MGL by ligands per se may not direct a
specific response, it may influence and impact responses via
coengagement of other receptors.49 Therefore, from a bottom-
up approach, it was necessary to investigate whether our
polymers could also interact with MGL as well as closely
related CTLs. The association and binding of glycopolymers to
the target lectins was investigated using multichannel surface
plasmon resonance (SPR).
Soluble, recombinant MGL extracellular portion (CRD
domain and coiled-coil neck) was immobilized on the chip
surface through EDC-NHS mediated amine coupling with
carboxylic acid coated alginate on the SPR sensor chip.50
Extracellular portions of the closely related immunological
CTLs: DC-SIGN, DC-SIGNR and Langerin were also
immobilized onto chips for parallel investigations to assess
their interactions with the N-acetylated glycopolymers (GP1
and GP2). The glycopolymers (range: 1.25−40 μM in serial
2:1 dilution) were flowed over, in parallel, across each lectin-
bearing channel, followed immediately by buffer alone (see
Supporting Information for full details). The sensorgrams
(Figure 1) show a clear concentration-dependent association of
PGalNAc GP1 to MGL with slow dissociation. GP1 did not
bind to the other lectins (DC-SIGN, DC-SIGNR, and
Langerin) inferring high selectivity for MGL. In contrast,
PGlcNAc, GP2 was observed to bind to DC-SIGN and other
related EPN-type lectins, but did not bind to MGL (Figure 1,
Table 2). The extent of binding can be quantified using the
SPR software via a two-state model for glycopolymer−lectin
interactions.26,50 From this fitting, two KD values are obtained.
For the purpose of this investigation a simple Langmuir-type
isotherm fitting of each interaction was employed as a
parsimonious model to quantify the glycopolymer-lectin
interaction as a single dissociation equilibrium constant (KD,
eq 1). Individual rate constants were obtained separately;
dissociate rate (koff) from the dissociation phase (eq 3) and an
apparent association rate, as the quotient of KD and koff.
Investigating the Effect of Chain Length and Polymer
Architecture on Binding Affinity. Typically, plant- and
human-derived lectins exist as multimeric assemblies, and as a
result, individual CTL−sugar interactions are weak. Multimeric,
or multivalent sugar ligands often confer much stronger binding
than monomeric and short oligomeric equivalents. This
phenomenon is widely referred to as the “glycoside cluster
effect”.51 One of the advantages of using RDRP protocols is the
ability to control polymer chain length and architecture. Thus,
it is possible to manipulate ligand multivalency by varying the










1 P(TMSPgMA) 10900a 13600b 15400 1.30
2 P(PgMA) 6900d 8700d 9700 1.40
3 GP1 20300d 25600d 22600 1.25
4 GP2 20300d 25600d 24300 1.26
aDetermined by MWmonomer × conversion × [M]0/[I]0 + MWinitiator.
bAs calculated by NMR of the α-end group to determine DPn.
cDetermined by size-exclusion chromatography (with DMF as the
eluent) using conventional calibration obtained with poly(methyl
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number and orientation of pendant sugar groups present within
target glycopolymers. Furthermore, the possibility of forming
well-defined block copolymers provides access to higher-
ordered structures such as micelles, vesicles, and nanogels
wherein the density of sugar ligands present can in intricately
controlled by the monomer feed. To this end, De Coen and co-
workers have investigated the potential of mannosylated
nanogels to target MR expressed on dendritic cells and found
that increased particle size and ligand (mannose) density
resulted in enhanced receptor binding and internalization.27
To investigate the effect of polymer chain length and
architecture on binding to MGL, a library of linear PGalNAc
polymers (GP3−GP7) of varying chain length (DPn 12−100,
Table S1, Figure S11) were prepared by ATRP employing a
benzyl initiator34 which enabled more accurate analysis of the
number-average molecular weight by 1H NMR by comparing
the distinctive benzyl protons (7.28−7.38 ppm) against OCH2-
R (4.59 ppm) of the polymer side chain (Figure S12−S17).
Likewise, alternative architectures were prepared using 4-arm
(pentaerythritol-based) and 8-arm (lactose-based) initiators
(Figure 2). Employing ATRP, the copper and ligand
concentration was adjusted to account for each initiating
group. The DPn of the 4-arm star PGalNAc (GP8, Mn,Th =
45600 g·mol−1, Đ = 1.30, Table S1, Figure S11) was
determined as 30 per arm according to the monomer
conversion (ρ ∼ 60%) from an [M]/[I] ratio of 200 employed
during P(TMSPgMA) scaffold synthesis. The core methylene
protons (4.33 ppm) from the initiator were obscured, which
prohibited accurate determination of DPn by
1H NMR (Figure
S18). Likewise the DPn of the 8-arm star PGalNAc (GP9, Mn,Th
= 68000 g·mol−1, Đ = 1.22, Table S1, Figure S11) was also
determined by monomer conversion as the core lactose ring
protons (3.84−5.86 ppm) could not be reliably integrated by
1H NMR (Figure S19). Polymerization from the 8-arm initiator
was carried out under more diluted conditions (25 wt %) with
[M]/[I] ratio of 360 and was terminated at lower monomer
conversion (ρ ∼ 49%) to reduce the occurrence of star−star
coupling,52,53 furnishing an 8-arm star PGalNAc with DPn of 22
per arm.
During the initial study (GP1−2), all lectins were covalently
bound to SPR chips via established amine coupling chemistry.26
Removal of bound polymers from covalently immobilized
lectins, usually via chelation chemistry (EGTA)54 or simple acid
treatment (pH 3 glycine buffer),26 limits the number of
sequential experiments due to denaturation of the bound
proteins. For a more reliable comparison of the PGalNAc
library (GP3−9), fresh lectin was used for each SPR
experiment to ensure the binding was not influenced by the
previous experiment. This was carried out using Bio-Rad
Laboratories ProteOn HTE Sensor chip, which contains tris-
nitrilotriacetic acid, reported to have subnanomolar affinity
toward His-tagged molecules.55 Thus, His-tagged MGL was
reversibly immobilized to a nickel-sulfate-activated SPR chip
prior to analysis. Polymer-bound lectins were then rapidly
removed using chelating agent EGTA before immobilization of
a fresh batch of His-tagged MGL between each subsequent
experiment.
The binding of PGalNAc to MGL was largely unchanged as a
function of the polymer valency (Figure 3). Although
increasing the linear chain length, from DPn = 12 to DPn =
100 (GP3−7) was found to lower the overall KD of the
polymer, the differences were not significant (517−169 nM,
Figure 1. SPR sensorgrams for the binding of glycopolymers GP1 (A−D) and GP2 (E−H) with lectins MGL, DC-SIGN, DC-SIGNR, and
Langerin. GP1/GP2 were flowed at 0.25 μLs1− for 375 s with varying concentration range to determine association. Buffer was flowed between t =
375 and 900 s to establish the dissociation phase.
Table 2. Binding Parameters of Glycopolymers GP1 and
GP2 with Human Lectins Obtained from SPR, eq 2, and eq 3
pol lectin
kon,app












DC-SIGN 2.49 3.59 1442
DC-SIGNR 1.12 3.24 2907
Langerin 8.58 4.95 577
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Figure 3, Table 3). The architecture of the PGalNAc polymers
also had little effect on the binding to MGL with the 4-arm star
(GP8) and 8-arm star PGalNAc (GP9), exhibiting comparable
binding to the linear analogues (157 nM and 240 nM,
respectively, Figure 3, Table 3). A similar observation was
previously reported by Stenzel and co-workers, whereby the
binding of glucose-containing 4-arm star glycopolymers to
ConA, did not show a significant effect on binding compared to
linear analogues.18 As the association rate directly reflects the
dissociation constant by our method, a similar trend was
observed whereby PGalNAc appeared to bind marginally faster
as a function of increasing valency (410−1870 M−1·s−1, Table
3), whereas only minor changes in the dissociation rates were
determined (1.66 × 10−4 s−1−3.45 × 10−4 s−1, Table 3) with no
obvious trend with respect to valency.
To date, the structure of MGL has not been fully elucidated,
but it has been reported to share similarities with DC-SIGN
and mannose binding protein (MBP) where the CRDs are
relatively distant and face away from one another. Such an
orientation might be expected to be ideal for cross-linking via
multivalent ligands.56 Indeed, one of the immunological
functions of MGL has been attributed to cross-linking of
CD45 expressed on the surface of activated T cells, modulating
their behavior.57 Structurally, chemical cross-linking experi-
ments have shown that MGL exists as a homotrimer.56
Trimerization occurs in the neck domain and is independent
Figure 2. PGalNAc library synthesized by ATRP to investigate the effect of ligand valency on lectin binding.
Figure 3. Binding constants of glycopolymers GP3-GP9 with MGL
determined from SPR (Figure S20).
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of the CRD, with the junction between the two domains being
protease-sensitive. This indicates that the CRD consists of three
discrete, distally orientated sugar binding sites that are
potentially dynamic and capable of adjusting to compliment
the glycan clusters presented to the lectin surface, similar to
MBP.56 Therefore, it is proposed that the three binding sites
interact independently with the PGalNAc polymers employed
during this investigation. On a molecular level, this translates to
the polymers not having to traverse the multiple binding sites
of a single MGL trimer to enhance binding.
Relative Binding of PGalNAc with ASGPR and MGL. In
comparison to MGL, ASGPR was discovered much earlier,58
and the structure and function has been more extensively
explored.59 Native human ASGPR consists of two different
chains, H1 and H2, forming a hetero-oligomer.60 Despite this,
to date there are currently no crystal structures of the complete
extracellular domain of the native H1/H2 heterooligomer, but
the arrangement and orientation of the CRD are well-
investigated, and optimal ASGPR ligands reported in the
literature are selected on the basis of the spatial arrangement of
Gal residues within the native tri/tetra-antennary N-glycans.61
The recombinant ASGPR used during this investigation (CRD
and neck domain of H1 subunit), is a self-assembled
homotrimer,62 the structure of which closely resembles the
native hetero-oligomer lectin, in which the binding sites are in
close proximity,54 presenting an interface more suitable for
clustered glycosides, typically at the termini of a single,
branched oligosaccharide. From previous literature pertaining
to monosaccharide selectivity,63 it was hypothesized that
APSGR would exhibit similar binding selectivity to MGL.
Having demonstrated binding of PGalNAc (GP1, 1.62 μM),
and a lack of binding of PGlcNAc (GP2) to ASGPR (Figure
4A,B), the effect of chain length and architecture was again
investigated. The overall binding of PGalNAc (GP3-GP9) to
ASGPR was found to be lower than MGL, particularly for short
polymer chain lengths (GP3−5, Table 3). However, a more
pronounced effect on binding with changing the valency of
PGalNAc was observed.
At shorter chain lengths, the binding of linear PGalNAc
(GP3−5) to ASGPR was comparable (GP3−5, 6.7−5.5 μM).
When the chain length was increased further, the dissociation
constant decreased much more significantly than previously
observed for MGL (GP6−7, 712−372 nM). Similarly to MGL,
no significant effect was observed upon changing the polymer
architecture (GP8−9, 560−341 nM). Molecularly, this
indicates that low-molecular-weight PGalNAc (GP3−5) share
similar binding modes, as indicated by minimal changes in the
KD. ASGPR has been reported to bind markedly weaker to
monovalent GalNAc ligands, and as such, ASGPR ligands are
often based on a tri/tetra-antennary design to compliment the
more rigid, proximal binding sites of the multivalent ASGPR
oligomer.64,65 When the chain length of the PGalNAc ligand is
increased beyond DPn = 64, the binding to ASGPR is markedly
enhanced as a result of the “glycoside cluster effect” whereby
the multivalent PGalNAc ligands are capable of binding to
multiple binding sites of ASGPR, thus overcoming the
individually weak interactions.
The differential binding of MGL and ASGPR was further
exemplified using a GalNAc-BSA conjugate, where single
GalNAc moieties are randomly exposed through conjugation
to surface serine and threonine residues. Only binding to MGL,
with its distally orientated, flexible CRD, was observed, and no
binding was observed to the more rigid, proximal binding sites
of ASGPR which requires more closely configured sugar ligands




a (g·mol−1) Đc KD (nM) kon,app (× 10
2 M−1·s−1) koff (× 10
‑4·s−1) KD (nM) kon,app (× 10
2 M−1·s−1) koff (× 10
−4·s−1)
GP3 12 4700 1.15 517 4.10 2.12 6653 0.35 2.33
GP4 23 8800 1.34 390 4.27 1.66 6652 0.39 2.58
GP5 40 15100 1.30 388 8.90 3.45 5535 0.71 3.94
GP6 64 24000 1.13 211 9.17 1.94 712 3.56 2.57
GP7 100 37300 1.21 169 15.70 2.64 372 12.00 4.47
GP8 30/armb 45600b 1.30 157 18.70 2.94 341 10.20 3.47
GP9 22/armb 68000b 1.22 240 13.50 3.26 560 8.23 4.61
aDetermined by 1H NMR via integration of the benzyl protons (7.28−7.38 ppm) of the chain end against OCH2-R (4.59 ppm) of the polymer.
bApproximated from data obtained for the polymer scaffold (Table S1). cDetermined by size-exclusion chromatography (with DMF as the eluent)
using conventional calibration obtained with poly(methyl methacrylate) standards (Figure S11). dDetermined SPR whereby GP3−9 were flowed at
0.25 μLs-1 for 375 s to afford association before buffer was flowed (t = 375−900 s) to establish the dissociation phase (Figures S20,S21).
Figure 4. SPR sensorgrams for the binding of glycopolymers GP1 (A) and GP2 (B) with ASGPR. GP1/GP2 were flowed at 0.25 μL s−1 for 300 s
with varying concentration range to determine association. Buffer was flowed between t = 300 and 700 s to establish the dissociation phase. Binding
constants of glycopolymers GP3−GP9 with APSGR determined from SPR (Figure S21).
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(Figure 5). The PGalNAc polymers synthesized during this
investigation were predicted to be long enough to span the
proximal binding sites of the ASGPR which are separated by
approximately 15−25 Å.66 With this in mind, the shortest
PGalNAc (DPn = 12.5, GP3) should be sufficiently long
enough to bind to at least two of the binding sites based on a
perfectly linear conformation, while GP5 (DPn = 40) should be
sufficiently long enough to bind to all three binding sites of the
trimer. However, the glycopolymers do not exist as ideal linear
chains in solution, and as a result changes in the KD were only
observed at longer chain lengths (GP6−GP7, DPn = 64, 100).
Thus, the “glycoside cluster effect” was apparent at longer chain
lengths as the conformation of the polymer in solution
promotes binding at multiple sites of the lectin CRD.
Furthermore, beyond a critical chain length, secondary
interactions that result in cross-linking between ASGPR
oligomers are possible which could contribute to the stronger
binding interactions observed.
Bertozzi et al. previously described an analogous system in
plant lectins; Helix pomatia agglutinin (HPA) and soybean
agglutinin (SBA), where HPA (proximal binding sites) was
found to interact strongly in a valence-independent manner and
SBA (distant binding sites) to reversibly “bind and slide”,
leading to weaker interactions.19 Conversely, this investigation
has demonstrated that binding to ASGPR, with proximal
binding sites, occurs in a valence-dependent manner, whereas
MGL, with its flexible, distal binding sites binds independent of
valence with affinity attributed a preference for multimolecular
lectin binding via cross-linking through the glycopolymer
scaffold. These contrasting conclusions serve to highlight the
complexity of lectin/glycopolymer interactions which are
strongly dependent upon the nature of lectin(s) and polymers
under investigation.
■ CONCLUSIONS
A library of PGalNAc glycopolymers have been used for the
first time to perform binding studies with human CTL’s MGL
and ASGPR. A polyalkyne scaffold prepared by Cu(I)-mediated
radical polymerization was functionalized with azido-GalNAc
and azido-GlcNAc respectively, and the binding and selectivity
of the resulting polymers was assessed against target lectins
MGL and ASGPR as well as related CTLs DC-SIGN, DC-
SIGNR, and Langerin using SPR. PGalNAc was found to
specifically bind to MGL and shows little affinity for related
CTLs. Conversely, PGlcNAc exhibits little affinity for MGL but
binds to the related CTLs with varying affinity. Increasing the
ligand valency by increasing the DPn of the PGalNAc resulted
in only a small increase in affinity, which remained unchanged
as a function of polymer architecture. This is attributed to the
distal orientation and flexibility of the carbohydrate binding
domain of MGL. ASGPR, which is known to have a more
proximal orientated binding domain, exhibits comparable
selectivity of PGalNAc and conforms in part to the “glycoside
cluster effect”. For example, increasing the GalNAc valency by
increasing the DPn of the PGalNAc exhibited a marked increase
in affinity. The specific binding thresholds reported are
opportunistic for further exploitation, with potential implica-
tions in tissue-selective drug delivery. For example, it is known
that GalNAc based ligands can successfully target the liver via
ASGPR in vivo without being obstructed by the immune
system.67 Therefore, ASGPR represents a promising entry for
liver-specific drug and gene delivery using PGalNAc glycopol-
ymers. Alternatively, selectively targeting the immune system
using GalNAc-based systems represents a greater challenge due
to competitive uptake by the hepatic system. It is hoped that
the differential binding observed between MGL and ASGPR in
this study can be exploited to systemically target macrophages
and DCs via MGL without off-target uptake to liver via ASGPR.
Due to their pivotal role in tumor immunology, macrophages
and DCs could provide a set of clinically valuable targets.68
Thus, targeting tumor environments via the carbohydrate
binding properties of MGL could provide a favorable and
selective therapeutic delivery strategy because of its higher
expression in sites of solid tumors.69
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Figure 5. SPR sensorgrams for the binding of BSA-GalNAc conjugate
to MGL (A) and ASGPR (B). BSA-GalNAc conjugate was flowed at
0.25 μL s−1 for 300 s with varying concentration range to determine
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Manipulation of cytokine secretion in human
dendritic cells using glycopolymers with picomolar
affinity for DC-SIGN†
Daniel A. Mitchell,*ab Qiang Zhang,c Lenny Voorhaar,c David M. Haddleton, c
Shan Herath,d Anne S. Gleinich,a Harpal S. Randeva,ab Max Crispin,e Hendrik Lehnert,f
Russell Wallis,g Steven Pattersond and C. Remzi Becer *h
The human C-type lectin DC-SIGN (CD209) is a significant receptor on the surface of dendritic cells (DCs)–
crucial components of host defense that bridge the innate and adaptive immune systems. A range of linear
glycopolymers, constructed via controlled radical polymerization techniques have been shown to interact
with DC-SIGN with affinities in the physiologically active range. However, these first generation
glycopolymers possess limited structural definition and their effects on DCs were not known. Here we
report the development of star-shaped mannose glycopolymers with the aim of targeting the clustered
domain arrangement of DC-SIGN and these were shown to bind with picomolar affinity. Increased
secretion of IL-10 with simultaneous decrease in secreted IL-12p70 occurred in activated DCs incubated
with star-shaped glycopolymers – a cytokine secretion pattern characteristic of wound-healing tissue
environments. Incorporating stellar architecture into glycopolymer design could be key to developing
selective and very high-affinity therapeutic materials with distinct immunomodulatory and tissue repair
potential.
Introduction
The recognition of repeating molecular patterns is a major
function of the human immune system, enabling it to interact
with and interpret various biological structures. These include
the surfaces of pathogens such as viruses, fungi and bacteria, in
addition to host structures such as glycoproteins and apoptotic
cells.1,2 C-type lectins are a major class of pattern recognition
molecules in humans that interact with complex carbohydrates
such as microbial polysaccharides and oligosaccharides present
on human and viral glycoproteins and glycolipids.3 In partic-
ular, the C-type lectin DC-SIGN (dendritic cell-specic
intercellular adhesion molecule-3 grabbing nonintegrin;
CD209; CLEC4L) is signicantly implicated in human disease
through its interactions with viral carbohydrates on HIV and
mycobacterial lipoarabinomannans (e.g. tuberculosis), in addi-
tion to its ability to transduce intracellular signaling events and
inuence dendritic cell responses.4–7 DC-SIGN is also important
in the proper responses to specic apoptotic cell uptake by
dendritic cells (DCs).2 DCs are especially important components
of the human immune system owing to their roles as highly
efficient surveillance entities and professional antigen pre-
senting cells. DCs are the only cell type with the ability to acti-
vate näıve T lymphocytes, making them very powerful bridges
between innate and adaptive immunity.8 NMR analyses of
DC-SIGN-oligosaccharide interactions in solution suggest
discrete binding modes of the carbohydrate-recognition
domain for distinct glycan types that in turn are thought to
drive different cell signaling pathways.9 Furthermore, the
distribution of DCs (and DC-SIGN-positive cells such as selected
macrophage subpopulations) within discrete regions of tissues
of the human body makes them attractive targets for site-
specic therapeutic intervention in a broad range of diseases
with immune system involvement.10,11
Designed glycopolymers have been successfully generated
for high affinity interactions with human DC-SIGN.12–15 This has
included the development of size- and sequence-controlled
polymers, in addition to conformation-controlled polymers
and glycoconjugates, collectively offering a diverse range of
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strategies for DC-SIGN targeting and exploitation. However, the
concept of polymer architecture as a rational design strategy for
DC-SIGN targeting with these classes of glycopolymer has yet to
be employed and furthermore, the impact of advanced glyco-
polymers on dendritic cell function has yet to be investigated
(Fig. 1). Knowledge of the tetrameric structure of DC-SIGN,
wherein four mannoside-selective carbohydrate recognition
domains (CRDs) are clustered at the top of a coiled-coil stalk
projecting from the cell surface,16,17 allows for the rational
construction of novel glycopolymers for further affinity
enhancement and potential biological impact. Understanding
of the role of DC-SIGN stimulation in dendritic cell responses
holds potential for efficient, high affinity ligands to serve as
immunomodulators as well as antiviral agents. The main text of
the article should appear here with headings as appropriate.
Materials and methods
Instrumentation
NMR spectra were recorded on a Bruker DPX-300 and DPX-400
using deuterated solvents. FTIR spectra were recorded on
a Bruker Vector 22 FTIR spectrometer. For SEC a Varian PL
390-LC system was used, equipped with refractive index and
viscosimetry detectors, using either CHCl3 or DMF (LiBr 1 g l
1)
as the eluent (1 ml min1). Data analysis was performed using
Cirrus soware andmolecular weights were determined relative
to Polymer Labs pMMA standards. The LCST of the glycopol-
ymers was determined by measuring the cloud point of
a 5 mg ml1 solution of the polymer in water with a Stanford
Research Systems OptiMelt MPA100.
Synthesis of 2-methacrylic acid 3-trimethylsilanyl-prop-2-ynyl
ester (TMSMA)
A ask was charged with 3-trimethylsilanyl-prop-2-yn-1-ol
(25.0 g, 195 mmol) and triethylamine (41.0 ml, 294 mmol) in
THF (250 ml) and cooled with dry ice. A solution of 2-methyl-
acryloyl chloride (23.0 ml, 235 mmol) in THF (50 ml) was added
drop wise. The mixture was stirred for 1 hour while cooling with
dry ice and stirred overnight at room temperature, during which
yellow coloured salts were formed. The mixture was puried on
a basic Al2O3 column and the solvent was removed under
reduced pressure, leaving behind a clear yellow liquid. The yield
was 35.0 g (178 mmol, 92%) 1H NMR (CDCl3, 298 K, 300 MHz)
d (ppm) ¼ 0.18 (s, 9H, Si(CH3)3); 1.96 (m, 3H, CH3C]CH2); 4.76
(s, 2H, OCH2); 5.62 (m, 1H, C]CHH); 6.17 (m, 1H, C]CHH).
Typical atom transfer radical polymerization procedure
A Schlenk tube was charged with initiator (1.0 mmol), monomer
(50 mmol), N-(ethyl)-2-pyridylmethanimine ligand (2.0 mmol)
and toluene (same volume as monomer). Two different
methods have been used to remove the oxygen from the solu-
tion, which have been found to be equally effective. The rst
method was a freeze–pump–thaw cycle, which was executed
three times. The secondmethod was bubbling the solution with
nitrogen for at least 20 minutes. A second Schlenk tube was
charged with Cu(I)Br (1.0 mmol) and a stirring bar and the
oxygen was removed by evacuating and subsequently lling the
tube with nitrogen three times. The solution was transferred to
the second tube using a cannula and a vacuum to start the
transfer. The solution was heated to 90 C while being kept
under nitrogen atmosphere for the entire duration of the reac-
tion. Samples were taken periodically using a degassed syringe
in case of the kinetic experiments. The polymerization was
stopped by cooling the mixture to room temperature and
exposing it to oxygen. The mixture was diluted with CH2Cl2
(approximately same volume as mixture) and passed through
a basic Al2O3 column. The polymer was precipitated into a 5 : 1
vol/vol methanol/water mixture (pTMSMA). The solid was iso-
lated by ltration and dried in a vacuum oven overnight. In
most experiments with the star-shaped initiators the amount of
toluene used was higher to prevent star–star coupling. This was
either twice (for 5-arm star) or three times (8-arm star) the
volume of the monomer.
Deprotection of pTMSMA
The pTMSMA (0.5 g) was dissolved in THF (35 ml) and glacial
acetic acid (0.22 ml, 1.5 equiv. with respect to the TMS groups)
was added. The solution was bubbled with nitrogen and cooled
with dry ice for at least 15 minutes. A 0.2 M solution of TBAF in
THF (50 ml, 4.0 equiv.) was added dropwise with a syringe while
stirring the solution and cooling with dry ice. The dry ice was
removed aer 30 minutes and the mixture was stirred overnight
at room temperature. The mixture was concentrated under
reduced pressure, puried on a silica column and concentrated
again. The polymer was precipitated in petroleum ether cooled
with dry ice and acetone. The white powder was isolated by
ltration and dried in a vacuum oven overnight. The depro-
tection was conrmed by the appearance of a peak at 2.5 ppm in
the 1H NMR and the disappearance of the 0.2 ppm peak.
Synthesis of a-mannose azide
Sodium azide (7.26 g, 111 mmol), D-(+)-mannose (2.00 g,
11.1 mmol) and triethylamine (15.5 ml, 111 mmol) were dis-
solved in water (40 ml) and cooled to 0 C. 2-Chloro-1,3-
dimethylimidazolinium chloride (5.61 g, 33.3 mmol) was
added and themixture was stirred for 1 hour at 0 C. The solvent
was removed under reduced pressure and EtOH (40 ml) was
added. The solids were removed by ltration and the solution
was puried on a long Amberlite IR-120 column, using EtOH as
Fig. 1 Representative chemical structures of the mannose glycopol-
ymers. R ¼ Br in the initiator structure.
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6974–6980 | 6975






























































































the eluent. The mixture was checked with FTIR to conrm the
removal of all sodium azide (n ¼ 2030 cm1). The solvent was
removed under reduced pressure, water (30 ml) was added and
the mixture was washed with dichloromethane (5  15 ml). The
solvent was removed under reduced pressure, water (10 ml) was
added and the solution was freeze-dried overnight to give
a-mannose azide (1.59 g, 78 mmol, 70%) as an off-white solid.
1H NMR (D2O, 298 K, 400 MHz) d (ppm) ¼ 5.45 (1H), 3.95–3.60
(6H). 13C NMR (D2O, 298 K, 400 MHz) d (ppm) ¼ 89.72 (C1),
74.65, 69.86, 69.77, 66.40, 60.83 (C6). FT-IR (H2O) n (cm
1) ¼
2112 (N3).
Mannose azide clicking to propargyl polymers
A solution containing propargyl polymer (100 mg, 0.81 mmol
propargyl groups), mannose azide (213 mg, 1.05 mmol) and
CuBr (116 mg, 0.81 mmol) in DMSO (10 ml) was bubbled with
nitrogen for 20 minutes. Ethyl ligand (216 mg, 1.61 mmol) was
added and the solution was bubbled with nitrogen for several
more minutes. The solution was subsequently stirred at
ambient temperature for two days. The mixture was puried by
dialysis (MWCO: 1000) against distilled water for two days,
while changing the water at least four times. It was then
concentrated under reduced pressure and freeze-dried
overnight.
Glycopolymer synthesis and characterization
Before the click reactions could take place, the propargyl groups
of the pTMSMA polymers need to be deprotected by removal of
the TMS group. This was performed by reacting the polymer
with CH3COOH and TBAF in THF. The deprotection can be
followed by 1H NMR (Fig. S1†). The peak of the TMS group at
0.2 ppm disappears and a peak appears at 2.5 ppm for the
propargylic proton. Aer removing the water from the reaction
mixture, EtOH was added to lter the unreacted sodium azide
from the mixture. However, some of the sodium azide was still
soluble in EtOH, as is shown in the FTIR spectrum in Fig. S2.†
As sodium azide can form explosive compounds when it is
brought into contact with halogenated solvents, it was neces-
sary to remove this from the mixture before continuing with
subsequent purication steps. It was found that this last trace of
sodium azide could be removed on an Amberlite IR-120 column
using EtOH as the eluent. TEA was also removed from the
mixture with this column. The remaining DMC was removed by
washing the mixture in water with CH2Cl2. Mannose azide was
attached to each of the different synthesized propargyl polymers
using click chemistry. The reaction can be observed using 1H
NMR through the appearance of a triazole peak at 8.30 ppm
(Fig. S3†). The peaks at 6.0 ppm and 5.4–4.3 ppm are from the
mannose. The kinetic plot for the polymerization of TMSMA
shows that it takes roughly 15 minutes for the polymerization to
initiate (Fig. S5†). Aer that the conversion is linear up to at
least 95%. The increase of Mn with conversion is almost linear
within the margin of error. PDI values are all very close together
around 1.3. The homopolymerization of TMSMA using the
8-arm initiator was performed in 75% solvent to avoid coupling
of the star polymers. The rst-order kinetic plot is linear up to
50% conversion. A short initiation period was observed that was
also seen in the homopolymerization of TMSMA with the
disulde initiator. The increase in molecular weight is mostly
linear with relation to the conversion (PDI  1.25). The theo-
retical molecular weight of the synthesized linear, 5 arm and
8 arm glycopolymers have been calculated as 35 700 g mol1,
37 100 g mol1, and 39 600 g mol1, respectively. The measured
number average molecular weight of the linear, 5-arm, and
8-arm glycopolymers were found as 41 000 g mol1,
42 100 g mol1, and 45 600 g mol1, respectively.
Protein expression and surface plasmon resonance
Soluble recombinant DC-SIGN was generated in E. coli and
puried via affinity chromatography usingmannose–sepharose,
as described previously and immobilized16 on GLM sensor chips
via amine coupling for use in the Bio-Rad ProteOn XPR36
instrument (Bio-Rad Laboratories, Hercules, USA).12 Glycopol-
ymer samples were dissolved in running buffer (10 mM HEPES
pH 7.4, 150mMNaCl, 5 mMCaCl2, 0.01% (v/v) Tween-20, 0.01%
(w/v) NaN3) and owed over sensor chips at a ow rate of
25 ml ml1 at 25 C. Sensorgram data were collected and refer-
ence subtraction performed against a blank channel treated
with amine coupling activators and subsequently blocked with
1 M ethanolamine. Kinetic parameters were determined using
the Bia-evaluation soware (GE Healthcare) utilizing heteroge-
neous ligand tting models.
Blood samples
Peripheral bloodmononuclear cells (PBMCs) were isolated from
blood leukocyte cones (National Blood Transfusion Service, UK)
by density gradient centrifugation with Lymphoprep™ 1077
(PAA Laboratories, GmbH, UK) followed by a 50% Percoll
(Sigma, UK) gradient to obtain a high-density fraction enriched
in lymphocytes and a low-density fraction enriched in mono-
cytes. Fractions were aliquoted and stored in liquid N2 until
required.
Generation of dendritic cells
Monocyte derived dendritic cells (moDCs) were isolated from
the monocyte rich fraction by magnetic bead separation using
anti-CD14 coated magnetic beads (Miltenyi Biotec). Puried
monocytes were cultured in complete medium (RPMI contain-
ing 10% FBS, 100 IU ml1 penicillin, 0.1 mg ml1 streptomycin,
and 2 mM L-glutamine; Sigma-Aldrich) supplemented with
GM-CSF (100 ng ml1) and IL-4 (50 ng mLl1; R&D Systems),
this being replenished every other day. On day 7, DCs were
harvested, washed twice and resuspended in serum-free RPMI-
1640 prior to staining for ow cytometry.
Flow cytometry
Dendritic cells were harvested, washed and stained with either
5-arm polymer-FITC, 8-arm polymer-FITC, a linear polymer-
FITC or gp120-FITC (generated from soluble recombinant
gp120 produced in HEK cells as previously described) at the
concentrations indicated in the results. To assess the ability of
6976 | Chem. Sci., 2017, 8, 6974–6980 This journal is © The Royal Society of Chemistry 2017






























































































the polymers to bind to the gp120 site, DCs were incubated with
unlabeled polymer (at the concentrations indicated in the
results) for 45 minutes at room temperature and then treated
with gp120-FITC (1 mg ml1) for a further 30 minutes at room
temperature. To determine binding of gp120 to CD4+ cells, DCs
and lymphocytes were rstly incubated with unlabeled gp120 at
1 mgml1 for 45min at room temperature and then stained with
anti-CD4-APC, anti-CD3-Percp, and gp120-FITC for a further
30 minutes. Following all the incubations, cells were washed
and xed with BD stabilizing xative (BD Biosciences).
Unstained DCs were used as a control. One hundred thousand
cells were acquired within a live gate using a 3-laser congu-
ration LSRII ow cytometer (BD Biosciences, USA), and analysed
by FlowJo (Tree Star Inc, USA).
Cytokine assays
Sets of dendritic cell cultures, derived from four separate
donors, were incubated with 1 mg ml1 gp120 and also dened
quantities of the three species of glycopolymer (8-arm, 5-arm
and linear; at 1, 3 and 10 mg ml1). Aer 24 hours, one group of
DC cultures was activated with 1 mg ml1 lipopolysaccharide
(LPS; Sigma, Poole, UK) and 20 ng ml1 interferon gamma
(IFN-g), the other le unstimulated. Supernatants (100 ml) from
the assorted cultures were recovered aer a further 24 hours via
centrifugation at 2000 rpm. Samples were diluted 1 : 1 in
DMEM cell culture mediumwithout supplements and duplicate
measurements were made using Luminex bead immunoassay.
A panel of nine cytokines was analyzed simultaneously using
the commercial Bio-Rad Th1 and Th2 kit within the Bio-plex 200
Multiplex System in accordance with manufacturer instructions
(Bio-Rad Laboratories, Hercules, USA). Quantitative readouts
were obtained for the following cytokines: tumor necrosis factor
alpha (TNF-a), IFN-g, interleukins (IL)-2, IL-4, IL-5, IL-10,
IL-12p70, IL-13, and granulocyte/monocyte-colony stimulating
factor (GM-CSF).
Research using human material was carried out in accor-
dance with institutional guidelines issued by the University of
Warwick and Imperial College London, and with the principles
expressed in the Declaration of Helsinki. Ethical approval was
obtained from the Riverside Research Ethics Committee and
informed written consent was obtained prior to patient blood
collection. Data from human-derived material were processed
anonymously.
Results and discussion
Carbohydrates in the form of oligosaccharides and poly-
saccharides represent a large, crucial and exciting family of
molecules in the development of novel therapeutics. Uncover-
ing the roles of complex carbohydrates in human physiology
and disease coincides with the advancement of our under-
standing of carbohydrate-binding receptors such as DC-SIGN.
Initially identied as a molecule exploited by HIV-1 in order
to promote viral trafficking and within-host survival, it has since
emerged recently that DC-SIGN is central to important physio-
logical processes such as healthy responses during apoptotic
cell clearance and foeto-maternal tolerance.2,18 Studies into the
impact of glycan ligands for DC-SIGN on immune cells indicate
that this receptor is capable of driving anti-inammatory and
immunosuppressive cell signaling with major effects on gene
expression and cellular responses.6,7 Whilst undesirable in the
context of certain infections, these responses are benecial in
the active processes of wound healing and the resolution of
inammatory episodes. It is becoming increasingly clear that
these tissue repair and protection mechanisms are highly active
and require advanced immune system involvement. Of signi-
cance is the association of molecules such as DC-SIGN with
tissue environments such as placenta, uterus and gut, where
tight control of tissue growth & stability and blood supply in the
presence of abundant non-self material is essential.11
Understanding the structure and function of DC-SIGN allows
us to design and prepare advanced synthetic ligands for this
molecule and investigate opportunities for exploiting its anti-
inammatory properties. The strategy of generating dened
star-shaped glycopolymers (GPs) to achieve enhanced binding
to the tetrameric conguration of DC-SIGN has been very
successful, showing increases in affinity exceeding an order of
magnitude, in addition to demonstrating strong interactions
with DCs. We speculate that the star-shaped architecture spans
the four CRDs within the DC-SIGN tetramer, increasing the
strength of the interaction and potentially inuencing the
consequences of DC-SIGN engagement. It is assumed that
DC-SIGN can only transduce signals when clustered in multi-
meric complexes with multiple glycan ligands expressed on
a large surface area, although small ligands such as Lewis-x
oligosaccharides have been shown to drive signaling and gene
expression responses in DCs via DC-SIGN engagement.
Furthermore, NMR analyses of DC-SIGN–oligosaccharide
interactions in solution suggest discrete binding modes of the
carbohydrate-recognition domain for distinct glycan types that
in turn are thought to drive different cell signaling pathways.
Therefore, the consequences of DC-SIGN engagement by gly-
copolymers could be inuenced and even tuned by variations in
sugar composition, architecture and size.
Star-shaped GPs bind to recombinant DC-SIGN with sub-
nanomolar affinity. Interaction analysis in real time via
surface plasmon resonance (SPR) demonstrated distinct and
strong binding between immobilized DC-SIGN and all of the
GPs examined (Fig. 2), consistent with previous studies.12 As
expected, the star-shaped GPs showed greater affinity compared
with the linear GP of equal molecular weight and dissociation
rates (koff) were markedly slow, in keeping with strong multi-
valent interactions with the oligomeric DC-SIGN protein.
Apparent KD values of 65.1 pM and 72.5 pMwere determined for
the star-shaped 5-arm and 8-arm glycopolymers, respectively
(Table 1).
Star-shaped glycopolymers show improved and dose-
dependent binding to human dendritic cells
To determine whether the polymers bound directly to dendritic
cells (DCs), DCs were stained with FITC-labeled polymers at
a range of polymer concentrations. Fig. 3A–C shows that all GPs
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6974–6980 | 6977






























































































bound to DCs to some degree with the 5-arm and 8-arm glyco-
polymers binding better than the linear polymer. We also
assessed the binding of gp120 to DCs and found that binding
followed a similar prole to the star-shaped glycopolymers
(Fig. 3D). In a direct comparison between the polymers and
gp120, we found that the 5-arm and 8-arm GPs bound with
a similar intensity as compared to the gp120 at the highest dose
of 10 mg ml1 (see ESI†).
In addition to assessing the intrinsic binding of GPs to DCs
we also determined whether they exerted any measurable
inuence on the activation status of the treated DCs by
analyzing their cell-surface markers. We found that following
24 hours of exposure to the polymers generated here, there was
no signicant change in DC expression of the canonical acti-
vation markers CD80, CD83, CD86 or HLA-DR when examining
cells from three separate donors.
There is a likelihood that these mannose glycopolymers also
interact with dendritic cell and macrophage subpopulations
that express the mannose receptor (CD206), in addition to
specialised endothelial cells that express receptors such as
DC-SIGNR (CD299). Where the very high affinity interactions
between the star-shaped glycopolymers and DC-SIGN could
possess signicant selectivity would be in discrete tissue spaces
such as inamed synovium associated with rheumatoid
arthritis, where salient subpopulations of DC-SIGN-positive
macrophages are upregulated.19
Competition of glycopolymers with gp120 for binding sites on
dendritic cells due to cellular CD4 expression
To determine whether the polymers competed with the gp120
for the same cellular binding site, we incubated DCs with
unlabeled polymers and then stained the cells with FITC-
labeled gp120 (Fig. 4). Our results show that although there
was a slight shi in binding when polymer was present, none of
the polymers signicantly abrogated gp120 binding.
To assess whether this was due to the gp120 using more than
one binding partner on cell surfaces, we looked at determining
the expression of the major gp120 ligand – CD4 – on both DCs
and T cells. Our results show that gp120 is able to bind to CD4
molecules on both DCs and T cells – a site to which gp120
binding is not carbohydrate-dependent (Fig. 5). Consequently
our results demonstrate that the polymers bind to separate sites
on cells from those utilized and possibly preferred by gp120.
The ow cytometry studies involving HIV gp120 interactions
with DCs raise a very important issue in the use of glycopol-
ymers as agents for viral blockade. The presence of CD4 on
moDCs (and also native peripheral DC populations) serves as
a very effective adhesion route for HIV, such that polymer-based
barrier preparations could be compromised in vivo. This would
be consistent with in vivo ndings that DC-SIGN is associated
with parenteral but not mucosal trafficking of HIV.20 However, it
is yet to be known whether the presence of glycopolymers could
affect HIV infection of CD4+ T cells in trans and whether gly-
copolymers would be effective in blocking DC interactions with
other dangerous glycosylated viruses that are known to interact
Fig. 2 Real-time analysis of GP interactions with DC-SIGN. SPR sen-
sorgrams were collected at 25 C and a flow rate of 25 mL min1 and
demonstrate clear interactions between linear glycopolymer P1 (Panel
A), 5-arm star glycopolymer P2 (Panel B) and 8-arm star glycopolymer
P3 (Panel C) and immobilized DC-SIGN extracellular domain. The
sensorgram curves illustrate slow dissociation, especially of the 5-arm
and 8-arm GPs during the wash phase (indicated by the guideline at
900 s).
Table 1 Binding kinetics and apparent KD values of the linear, 5-arm
star-shaped, and 8-arm star-shaped glycopolymers
Run Type kon (M
1 s1) koff (s
1) KD (M)
P1 Linear 1.24  106 1.34  104 1.08  1010
P2 5-Arm star 1.01  106 7.33  105 7.25  1011
P3 8-Arm star 0.93  106 6.03  105 6.51  1011
Fig. 3 Concentration-dependent glycopolymer binding to DCs.
Dendritic cells were labeled with the indicated concentration of FITC-
labeled glycopolymers/glycoprotein (Panel A – Linear P1; Panel B – 5-
arm star P2; Panel C – 8-arm star P3; and Panel D – gp120) and
analyzed by flow cytometry. The data are representative of one of 3
donors.
6978 | Chem. Sci., 2017, 8, 6974–6980 This journal is © The Royal Society of Chemistry 2017






























































































with DC-SIGN such as hepatitis C virus (HCV), Ebola and
Dengue.
Glycopolymers modulate cytokine production by activated
DCs
Cytokine analysis was carried out on supernatants recovered
from DCs exposed to glycopolymers and consensus activation
stimuli (LPS plus IFN-g). Prior to supernatant harvesting, the
DCs appeared healthy and normal in the presence of glycopol-
ymers, suggesting that these materials were tolerated and not
markedly toxic at the quantities used (1–10 mg ml1). Measured
cytokine secretion levels were negligible in all of the DC cultures
that were not stimulated with LPS and IFN-g, suggesting that
the GPs themselves do not invoke major secreted DC activation
responses. In DC cultures activated with LPS and IFN-g, key
cytokines such as TNF-a were up-regulated in all cultures, as
expected, and the exposure of DCs to star-shaped GPs led to
signicant changes in the secretion of two cytokines – IL-10 and
IL-12p70. Levels of secreted IL-10 were signicantly increased
only in supernatants from activated DCs exposed to the 8-arm
and 5-arm GPs, and only at the highest concentration used
(10 mg ml1; Fig. 6A). Equivalent quantities of the linear GP did
not invoke signicant changes in IL-10 secretion. Levels of
IL-12p70 were signicantly reduced by all three species of GP in
a dose dependent manner (Fig. 6B–D). Interestingly, the linear
GP showed an effect in reducing IL-12p70 secretion (Fig. 6B).
This suggests that whilst showing lower levels of binding to
DC-SIGN and to DCs, linear GPs may still inuence certain DC
responses.
The changes in cytokine secretion by DCs invoked by the
star-shaped polymers are consistent with those observed in
mammalian wound healing. IL-10 is a potent immunosup-
pressive cytokine with broad effects on inammation and its
mediators.21 IL-12p70 is a pro-inammatory cytokine and
a potent inhibitor of angiogenesis (blood vessel growth).22 The
combination of IL-10 increase and IL-12 decrease represents
a rapid and effective means of reducing inammation and
restoring organized blood ow to a site of tissue injury. In
general, qualitative changes in secretion of these two cytokines
are in keeping with the consequences of DC-SIGN engagement
by biologically-sourced mannosylated ligands. However, a key
difference is that in the case of the glycopolymers, the chemical
denition is very precise. In contrast, biological high mannose
ligands such as gp120, yeast mannan and mycobacterial
Fig. 4 Competition of polymer vs. gp120 binding to dendritic cells.
Dendritic cells were firstly incubated with the indicated concentration
of unlabeled polymer (Panel A – Linear P1; Panel B – 5-arm star P2;
Panel C – 8-arm star P3; Panel D – summary of polymers at
10 mg ml1) and then probed with FITC gp120. Cells were analyzed by
flow cytometry and the data represent one of 3 donors.
Fig. 5 Competition binding of gp120 against CD4. Dendritic cells and
lymphocytes were first incubated with an unlabeled gp120 and then
stained with an anti-CD4 antibody. Cells were analyzed by flow
cytometry and the data represents one of 2 donors.
Fig. 6 Effects of glycopolymers on cytokine secretion by activated
DCs. Cells were incubated with GPs before activation with LPS and
IFN-g and multiplex cytokine assay. IL-10 secretion was significantly
increased in DC cultures from 4 donors incubated with 8-arm star P3
and 5-arm star P2 GPs at 10 mg ml1 compared with controls, but not
with linear GP P1 (Panel A). IL-12p70 secretion was significantly
decreased compared to controls in cells exposed to increasing
concentrations of linear GP P1 (Panel B), 5-arm star GP P2 (Panel C)
and 8-arm star GP P3 (Panel D) (all P values calculated from paired
t-tests).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6974–6980 | 6979






























































































lipoarabinomannan are notoriously heterogeneous.23–25
Furthermore, the low cost of polymer precursors and the simple
synthesis workow make the glycopolymers described here an
attractive and affordable means of generating abundant, water-
soluble material with advanced immunological activity.
Conclusions
To summarize, we report the synthesis and characterization of
highly water-soluble advanced glycopolymer sets of dened size
and shape designed to interact profoundly with the key human
lectin DC-SIGN. Biophysical studies demonstrate remarkable
glycopolymer-DC-SIGN interactions with affinities in the pico-
molar range and positive binding to human monocyte-derived
dendritic cells. Star-shaped glycopolymers invoke signicant
changes in the production of two key cytokines, IL-10 and
IL-12p70, when incubated with dendritic cells at pharmaco-
logically realistic concentrations. Importantly, IL-10 levels rise
and IL-12 levels fall in response to the glycopolymers and this
cytokine release pattern is reminiscent of tissue environments
associated with active wound healing, anti-inammation, and
also healthy pregnancy at the feto-maternal interface. In our
experiments, however, the glycopolymers do not affect the
ability of HIV gp120 to interact with monocyte-derived dendritic
cells – previously a major direction for both DC-SIGN and gly-
copolymer research. We propose novel roles for glycopolymers
of this kind, shiing the focus away from HIV prophylaxis
towards the treatment of conditions that require immune
modulation that promotes wound healing and inammatory
resolution. Examples of such conditions could include burns &
chronic skin lesions, in addition to chronic inammatory
diseases with immunological involvement such as rheumatoid
arthritis, multiple sclerosis and Crohn's disease.
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